

Express Mail Label No. EL827033137US
Attorney Docket No.: 018501-000830US
Client Reference No.: COCA 007-1

Methods of Diagnosis of Colorectal Cancer, Compositions and Methods of Screening for Colorectal Cancer Modulators

Entity: Small

07-03-2008 16:00

Methods of Diagnosis of Colorectal Cancer, Compositions and Methods of Screening for Colorectal Cancer Modulators

5

CROSS-REFERENCES TO RELATED APPLICATIONS

[01] This application is a continuation in part of US Patent Application USSN 09/663,733 filed September 15, 2000, which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

[02] The invention relates to the identification of expression profiles and the nucleic acids involved in colorectal cancer, and to the use of such expression profiles and nucleic acids in diagnosis and prognosis of colorectal cancer. The invention further relates to methods for identifying and using candidate agents and/or targets which modulate colorectal cancer.

BACKGROUND OF THE INVENTION

[03] Cancer of the colon and/or rectum (referred to as "colorectal cancer") are significant in Western populations and particularly in the United States. Cancers of the colon and rectum occur in both men and women most commonly after the age of 50. These develop as the result of a pathologic transformation of normal colon epithelium to an invasive cancer. There have been a number of recently characterized genetic alterations that have been implicated in colorectal cancer, including mutations in two classes of genes, tumor-suppressor genes and proto-oncogenes, with recent work suggesting that mutations in DNA repair genes may also be involved in tumorigenesis. For example, inactivating mutations of both alleles of the adenomatous polyposis coli (APC) gene, a tumor suppressor gene, appears to be one of the earliest events in colorectal cancer, and may even be the initiating event. Other genes implicated in colorectal cancer include the MCC gene, the p53 gene, the DCC (deleted in colorectal carcinoma) gene and other chromosome 18q genes, and genes in the TGF- β signaling pathway. For a review, see *Molecular Biology of Colorectal Cancer*, pp. 238-299, in *Curr. Probl. Cancer*, Sept/Oct 1997; see also Willams, *Colorectal Cancer*

10
15
20
25
30

(1996); Kinsella & Schofield, *Colorectal Cancer: A Scientific Perspective* (1993); *Colorectal Cancer: Molecular Mechanisms, Premalignant State and its Prevention* (Schmiegel & Scholmerich eds., 2000); *Colorectal Cancer: New Aspects of Molecular Biology and Their Clinical Applications* (Hanski *et al.*, eds 2000); McArdle *et al.*, *Colorectal Cancer* (2000);
5 Wanebo, *Colorectal Cancer* (1993); Levin, *The American Cancer Society: Colorectal Cancer* (1999); *Treatment of Hepatic Metastases of Colorectal Cancer* (Nordlinger & Jaeck eds., 1993); *Management of Colorectal Cancer* (Dunitz *et al.*, eds. 1998); *Cancer: Principles and Practice of Oncology* (Devita *et al.*, eds. 2001); *Surgical Oncology: Contemporary Principles and Practice* (Kirby *et al.*, eds. 2001); Offit, *Clinical Cancer Genetics: Risk Counseling and*
10 *Management* (1997); *Radioimmunotherapy of Cancer* (Abrams & Fritzberg eds. 2000); Fleming, *AJCC Cancer Staging Handbook* (1998); *Textbook of Radiation Oncology* (Leibel & Phillips eds. 2000); and *Clinical Oncology* (Abeloff *et al.*, eds. 2000).

[04] Imaging of colorectal cancer for diagnosis has been problematic and limited. In addition, metastasis of the tumor to the lumen, and metastasis of tumor cells to regional lymph nodes are important prognostic factors (*see, e.g., PET in Oncology: Basics and Clinical Application* (Ruhlmann *et al.* eds. 1999). For example, five year survival rates drop from 80 percent in patients with no lymph node metastases to 45 to 50 percent in those patients who do have lymph node metastases. A recent report showed that micrometastases can be detected from lymph nodes using reverse transcriptase-PCR methods based on the presence of mRNA for carcinoembryonic antigen, which has previously been shown to be present in the vast majority of colorectal cancers but not in normal tissues. Liefers *et al.*, *New England J. of Med.* 339(4):223 (1998).

[05] Thus, methods that can be used for diagnosis and prognosis of colorectal cancer would be desirable. Accordingly, provided herein are methods that can be
25 used in diagnosis and prognosis of colorectal cancer. Further provided are methods that can be used to screen candidate bioactive agents for the ability to modulate colorectal cancer. Additionally, provided herein are molecular targets for therapeutic intervention in colorectal and other cancers.

30 BRIEF SUMMARY OF THE INVENTION

[06] The present invention provides novel methods for diagnosis and prognosis evaluation for colorectal cancer, as well as methods for screening for compositions which modulate colorectal cancer. Methods of treatment of colorectal cancer, as well as compositions, are also provided herein.

[07] In one aspect, a method of screening drug candidates comprises providing a cell that expresses an expression profile gene selected from those of Table I. The method further includes adding a drug candidate to the cell and determining the effect of the drug candidate on the expression of the expression profile gene.

5 [08] In one embodiment, the method of screening drug candidates includes comparing the level of expression in the absence of the drug candidate to the level of expression in the presence of the drug candidate, wherein the concentration of the drug candidate can vary when present, and wherein the comparison can occur after addition or removal of the drug candidate. In a preferred embodiment, the cell expresses at least two
10 expression profile genes. The profile genes may show an increase or decrease.

[09] Also provided herein is a method of screening for a bioactive agent capable of binding to a colorectal cancer modulator protein, the method comprising combining the colorectal cancer modulator protein and a candidate bioactive agent, and determining the binding of the candidate agent to the colorectal cancer modulator protein. Preferably the colorectal cancer modulator protein is a product encoded by a gene of Table 1
15 or Table 2.

[10] Further provided herein is a method for screening for a bioactive agent capable of modulating the activity of a colorectal cancer modulator protein. In one embodiment, the method comprises combining the colorectal cancer modulator protein and a candidate bioactive agent, and determining the effect of the candidate agent on the bioactivity
20 of the colorectal cancer modulator protein. Preferably the colorectal cancer modulator protein is a product encoded by a gene of Table 1 or Table 2.

[11] Also provided is a method of evaluating the effect of a candidate colorectal cancer drug comprising administering the drug to a transgenic animal expressing or
25 over-expressing the colorectal cancer modulator protein, or an animal lacking the colorectal cancer modulator protein, for example as a result of a gene knockout.

[12] Additionally, provided herein is a method of evaluating the effect of a candidate colorectal cancer drug comprising administering the drug to a patient and removing a cell sample from the patient. The expression profile of the cell is then determined. This
30 method may further comprise comparing the expression profile to an expression profile of a healthy individual. In a preferred embodiment, said expression profile includes a gene of Table 1 or Table 2.

[13] Moreover, provided herein is a biochip comprising one or more nucleic acid segments of Table 1 or Table 2, wherein the biochip comprises fewer than 1000 nucleic acid probes. Preferable at least two nucleic acid segments are included.

5 [14] Furthermore, a method of diagnosing a disorder associated with colorectal cancer is provided. The method comprises determining the expression of a gene of Table 1 or Table 2, in a first tissue type of a first individual, and comparing the distribution to the expression of the gene from a second normal tissue type from the first individual or a second unaffected individual. A difference in the expression indicates that the first individual has a disorder associated with colorectal cancer.

10 [15] In another aspect, the present invention provides an antibody which specifically binds to a protein encoded by a nucleic acid of Table 1 or Table 2 or a fragment thereof. Preferably the antibody is a monoclonal antibody. The antibody can be a fragment of an antibody such as a single stranded antibody as further described herein, or can be conjugated to another molecule. In one embodiment, the antibody is a humanized antibody.

15 [16] In one embodiment a method for screening for a bioactive agent capable of interfering with the binding of a colorectal cancer modulating protein (colorectal cancer modulator protein) or a fragment thereof and an antibody which binds to said colorectal cancer modulator protein or fragment thereof. In a preferred embodiment, the method comprises combining a colorectal cancer modulator protein or fragment thereof, a candidate bioactive agent and an antibody which binds to said colorectal cancer modulator protein or fragment thereof. The method further includes determining the binding of said colorectal cancer modulator protein or fragment thereof and said antibody. Wherein there is a change in binding, an agent is identified as an interfering agent. The interfering agent can be an agonist or an antagonist. Preferably, the agent inhibits colorectal cancer.

20 [17] In a further aspect, a method for inhibiting colorectal cancer is provided. The method can be performed in vitro or in vivo, preferably in vivo to an individual. In a preferred embodiment the method of inhibiting colorectal cancer is provided to an individual with cancer. As described herein, methods of inhibiting colorectal cancer can be performed by administering an inhibitor of the activity of a protein encoded by a nucleic acid of Table 1 or Table 2, including an antisense molecule to the gene or its gene product.

25 [18] Also provided herein are methods of eliciting an immune response in an individual. In one embodiment a method provided herein comprises administering to an individual a composition comprising a colorectal cancer modulating protein, or a fragment

thereof. In another embodiment, the protein is encoded by a nucleic acid selected from those of Table 1 or Table 2. In another aspect, said composition comprises a nucleic acid comprising a sequence encoding a colorectal cancer modulating protein, or a fragment thereof.

5 [19] Further provided herein are compositions capable of eliciting an immune response in an individual. In one embodiment, a composition provided herein comprises a colorectal cancer modulating protein, preferably encoded by a nucleic acid of Table 1 or Table 2, or a fragment thereof, and a pharmaceutically acceptable carrier. In another embodiment, said composition comprises a nucleic acid comprising a sequence
10 encoding a colorectal cancer modulating protein, preferably selected from the nucleic acids of Table 1 or Table 2 and a pharmaceutically acceptable carrier.

 [20] Also provided are methods of neutralizing the effect of a colorectal cancer protein, or a fragment thereof, comprising contacting an agent specific for said protein with said protein in an amount sufficient to effect neutralization. In another embodiment, the
15 protein is encoded by a nucleic acid selected from those of Table 1 or Table 2.

 [21] In another aspect of the invention, a method of treating an individual for colorectal cancer is provided. In one embodiment, the method comprises administering to said individual an inhibitor of a colorectal cancer modulating protein. In another
20 embodiment, the method comprises administering to a patient having colorectal cancer an antibody to a colorectal cancer modulating protein conjugated to a therapeutic moiety. Such a therapeutic moiety can be a cytotoxic agent or a radioisotope.

 [22] Compounds and compositions are also provided. Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention.

25 BRIEF DESCRIPTION OF THE DRAWINGS
 [NOT APPLICABLE]

 DETAILED DESCRIPTION OF THE INVENTION

 [23] The present invention provides novel methods for diagnosis and
30 prognosis evaluation for colorectal cancer, as well as methods for screening for compositions which modulate colorectal cancer. The methods herein are related to those of U.S. Patent Application Serial No. 09/525,993 and International Patent Application No. PCT/US00/07044, each of which is incorporated herein in its entirety.

[24] By "colorectal cancer" herein is meant a colon and/or rectal tumor or cancer that is classified as Dukes stage A or B as well as metastatic tumors classified as Dukes stage Cor D (see, e.g., Cohen *et al.*, *Cancer of the Colon*, in *Cancer: Principles and Practice of Oncology*, pp. 1144-1197 (Devita *et al.*, eds., 5th ed. 1997); see also *Harrison's Principles of Internal Medicine*, pp. 1289-129 (Wilson *et al.*, eds., 12th ed., 1991).

"Treatment, monitoring, detection or modulation of colorectal cancer" includes treatment, monitoring, detection, or modulation of colorectal disease in those patients who have colorectal disease (Dukes stage A, B, C or D) in which gene expression from a gene in Table 1 or 2, is increased or decreased, indicating that the subject is more likely to progress to metastatic disease than a patient who does not have an increase or decrease in gene expression of a gene in Table 1 or 2. In Dukes stage A, the tumor has penetrated into, but not through, the bowel wall. In Dukes stage B, the tumor has penetrated through the bowel wall but there is not yet any lymph involvement. In Dukes stage C, the cancer involves regional lymph nodes. In Dukes stage D, there is distant metastasis, e.g., liver, lung, etc.

[25] Table 1 provides unigene cluster identification numbers for the nucleotide sequence of genes that exhibit increased expression in colorectal cancer samples. Tables 1 also provides an exemplar accession number that provides a nucleotide sequence that is part of the unigene cluster. Table 2 provides the nucleic acid and protein sequence of the CBF9 gene as well as the Unigene and Exemplar accession numbers for CBF9.

[26] In one aspect, the expression levels of genes are determined in different patient samples for which either diagnosis or prognosis information is desired, to provide expression profiles. An expression profile of a particular sample is essentially a "fingerprint" of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is unique to the state of the cell. That is, normal tissue may be distinguished from colorectal cancer tissue, and within colorectal cancer tissue, different prognosis states (good or poor long term survival prospects, for example) may be determined. By comparing expression profiles of colon tissue in known different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. The identification of sequences that are differentially expressed in colorectal cancer versus normal colon tissue, as well as differential expression resulting in different prognostic outcomes, allows the use of this information in a number of ways. For example, the evaluation of a particular treatment regime may be evaluated: does a chemotherapeutic drug act to improve the long-term

prognosis in a particular patient. Similarly, diagnosis may be done or confirmed by comparing patient samples with the known expression profiles. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates with an eye to mimicking or altering a particular expression profile; for example, screening can be done for drugs that suppress the colorectal cancer expression profile or convert a poor prognosis profile to a better prognosis profile. This may be done by making biochips comprising sets of the important colorectal cancer genes, which can then be used in these screens. These methods can also be done on the protein basis; that is, protein expression levels of the colorectal cancer proteins can be evaluated for diagnostic and prognostic purposes or to screen candidate agents. In addition, the colorectal cancer nucleic acid sequences can be administered for gene therapy purposes, including the administration of antisense nucleic acids, or the colorectal cancer proteins (including antibodies and other modulators thereof) administered as therapeutic drugs.

[27] Thus the present invention provides nucleic acid and protein sequences that are differentially expressed in colorectal cancer, herein termed "colorectal cancer sequences". As outlined below, colorectal cancer sequences include those that are up-regulated (i.e. expressed at a higher level) in colorectal cancer, as well as those that are down-regulated (i.e. expressed at a lower level) in colorectal cancer. In a preferred embodiment, the colorectal cancer sequences are from humans; however, as will be appreciated by those in the art, colorectal cancer sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other colorectal cancer sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc). colorectal cancer sequences from other organisms may be obtained using the techniques outlined below.

[28] Colorectal cancer sequences can include both nucleic acid and amino acid sequences. In a preferred embodiment, the colorectal cancer sequences are recombinant nucleic acids. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed in vitro, in general, by the manipulation of nucleic acid by polymerases and endonucleases, in a form not normally found in nature. Thus an isolated nucleic acid, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e. using the in vivo cellular machinery of the

host cell rather than in vitro manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention.

[29] Similarly, a "recombinant protein" is a protein made using recombinant techniques, i.e. through the expression of a recombinant nucleic acid as depicted above. A recombinant protein is distinguished from naturally occurring protein by at least one or more characteristics. For example, the protein may be isolated or purified away from some or all of the proteins and compounds with which it is normally associated in its wild type host, and thus may be substantially pure. For example, an isolated protein is unaccompanied by at least some of the material with which it is normally associated in its natural state, preferably constituting at least about 0.5%, more preferably at least about 5% by weight of the total protein in a given sample. A substantially pure protein comprises at least about 75% by weight of the total protein, with at least about 80% being preferred, and at least about 90% being particularly preferred. The definition includes the production of a colorectal cancer protein from one organism in a different organism or host cell. Alternatively, the protein may be made at a significantly higher concentration than is normally seen, through the use of an inducible promoter or high expression promoter, such that the protein is made at increased concentration levels. Alternatively, the protein may be in a form not normally found in nature, as in the addition of an epitope tag or amino acid substitutions, insertions and deletions, as discussed below.

[30] In a preferred embodiment, the colorectal cancer sequences are nucleic acids. As will be appreciated by those in the art and is more fully outlined below, colorectal cancer sequences are useful in a variety of applications, including diagnostic applications, which will detect naturally occurring nucleic acids, as well as screening applications; for example, biochips comprising nucleic acid probes to the colorectal cancer sequences can be generated. In the broadest sense, then, by "nucleic acid" or "oligonucleotide" or grammatical equivalents herein means at least two nucleotides covalently linked together. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, as outlined below, nucleic acid analogs are included that may have alternate backbones, comprising, for example, phosphoramidate (Beaucage et al., Tetrahedron 49(10):1925 (1993) and references therein; Letsinger, J. Org. Chem. 35:3800 (1970); Sprinzl et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl. Acids Res. 14:3487 (1986); Sawai et al, Chem. Lett. 805 (1984), Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); and Pauwels et al., Chemica Scripta 26:141 (1986)),

phosphorothioate (Mag et al., *Nucleic Acids Res.* 19:1437 (1991); and U.S. Patent No. 5,644,048), phosphorodithioate (Briu et al., *J. Am. Chem. Soc.* 111:2321 (1989), O-methylphosphoroamidite linkages (see Eckstein, *Oligonucleotides and Analogues: A Practical Approach*, Oxford University Press), and peptide nucleic acid backbones and linkages (see Egholm, *J. Am. Chem. Soc.* 114:1895 (1992); Meier et al., *Chem. Int. Ed. Engl.* 31:1008 (1992); Nielsen, *Nature*, 365:566 (1993); Carlsson et al., *Nature* 380:207 (1996), all of which are incorporated by reference). Other analog nucleic acids include those with positive backbones (Denpcy et al., *Proc. Natl. Acad. Sci. USA* 92:6097 (1995); non-ionic backbones (U.S. Patent Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; Kiedrowshi et al., *Angew. Chem. Intl. Ed. English* 30:423 (1991); Letsinger et al., *J. Am. Chem. Soc.* 110:4470 (1988); Letsinger et al., *Nucleoside & Nucleotide* 13:1597 (1994); Chapters 2 and 3, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook; Mesmaeker et al., *Bioorganic & Medicinal Chem. Lett.* 4:395 (1994); Jeffs et al., *J. Biomolecular NMR* 34:17 (1994); *Tetrahedron Lett.* 37:743 (1996)) and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids (see Jenkins et al., *Chem. Soc. Rev.* (1995) pp169-176). Several nucleic acid analogs are described in Rawls, *C & E News* June 2, 1997 page 35. All of these references are hereby expressly incorporated by reference. These modifications of the ribose-phosphate backbone may be done for a variety of reasons, for example to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip.

[31] As will be appreciated by those in the art, all of these nucleic acid analogs may find use in the present invention. In addition, mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.

[32] Particularly preferred are peptide nucleic acids (PNA) which includes peptide nucleic acid analogs. These backbones are substantially non-ionic under neutral conditions, in contrast to the highly charged phosphodiester backbone of naturally occurring nucleic acids. This results in two advantages. First, the PNA backbone exhibits improved hybridization kinetics. PNAs have larger changes in the melting temperature (T_m) for mismatched versus perfectly matched basepairs. DNA and RNA typically exhibit a 2-4°C drop in T_m for an internal mismatch. With the non-ionic PNA backbone, the drop is closer to

7-9°C. Similarly, due to their non-ionic nature, hybridization of the bases attached to these backbones is relatively insensitive to salt concentration. In addition, PNAs are not degraded by cellular enzymes, and thus can be more stable.

[33] The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand ("Watson") also defines the sequence of the other strand ("Crick"); thus the sequences described herein also includes the complement of the sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid contains any combination of deoxyribo- and ribo-nucleotides, and any combination of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc. As used herein, the term "nucleoside" includes nucleotides and nucleoside and nucleotide analogs, and modified nucleosides such as amino modified nucleosides. In addition, "nucleoside" includes non-naturally occurring analog structures. Thus for example the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside.

[34] A colorectal cancer sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the colorectal cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions.

[35] The isolation of mRNA comprises isolating total cellular RNA by disrupting a cell and performing differential centrifugation. Once the total RNA is isolated, mRNA is isolated by making use of the adenine nucleotide residues known to those skilled in the art as a poly (A) tail found on virtually every eukaryotic mRNA molecule at the 3' end thereof. Oligonucleotides composed of only deoxythymidine [olgo(dT)] are linked to cellulose and the oligo(dT)-cellulose packed into small columns. When a preparation of total cellular RNA is passed through such a column, the mRNA molecules bind to the oligo(dT) by the poly (A) tails while the rest of the RNA flows through the column. The bound mRNAs are then eluted from the column and collected.

[36] The colorectal cancer sequences of the invention can be identified as follows. Samples of normal and tumor tissue are applied to biochips comprising nucleic acid probes. The samples are first microdissected, if applicable, and treated as described above for the preparation of mRNA. Suitable biochips are commercially available, for example

from Affymetrix. Gene expression profiles as described herein are generated, and the data analyzed.

[37] In a preferred embodiment, the genes showing changes in expression as between normal and disease states are compared to genes expressed in other normal tissues, including, but not limited to lung, heart, brain, liver, breast, kidney, muscle, prostate, small intestine, large intestine, spleen, bone, and placenta. In a preferred embodiment, those genes identified during the colorectal cancer screen that are expressed in any significant amount in other tissues are removed from the profile, although in some embodiments, this is not necessary. That is, when screening for drugs, it is preferable that the target be disease specific, to minimize possible side effects.

[38] In a preferred embodiment, colorectal cancer sequences are those that are up-regulated in colorectal cancer ; that is, the expression of these genes is higher in colorectal carcinoma as compared to normal colon tissue. "Up-regulation" as used herein means at least about a 1.1 fold change, preferably a 1.5 or two fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred. All accession numbers herein are for the GenBank sequence database and the sequences of the accession numbers are hereby expressly incorporated by reference. GenBank is known in the art, see, e.g., Benson, DA, et al., Nucleic Acids Research 26:1-7 (1998) and <http://www.ncbi.nlm.nih.gov/>. In addition, these genes were found to be expressed in a limited amount or not at all in heart, brain, lung, liver, breast, kidney, prostate, small intestine and spleen.

[39] In a preferred embodiment, colorectal cancer sequences are those that are down-regulated in colorectal cancer ; that is, the expression of these genes is lower in colorectal carcinoma as compared to normal colon tissue. "Down-regulation" as used herein means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred.

[40] Colorectal cancer proteins of the present invention may be classified as secreted proteins, transmembrane proteins or intracellular proteins. In a preferred embodiment the colorectal cancer protein is an intracellular protein. Intracellular proteins may be found in the cytoplasm and/or in the nucleus. Intracellular proteins are involved in all aspects of cellular function and replication (including, for example, signaling pathways); aberrant expression of such proteins results in unregulated or dysregulated cellular processes. For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity,

polymerase activity and the like. Intracellular proteins also serve as docking proteins that are involved in organizing complexes of proteins, or targeting proteins to various subcellular localizations, and are involved in maintaining the structural integrity of organelles.

[41] An increasingly appreciated concept in characterizing intracellular proteins is the presence in the proteins of one or more motifs for which defined functions have been attributed. In addition to the highly conserved sequences found in the enzymatic domain of proteins, highly conserved sequences have been identified in proteins that are involved in protein-protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB domains, which are distinct from SH2 domains, also bind tyrosine phosphorylated targets. SH3 domains bind to proline-rich targets. In addition, PH domains, tetratricopeptide repeats and WD domains to name only a few, have been shown to mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. As will be appreciated by one of ordinary skill in the art, these motifs can be identified on the basis of primary sequence; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule and/or molecules with which the protein may associate.

[42] In a preferred embodiment, the colorectal cancer sequences are transmembrane proteins. Transmembrane proteins are molecules that span the phospholipid bilayer of a cell. They may have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described for intracellular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins.

[43] Transmembrane proteins may contain from one to many transmembrane domains. For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain. However, various other proteins including channels and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors are classified as "seven transmembrane domain" proteins, as they contain 7 membrane spanning regions. Important transmembrane protein receptors include, but are not limited to

insulin receptor, insulin-like growth factor receptor, human growth hormone receptor, glucose transporters, transferrin receptor, epidermal growth factor receptor, low density lipoprotein receptor, epidermal growth factor receptor, leptin receptor, interleukin receptors, e.g. IL-1 receptor, IL-2 receptor, etc.

5 [44] Characteristics of transmembrane domains include approximately 20 consecutive hydrophobic amino acids that may be followed by charged amino acids. Therefore, upon analysis of the amino acid sequence of a particular protein, the localization and number of transmembrane domains within the protein may be predicted.

10 [45] The extracellular domains of transmembrane proteins are diverse; however, conserved motifs are found repeatedly among various extracellular domains. Conserved structure and/or functions have been ascribed to different extracellular motifs. For example, cytokine receptors are characterized by a cluster of cysteines and a WSXWS (W= tryptophan, S= serine, X=any amino acid) motif. Immunoglobulin-like domains are highly conserved. Mucin-like domains may be involved in cell adhesion and leucine-rich repeats participate in protein-protein interactions.

15 [46] Many extracellular domains are involved in binding to other molecules. In one aspect, extracellular domains are receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like. For example, growth factors such as EGF, FGF and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include cytokines, mitogenic factors, neurotrophic factors and the like. Extracellular domains also bind to cell-associated molecules. In this respect, they mediate cell-cell interactions. Cell-associated ligands can be tethered to the cell for example via a glycosylphosphatidylinositol (GPI) anchor, or may themselves be transmembrane proteins. Extracellular domains also associate with the extracellular matrix and contribute to the maintenance of the cell structure.

20 [47] Colorectal cancer proteins that are transmembrane are particularly preferred in the present invention as they are good targets for immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities.

25 [48] It will also be appreciated by those in the art that a transmembrane protein can be made soluble by removing transmembrane sequences, for example through recombinant methods. Furthermore, transmembrane proteins that have been made soluble

can be made to be secreted through recombinant means by adding an appropriate signal sequence.

[49] In a preferred embodiment, the colorectal cancer proteins are secreted proteins; the secretion of which can be either constitutive or regulated. These proteins have a signal peptide or signal sequence that targets the molecule to the secretory pathway. Secreted proteins are involved in numerous physiological events; by virtue of their circulating nature, they serve to transmit signals to various other cell types. The secreted protein may function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in close proximity to the cell that secreted the factor) or an endocrine manner (acting on cells at a distance). Thus secreted molecules find use in modulating or altering numerous aspects of physiology. colorectal cancer proteins that are secreted proteins are particularly preferred in the present invention as they serve as good targets for diagnostic markers, for example for blood tests.

[50] A colorectal cancer sequence is initially identified by substantial nucleic acid and/or amino acid sequence homology to the colorectal cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions.

[51] As used herein, the terms "colorectal cancer nucleic acid", "colorectal cancer protein" or "colorectal cancer polynucleotide" or "colorectal cancer-associated transcript" refers to nucleic acid and polypeptide polymorphic variants, alleles, mutants, and interspecies homologs that: (1) have a nucleotide sequence that has greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater nucleotide sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a nucleotide sequence of or associated with a unigene cluster of Tables 1 or Table 2; (2) bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising an amino acid sequence encoded by a nucleotide sequence of or associated with a unigene cluster of Table 1 or Table 2, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to a nucleic acid sequence, or the complement thereof of Table 1 or Table 2 and conservatively modified variants thereof or (4) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater amino sequence identity, preferably over a region of over a region of at least about

25, 50, 100, 200, 500, 1000, or more amino acid, to an amino acid sequence encoded by a nucleotide sequence of or associated with a unigene cluster of Table 1 or Table 2. A polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e.g., human; rodent, e.g., rat, mouse, hamster; cow, pig, horse, sheep, or other mammal. A "colorectal cancer polypeptide" and a "colorectal cancer polynucleotide," include both naturally occurring or recombinant.

[52] Homology in this context means sequence similarity or identity, with identity being preferred. A preferred comparison for homology purposes is to compare the sequence containing sequencing errors to the correct sequence. This homology will be determined using standard techniques known in the art, including, but not limited to, the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, PNAS USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, WI), the Best Fit sequence program described by Devereux et al., Nucl. Acid Res. 12:387-395 (1984), preferably using the default settings, or by inspection.

[53] In a preferred embodiment, the sequences which are used to determine sequence identity or similarity are selected from the sequences set forth in Table 1 or Table 2. In one embodiment the sequences utilized herein are those set forth in Table 1 or Table 2. In another embodiment, the sequences are naturally occurring allelic variants of the sequences set forth in Table 1 or Table 2. In another embodiment, the sequences are sequence variants as further described herein.

[54] The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (*see, e.g.*, NCBI web site <http://www.ncbi.nlm.nih.gov/BLAST/> or the like). Such sequences are then said to be "substantially identical." This definition also refers to, or may be applied to, the complement of a test sequence. The definition also includes sequences that have deletions

and/or additions, as well as those that have substitutions, as well as naturally occurring, e.g., polymorphic or allelic variants, and man-made variants. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.

[55] For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

[56] A "comparison window", as used herein, includes reference to a segment of one of the number of contiguous positions selected from the group consisting typically of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (*see, e.g., Current Protocols in Molecular Biology* (Ausubel *et al.*, eds. 1995 supplement)).

[57] Preferred examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include the BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.*, *Nuc. Acids Res.* 25:3389-3402 (1977) and Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990). BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>).

This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*).

5 These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, e.g., for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino
10 acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences)
15 uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1989)) alignments (B) of
20 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

[58] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, *Proc. Nat'l. Acad. Sci. USA* 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a
25 match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001. Log values may be large negative numbers, e.g., 5, 10, 20, 30, 40, 40, 70, 90, 110, 150, 170,
30 etc.

[59] In one embodiment, the nucleic acid homology is determined through hybridization studies. Thus, for example, nucleic acids which hybridize under high stringency to the nucleic acid sequences which encode the peptides identified in Table 1 or Table 2, or their complements, are considered a colorectal cancer sequence. High stringency

conditions are known in the art; see for example Maniatis et al., *Molecular Cloning: A Laboratory Manual*, 2d Edition, 1989, and *Short Protocols in Molecular Biology*, ed. Ausubel, et al., both of which are hereby incorporated by reference. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, *Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Acid Probes*, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength pH. The T_m is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T_m , 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g. 10 to 50 nucleotides) and at least about 60°C for long probes (e.g. greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.

[60] In another embodiment, less stringent hybridization conditions are used; for example, moderate or low stringency conditions may be used, as are known in the art; see Maniatis and Ausubel, *supra*, and Tijssen, *supra*. For selective or specific hybridization, a positive signal is at least two times background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C.

[61] Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily

recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., and *Current Protocols in Molecular Biology*, ed. Ausubel, *et al.*

5 [62] For PCR, a temperature of about 36°C is typical for low stringency amplification, although annealing temperatures may vary between about 32°C and 48°C depending on primer length. For high stringency PCR amplification, a temperature of about 62°C is typical, although high stringency annealing temperatures can range from about 50°C to about 65°C, depending on the primer length and specificity. Typical cycle conditions for
10 both high and low stringency amplifications include a denaturation phase of 90°C - 95°C for 30 sec - 2 min., an annealing phase lasting 30 sec. - 2 min., and an extension phase of about 72°C for 1 - 2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis *et al.*, *PCR Protocols, A Guide to Methods and Applications* (1990).

15 [63] In addition, the colorectal cancer nucleic acid sequences of the invention are fragments of larger genes, i.e. they are nucleic acid segments. "Genes" in this context includes coding regions, non-coding regions, and mixtures of coding and non-coding regions. Accordingly, as will be appreciated by those in the art, using the sequences provided herein, additional sequences of the colorectal cancer genes can be obtained, using techniques
20 well known in the art for cloning either longer sequences or the full length sequences; see Maniatis *et al.*, and Ausubel, *et al.*, *supra*, hereby expressly incorporated by reference.

25 [64] An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described above. Yet another indication that two nucleic acid sequences are substantially identical is that the
30 same primers can be used to amplify the sequences.

 [65] Once the colorectal cancer nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire colorectal cancer nucleic acid. Once isolated from its natural source, e.g., contained within a plasmid or other vector

or excised therefrom as a linear nucleic acid segment, the recombinant colorectal cancer nucleic acid can be further-used as a probe to identify and isolate other colorectal cancer nucleic acids, for example additional coding regions. It can also be used as a "precursor" nucleic acid to make modified or variant colorectal cancer nucleic acids and proteins.

5 [66] The colorectal cancer nucleic acids of the present invention are used in several ways. In a first embodiment, nucleic acid probes to the colorectal cancer nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, for example for gene therapy and/or antisense applications. Alternatively, the colorectal cancer nucleic acids that include coding regions of
10 colorectal cancer proteins can be put into expression vectors for the expression of colorectal cancer proteins, again either for screening purposes or for administration to a patient.

15 [67] In a preferred embodiment, nucleic acid probes to colorectal cancer nucleic acids (both the nucleic acid sequences encoding peptides outlined in the Table 1 or Table 2 and/or the complements thereof) are made. The nucleic acid probes attached to the biochip are designed to be substantially complementary to the colorectal cancer nucleic acids, i.e. the target sequence (either the target sequence of the sample or to other probe sequences, for example in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by "substantially complementary" herein is meant
20 that the probes are sufficiently complementary to the target sequences to hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein.

25 [68] A nucleic acid probe is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about 80 bases
30 being preferred, and from about 30 to about 50 bases being particularly preferred. That is, generally whole genes are not used. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases.

 [69] In a preferred embodiment, more than one probe per sequence is used, with either overlapping probes or probes to different sections of the target being used. That

is, two, three, four or more probes, with three being preferred, are used to build in a redundancy for a particular target. The probes can be overlapping (i.e. have some sequence in common), or separate.

[70] As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By "immobilized" and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can be covalent or non-covalent. By "non-covalent binding" and grammatical equivalents herein is meant one or more of either electrostatic, hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By "covalent binding" and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions.

[71] In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.

[72] The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant any material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, Teflon, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silica-based materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably fluoresce. A preferred substrate is described in copending application entitled

Reusable Low Fluorescent Plastic Biochip, U.S. Application Serial No. 09/270,214, filed March 15, 1999, herein incorporated by reference in its entirety.

[73] Generally the substrate is planar, although as will be appreciated by those in the art, other configurations of substrates may be used as well. For example, the probes may be placed on the inside surface of a tube, for flow-through sample analysis to minimize sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics.

[74] In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, for example, the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, for example using linkers as are known in the art; for example, homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200, incorporated herein by reference). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.

[75] In this embodiment, the oligonucleotides are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5' or 3' terminus may be attached to the solid support, or attachment may be via an internal nucleoside.

[76] In an additional embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.

[01] Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U.S. Patent Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affimetrix GeneChip™ technology.

[78] In a preferred embodiment, colorectal cancer nucleic acids encoding colorectal cancer proteins are used to make a variety of expression vectors to express colorectal cancer proteins which can then be used in screening assays, as described below. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the colorectal cancer protein. The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

[79] Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. The transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the colorectal cancer protein; for example, transcriptional and translational regulatory nucleic acid sequences from *Bacillus* are preferably used to express the colorectal cancer protein in *Bacillus*. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.

[80] In general, the transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.

[81] Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid

promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention.

[82] In addition, the expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art.

[83] In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

[84] The colorectal cancer proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a colorectal cancer protein, under the appropriate conditions to induce or cause expression of the colorectal cancer protein. The conditions appropriate for colorectal cancer protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.

[85] Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are *Drosophila melanogaster* cells, *Saccharomyces cerevisiae* and other yeasts, *E. coli*, *Bacillus subtilis*, Sf9 cells, C129 cells, 293 cells, *Neurospora*, BHK, CHO, COS, HeLa cells, THP1 cell line (a macrophage cell line) and human cells and cell lines.

[86] In a preferred embodiment, the colorectal cancer proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include retroviral systems. A preferred expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are

hereby expressly incorporated by reference. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter. Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenylation signals include those derived from SV40.

[87] The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used. Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

[88] In a preferred embodiment, colorectal cancer proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; for example, the tac promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal peptide sequence that provides for secretion of the colorectal cancer protein in bacteria. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for *Bacillus subtilis*, *E. coli*, *Streptococcus cremoris*, and *Streptococcus lividans*, among others. The bacterial expression vectors are transformed

into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others.

5 [89] In one embodiment, colorectal cancer proteins are produced in insect cells. Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.

10 [90] In a preferred embodiment, colorectal cancer protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for *Saccharomyces cerevisiae*, *Candida albicans* and *C. maltosa*, *Hansenula polymorpha*, *Kluyveromyces fragilis* and *K. lactis*, *Pichia guilliermondii* and *P. pastoris*, *Schizosaccharomyces pombe*, and *Yarrowia lipolytica*.

15 [91] The colorectal cancer protein may also be made as a fusion protein, using techniques well known in the art. Thus, for example, for the creation of monoclonal antibodies, if the desired epitope is small, the colorectal cancer protein may be fused to a carrier protein to form an immunogen. Alternatively, the colorectal cancer protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the colorectal cancer protein is a colorectal cancer peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes.

20 [92] In one embodiment, the colorectal cancer nucleic acids, proteins and antibodies of the invention are labeled. By "labeled" herein is meant that a compound has at least one element, isotope or chemical compound attached to enable the detection of the compound. In general, labels fall into three classes: a) isotopic labels, which may be radioactive or heavy isotopes; b) immune labels, which may be antibodies or antigens; and c) colored or fluorescent dyes. The labels may be incorporated into the colorectal cancer nucleic acids, proteins and antibodies at any position. For example, the label should be capable of producing, either directly or indirectly, a detectable signal. The detectable moiety may be a radioisotope, such as ³H, ¹⁴C, ³²P, ³⁵S, or ¹²⁵I, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the label may be employed, including those methods described by Hunter et al., *Nature*, 144:945 (1962); David et al., *Biochemistry*, 13:1014 (1974); Pain et al., *J. Immunol. Meth.*, 40:219 (1981); and Nygren, J. *Histochem. and Cytochem.*, 30:407 (1982).

30 [93] Accordingly, the present invention also provides colorectal cancer protein sequences. A colorectal cancer protein of the present invention may be identified in

several ways. "Protein" in this sense includes proteins, polypeptides, and peptides terms which are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer.

[94] As will be appreciated by those in the art, the nucleic acid sequences of the invention can be used to generate protein sequences. There are a variety of ways to do this, including cloning the entire gene and verifying its frame and amino acid sequence, or by comparing it to known sequences to search for homology to provide a frame, assuming the colorectal cancer protein has homology to some protein in the database being used. Generally, the nucleic acid sequences are input into a program that will search all three frames for homology. This is done in a preferred embodiment using the following NCBI Advanced BLAST parameters. The program is blastx or blastn. The database is nr. The input data is as "Sequence in FASTA format". The organism list is "none". The "expect" is 10; the filter is default. The "descriptions" is 500, the "alignments" is 500, and the "alignment view" is pairwise. The "Query Genetic Codes" is standard (1). The matrix is BLOSUM62; gap existence cost is 11, per residue gap cost is 1; and the lambda ratio is .85 default. This results in the generation of a putative protein sequence.

[95] Also included within one embodiment of colorectal cancer proteins are amino acid variants of the naturally occurring sequences, as determined herein. Preferably, the variants are preferably greater than about 75% homologous to the wild-type sequence, more preferably greater than about 80%, even more preferably greater than about 85% and most preferably greater than 90%. In some embodiments the homology will be as high as about 93 to 95 or 98%. As for nucleic acids, homology in this context means sequence similarity or identity, with identity being preferred. This homology will be determined using standard techniques known in the art as are outlined above for the nucleic acid homologies.

[96] Colorectal cancer proteins of the present invention may be shorter or longer than the wild type amino acid sequences. Thus, in a preferred embodiment, included within the definition of colorectal cancer proteins are portions or fragments of the wild type sequences. herein. In addition, as outlined above, the colorectal cancer nucleic acids of the invention may be used to obtain additional coding regions, and thus additional protein sequence, using techniques known in the art.

[97] In a preferred embodiment, the colorectal cancer proteins are derivative or variant colorectal cancer proteins as compared to the wild-type sequence. That is, as outlined more fully below, the derivative colorectal cancer peptide will contain at least one amino acid substitution, deletion or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion or deletion may occur at any residue within the colorectal cancer peptide.

[98] Also included in an embodiment of colorectal cancer proteins of the present invention are amino acid sequence variants. These variants fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the colorectal cancer protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant colorectal cancer protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the colorectal cancer protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.

[99] While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed colorectal cancer variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example, M13 primer mutagenesis and PCR mutagenesis. Screening of the mutants is done using assays of colorectal cancer protein activities.

[100] Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger.

[101] Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain

circumstances. When small alterations in the characteristics of the colorectal cancer protein are desired, substitutions are generally made in accordance with the following chart:

Chart I

Original Residue	Exemplary Substitutions
Ala	Ser
Arg	Lys
Asn	Gln, His
Asp	Glu
Cys	Ser
Gln	Asn
Glu	Asp
Gly	Pro
His	Asn, Gln
Ile	Leu, Val
Leu	Ile, Val
Lys	Arg, Gln, Glu
Met	Leu, Ile
Phe	Met, Leu, Tyr
Ser	Thr
Thr	Ser
Trp	Tyr
Tyr	Trp, Phe
Val	Ile, Leu

[102] Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those shown in Chart I. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, e.g. seryl or threonyl is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue

having an electropositive side chain, e.g. lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g. glycine.

[103] The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analogue, although variants also are selected to modify the characteristics of the colorectal cancer proteins as needed. Alternatively, the variant may be designed such that the biological activity of the colorectal cancer protein is altered. For example, glycosylation sites may be altered or removed.

[104] Covalent modifications of colorectal cancer polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a colorectal cancer polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of a colorectal cancer polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking colorectal cancer to a water-insoluble support matrix or surface for use in the method for purifying anti-colorectal cancer antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxy-succinimide esters, for example, esters with 4-azido-salicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis-(succinimidyl-propionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)-dithio]propiolate.

[01] Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl, threonyl or tyrosyl residues, methylation of the α -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

[106] Another type of covalent modification of the colorectal cancer polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence colorectal cancer polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence colorectal cancer polypeptide.

[107] Addition of glycosylation sites to colorectal cancer polypeptides may be accomplished by altering the amino acid sequence thereof. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence colorectal cancer polypeptide (for O-linked glycosylation sites). The colorectal cancer amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the colorectal cancer polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

[108] Another means of increasing the number of carbohydrate moieties on the colorectal cancer polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, colorectal cancer Crit. Rev. Biochem., pp. 259-306 (1981).

[109] Removal of carbohydrate moieties present on the colorectal cancer polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

[110] Another type of covalent modification of colorectal cancer comprises linking the colorectal cancer polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

[111] colorectal cancer polypeptides of the present invention may also be modified in a way to form chimeric molecules comprising a colorectal cancer polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of a colorectal cancer polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the colorectal cancer polypeptide. The presence of such epitope-tagged forms of a colorectal cancer polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the colorectal cancer polypeptide to be readily purified by affinity purification

using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of a colorectal cancer polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule.

[112] Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; tubulin epitope peptide [Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].

[113] Also included with the definition of colorectal cancer protein in one embodiment are other colorectal cancer proteins of the colorectal cancer family, and colorectal cancer proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related colorectal cancer proteins from humans or other organisms. As will be appreciated by those in the art, particularly useful probe and/or PCR primer sequences include the unique areas of the colorectal cancer nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. The conditions for the PCR reaction are well known in the art.

[114] In addition, as is outlined herein, colorectal cancer proteins can be made that are longer than those depicted in the Table 1 or Table 2 for example, by the elucidation of additional sequences, the addition of epitope or purification tags, the addition of other fusion sequences, etc.

[115] Colorectal cancer proteins may also be identified as being encoded by colorectal cancer nucleic acids. Thus, colorectal cancer proteins are encoded by nucleic acids that will hybridize to the sequences of the sequence listings, or their complements, as outlined herein.

[116] In a preferred embodiment, when the colorectal cancer protein is to be used to generate antibodies, for example for immunotherapy, the colorectal cancer protein should share at least one epitope or determinant with the full length protein. By "epitope" or "determinant" herein is meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller colorectal cancer protein will be able to bind to the full length protein. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity. In a preferred embodiment, the epitope is selected from a peptide encoded by a nucleic acid of Table 1. In another preferred embodiment, the epitope is selected from the CBF9 peptide sequence shown in Table 2.

[117] In one embodiment, the term "antibody" includes antibody fragments, as are known in the art, including Fab, Fab2, single chain antibodies (Fv for example), chimeric antibodies, etc., either produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA technologies.

[118] Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the CBF9 peptide of Table 2, or a peptide encoded by a nucleic acid of Table 1 or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

[119] The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include the CBF9 polypeptide or a peptide encoded by a

nucleic acid of Table 1 or a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

[120] In one embodiment, the antibodies are bispecific antibodies.

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for a colorectal cancer protein or a fragment thereof, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit, preferably one that is tumor specific.

[121] In a preferred embodiment, the antibodies to colorectal cancer are capable of reducing or eliminating the biological function of colorectal cancer, as is described below. That is, the addition of anti-colorectal cancer antibodies (either polyclonal or preferably monoclonal) to colorectal cancer (or cells containing colorectal cancer) may reduce or eliminate the colorectal cancer activity. Generally, at least a 25% decrease in activity is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.

[122] In a preferred embodiment the antibodies to the colorectal cancer proteins are humanized antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired

specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise
5 substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et
10 al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-329 (1988); and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992)].

[123] Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred
15 to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeven et al., *Science*, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR
20 sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

[124] Human antibodies can also be produced using various techniques
25 known in the art, including phage display libraries [Hoogenboom and Winter, *J. Mol. Biol.*, 227:381 (1991); Marks et al., *J. Mol. Biol.*, 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, p. 77 (1985) and
30 Boerner et al., *J. Immunol.*, 147(1):86-95 (1991)]. Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire.

This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10, 779-783 (1992); Lonberg et al., Nature 368 856-859 (1994); Morrison, Nature 368, 812-13 (1994); Fishwild et al., Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14, 826 (1996); Lonberg and Huszar, Intern. Rev. Immunol. 13 65-93 (1995).

[125] By immunotherapy is meant treatment of colorectal cancer with an antibody raised against colorectal cancer proteins. As used herein, immunotherapy can be passive or active. Passive immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. As appreciated by one of ordinary skill in the art, the antigen may be provided by injecting a polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and under conditions for expression of the antigen.

[126] In a preferred embodiment the colorectal cancer proteins against which antibodies are raised are secreted proteins as described above. Without being bound by theory, antibodies used for treatment, bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted colorectal cancer protein.

[01] In another preferred embodiment, the colorectal cancer protein to which antibodies are raised is a transmembrane protein. Without being bound by theory, antibodies used for treatment, bind the extracellular domain of the colorectal cancer protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules. The antibody may cause down-regulation of the transmembrane colorectal cancer protein. As will be appreciated by one of ordinary skill in the art, the antibody may be a competitive, non-competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the colorectal cancer protein. The antibody is also an antagonist of the colorectal cancer protein. Further, the antibody prevents activation of the transmembrane colorectal cancer protein. In one aspect, when the antibody prevents the binding of other molecules to the colorectal cancer protein, the antibody prevents growth of the cell. The antibody also sensitizes the cell to cytotoxic agents, including, but not limited to TNF- α , TNF- β , IL-1, INF- γ and IL-2, or chemotherapeutic agents including 5FU, vinblastine,

actinomycin D, cisplatin, methotrexate, and the like. In some instances the antibody belongs to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity. Thus, colorectal cancer is treated by administering to a patient antibodies directed against the transmembrane colorectal cancer protein.

5 [128] In another preferred embodiment, the antibody is conjugated to a therapeutic moiety. In one aspect the therapeutic moiety is a small molecule that modulates the activity of the colorectal cancer protein. In another aspect the therapeutic moiety modulates the activity of molecules associated with or in close proximity to the colorectal cancer protein. The therapeutic moiety may inhibit enzymatic activity such as protease or
10 protein kinase activity associated with colorectal cancer .

[129] In a preferred embodiment, the therapeutic moiety may also be a cytotoxic agent. In this method, targeting the cytotoxic agent to tumor tissue or cells, results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with colorectal cancer . Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their
15 corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against colorectal cancer proteins, or binding of a radionuclide to a chelating agent that has been covalently
20 attached to the antibody. Targeting the therapeutic moiety to transmembrane colorectal cancer proteins not only serves to increase the local concentration of therapeutic moiety in the colorectal cancer afflicted area, but also serves to reduce deleterious side effects that may be associated with the therapeutic moiety.

[130] In another preferred embodiment, the colorectal cancer protein against
25 which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated to a protein which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the colorectal cancer protein can be targeted within a cell, i.e., the nucleus, an antibody thereto contains a signal for that target
30 localization, i.e., a nuclear localization signal.

[131] The colorectal cancer antibodies of the invention specifically bind to colorectal cancer proteins. By "specifically bind" herein is meant that the antibodies bind to the protein with a binding constant in the range of at least 10^{-4} - 10^{-6} M^{-1} , with a preferred range being 10^{-7} - 10^{-9} M^{-1} .

[132] In a preferred embodiment, the colorectal cancer protein is purified or isolated after expression. Colorectal cancer proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the colorectal cancer protein may be purified using a standard anti-colorectal cancer antibody column. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes, R., Protein Purification, Springer-Verlag, NY (1982). The degree of purification necessary will vary depending on the use of the colorectal cancer protein. In some instances no purification will be necessary.

[133] Once expressed and purified if necessary, the colorectal cancer proteins and nucleic acids are useful in a number of applications.

[134] In one aspect, the expression levels of genes are determined for different cellular states in the colorectal cancer phenotype; that is, the expression levels of genes in normal colon tissue and in colorectal cancer tissue (and in some cases, for varying severities of colorectal cancer that relate to prognosis, as outlined below) are evaluated to provide expression profiles. An expression profile of a particular cell state or point of development is essentially a "fingerprint" of the state; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is unique to the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Then, diagnosis may be done or confirmed: does tissue from a particular patient have the gene expression profile of normal or colorectal cancer tissue.

[01] "Differential expression," or grammatical equivalents as used herein, refers to both qualitative as well as quantitative differences in the genes' temporal and/or cellular expression patterns within and among the cells. Thus, a differentially expressed gene can qualitatively have its expression altered, including an activation or inactivation, in, for example, normal versus colorectal cancer tissue. That is, genes may be turned on or turned off in a particular state, relative to another state. As is apparent to the skilled artisan, any comparison of two or more states can be made. Such a qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard

techniques in one such state or cell type, but is not detectable in both. Alternatively, the determination is quantitative in that expression is increased or decreased; that is, the expression of the gene is either upregulated, resulting in an increased amount of transcript, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip™ expression arrays, Lockhart, Nature Biotechnology, 14:1675-1680 (1996), hereby expressly incorporated by reference. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, Northern analysis and RNase protection. As outlined above, preferably the change in expression (i.e. upregulation or downregulation) is at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably, at least about 200%, with from 300 to at least 1000% being especially preferred.

[136] As will be appreciated by those in the art, this may be done by evaluation at either the gene transcript, or the protein level; that is, the amount of gene expression may be monitored using nucleic acid probes to the DNA or RNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, for example through the use of antibodies to the colorectal cancer protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc. Thus, the proteins corresponding to colorectal cancer genes, i.e. those identified as being important in a colorectal cancer phenotype, can be evaluated in a colorectal cancer diagnostic test.

[137] In a preferred embodiment, gene expression monitoring is done and a number of genes, i.e. an expression profile, is monitored simultaneously, although multiple protein expression monitoring can be done as well. Similarly, these assays may be done on an individual basis as well.

[138] In this embodiment, the colorectal cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of colorectal cancer sequences in a particular cell. The assays are further described below in the example.

[139] In a preferred embodiment nucleic acids encoding the colorectal cancer protein are detected. Although DNA or RNA encoding the colorectal cancer protein may be detected, of particular interest are methods wherein the mRNA encoding a colorectal cancer protein is detected. The presence of mRNA in a sample is an indication that the colorectal cancer gene has been transcribed to form the mRNA, and suggests that the protein

is expressed. Probes to detect the mRNA can be any nucleotide/deoxynucleotide probe that is complementary to and base pairs with the mRNA and includes but is not limited to oligonucleotides, cDNA or RNA. Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be
5 examined on a solid support such as nylon membranes and hybridizing the probe with the sample. Following washing to remove the non-specifically bound probe, the label is detected. In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following
10 washing to remove the non-specifically bound probe, the label is detected. For example a digoxigenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding a colorectal cancer protein is detected by binding the digoxigenin with an anti-digoxigenin secondary antibody and developed with nitro blue tetrazolium and 5-bromo-4-chloro-3-indoyl phosphate.

[140] In a preferred embodiment, any of the three classes of proteins as described herein (secreted, transmembrane or intracellular proteins) are used in diagnostic assays. The colorectal cancer proteins, antibodies, nucleic acids, modified proteins and cells containing colorectal cancer sequences are used in diagnostic assays. This can be done on an individual gene or corresponding polypeptide level. In a preferred embodiment, the
15 expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes and/or corresponding polypeptides.

[141] As described and defined herein, colorectal cancer proteins, including intracellular, transmembrane or secreted proteins, find use as markers of colorectal cancer .

25 Detection of these proteins in putative colorectal cancer tissue or patients allows for a determination or diagnosis of colorectal cancer . Numerous methods known to those of ordinary skill in the art find use in detecting colorectal cancer . In one embodiment, antibodies are used to detect colorectal cancer proteins. A preferred method separates proteins from a sample or patient by electrophoresis on a gel (typically a denaturing and
30 reducing protein gel, but may be any other type of gel including isoelectric focusing gels and the like). Following separation of proteins, the colorectal cancer protein is detected by immunoblotting with antibodies raised against the colorectal cancer protein. Methods of immunoblotting are well known to those of ordinary skill in the art.

[142] In another preferred method, antibodies to the colorectal cancer protein find use in in situ imaging techniques. In this method cells are contacted with from one to many antibodies to the colorectal cancer protein(s). Following washing to remove non-specific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the colorectal cancer protein(s) contains a detectable label. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of colorectal cancer proteins. As will be appreciated by one of ordinary skill in the art, numerous other histological imaging techniques are useful in the invention.

[143] In a preferred embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method.

[144] In another preferred embodiment, antibodies find use in diagnosing colorectal cancer from blood samples. As previously described, certain colorectal cancer proteins are secreted/circulating molecules. Blood samples, therefore, are useful as samples to be probed or tested for the presence of secreted colorectal cancer proteins. Antibodies can be used to detect the colorectal cancer by any of the previously described immunoassay techniques including ELISA, immunoblotting (Western blotting), immunoprecipitation, BIACORE technology and the like, as will be appreciated by one of ordinary skill in the art.

[145] In a preferred embodiment, in situ hybridization of labeled colorectal cancer nucleic acid probes to tissue arrays is done. For example, arrays of tissue samples, including colorectal cancer tissue and/or normal tissue, are made. In situ hybridization as is known in the art can then be done.

[146] It is understood that when comparing the fingerprints between an individual and a standard, the skilled artisan can make a diagnosis as well as a prognosis. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis.

[147] In a preferred embodiment, the colorectal cancer proteins, antibodies, nucleic acids, modified proteins and cells containing colorectal cancer sequences are used in prognosis assays. As above, gene expression profiles can be generated that correlate to colorectal cancer severity, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of genes being preferred. As above, the colorectal

cancer probes are attached to biochips for the detection and quantification of colorectal cancer sequences in a tissue or patient. The assays proceed as outlined for diagnosis.

[148] In a preferred embodiment, any of the three classes of proteins as described herein are used in drug screening assays. The colorectal cancer proteins, antibodies, nucleic acids, modified proteins and cells containing colorectal cancer sequences are used in drug screening assays or by evaluating the effect of drug candidates on a "gene expression profile" or expression profile of polypeptides. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, Zlokarnik, et al., Science 279, 84-8 (1998), Heid, 1996 #69.

[149] In a preferred embodiment, the colorectal cancer proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified colorectal cancer proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the colorectal cancer phenotype. As above, this can be done on an individual gene level or by evaluating the effect of drug candidates on a "gene expression profile". In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, see Zlokarnik, supra.

[150] Having identified the differentially expressed genes herein, a variety of assays may be executed. In a preferred embodiment, assays may be run on an individual gene or protein level. That is, having identified a particular gene as up regulated in colorectal cancer, candidate bioactive agents may be screened to modulate this gene's response; preferably to down regulate the gene, although in some circumstances to up regulate the gene. "Modulation" thus includes both an increase and a decrease in gene expression. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tumor tissue, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4 fold increase in tumor compared to normal tissue, a decrease of about four fold is desired; a 10 fold decrease in tumor compared to normal tissue gives a 10 fold increase in expression for a candidate agent is desired.

[151] As will be appreciated by those in the art, this may be done by evaluation at either the gene or the protein level; that is, the amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or,

alternatively, the gene product itself can be monitored, for example through the use of antibodies to the colorectal cancer protein and standard immunoassays.

[152] In a preferred embodiment, gene expression monitoring is done and a number of genes, i.e. an expression profile, is monitored simultaneously, although multiple protein expression monitoring can be done as well.

[153] In this embodiment, the colorectal cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of colorectal cancer sequences in a particular cell. The assays are further described below.

[154] Generally, in a preferred embodiment, a candidate bioactive agent is added to the cells prior to analysis. Moreover, screens are provided to identify a candidate bioactive agent which modulates colorectal cancer, modulates colorectal cancer proteins, binds to a colorectal cancer protein, or interferes between the binding of a colorectal cancer protein and an antibody.

[155] The term "candidate bioactive agent" or "drug candidate" or grammatical equivalents as used herein describes any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for bioactive agents that are capable of directly or indirectly altering either the colorectal cancer phenotype or the expression of a colorectal cancer sequence, including both nucleic acid sequences and protein sequences. In preferred embodiments, the bioactive agents modulate the expression profiles, or expression profile nucleic acids or proteins provided herein. In a particularly preferred embodiment, the candidate agent suppresses a colorectal cancer phenotype, for example to a normal colon tissue fingerprint. Similarly, the candidate agent preferably suppresses a severe colorectal cancer phenotype. Generally a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.

[156] In one aspect, a candidate agent will neutralize the effect of a colorectal cancer protein. By "neutralize" is meant that activity of a protein is either inhibited or counter acted against so as to have substantially no effect on a cell.

[157] Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Preferred small molecules are less than 2000, or less than 1500 or less than 1000 or less than 500 D. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly

hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides.

[158] Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification to produce structural analogs.

[159] In a preferred embodiment, the candidate bioactive agents are proteins. By "protein" herein is meant at least two covalently attached amino acids, which includes proteins, polypeptides, oligopeptides and peptides. The protein may be made up of naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures. Thus "amino acid", or "peptide residue", as used herein means both naturally occurring and synthetic amino acids. For example, homo-phenylalanine, citrulline and noreleucine are considered amino acids for the purposes of the invention. "Amino acid" also includes imino acid residues such as proline and hydroxyproline. The side chains may be in either the (R) or the (S) configuration. In the preferred embodiment, the amino acids are in the (S) or L-configuration. If non-naturally occurring side chains are used, non-amino acid substituents may be used, for example to prevent or retard in vivo degradations.

[160] In a preferred embodiment, the candidate bioactive agents are naturally occurring proteins or fragments of naturally occurring proteins. Thus, for example, cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of procaryotic and eucaryotic proteins may be made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially preferred.

[161] In a preferred embodiment, the candidate bioactive agents are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or "biased" random peptides. By "randomized" or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.

[162] In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, for example, of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.

[163] In a preferred embodiment, the candidate bioactive agents are nucleic acids, as defined above.

[164] As described above generally for proteins, nucleic acid candidate bioactive agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. For example, digests of procaryotic or eucaryotic genomes may be used as is outlined above for proteins.

[165] In a preferred embodiment, the candidate bioactive agents are organic chemical moieties, a wide variety of which are available in the literature.

[166] After the candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing the target sequences to be analyzed is added to the biochip. If required, the target sequence is prepared using known techniques. For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR occurring as needed, as will be appreciated by those in the art. For example, an in vitro transcription with labels

covalently attached to the nucleosides is done. Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5.

[167] In a preferred embodiment, the target sequence is labeled with, for example, a fluorescent, a chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected. Alternatively, the label can be a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. As known in the art, unbound labeled streptavidin is removed prior to analysis.

[168] As will be appreciated by those in the art, these assays can be direct hybridization assays or can comprise "sandwich assays", which include the use of multiple probes, as is generally outlined in U.S. Patent Nos. 5,681,702, 5,597,909, 5,545,730, 5,594,117, 5,591,584, 5,571,670, 5,580,731, 5,571,670, 5,591,584, 5,624,802, 5,635,352, 5,594,118, 5,359,100, 5,124,246 and 5,681,697, all of which are hereby incorporated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.

[169] A variety of hybridization conditions may be used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allows formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to, temperature, formamide concentration, salt concentration, chaotropic salt concentration pH, organic solvent concentration, etc.

[170] These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Patent No. 5,681,697. Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.

[171] The reactions outlined herein may be accomplished in a variety of ways, as will be appreciated by those in the art. Components of the reaction may be added simultaneously, or sequentially, in any order, with preferred embodiments outlined below. In

addition, the reaction may include a variety of other reagents may be included in the assays. These include reagents like salts, buffers, neutral proteins, e.g. albumin, detergents, etc which may be used to facilitate optimal hybridization and detection, and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used, depending on the sample preparation methods and purity of the target.

[172] Once the assay is run, the data is analyzed to determine the expression levels, and changes in expression levels as between states, of individual genes, forming a gene expression profile.

[173] The screens are done to identify drugs or bioactive agents that modulate the colorectal cancer phenotype. Specifically, there are several types of screens that can be run. A preferred embodiment is in the screening of candidate agents that can induce or suppress a particular expression profile, thus preferably generating the associated phenotype. That is, candidate agents that can mimic or produce an expression profile in colorectal cancer similar to the expression profile of normal colon tissue is expected to result in a suppression of the colorectal cancer phenotype. Thus, in this embodiment, mimicking an expression profile, or changing one profile to another, is the goal.

[174] In a preferred embodiment, as for the diagnosis and prognosis applications, having identified the differentially expressed genes important in any one state, screens can be run to alter the expression of the genes individually. That is, screening for modulation of regulation of expression of a single gene can be done; that is, rather than try to mimic all or part of an expression profile, screening for regulation of individual genes can be done. Thus, for example, particularly in the case of target genes whose presence or absence is unique between two states, screening is done for modulators of the target gene expression.

[175] In a preferred embodiment, screening is done to alter the biological function of the expression product of the differentially expressed gene. Again, having identified the importance of a gene in a particular state, screening for agents that bind and/or modulate the biological activity of the gene product can be run as is more fully outlined below.

[176] Thus, screening of candidate agents that modulate the colorectal cancer phenotype either at the gene expression level or the protein level can be done.

[177] In addition screens can be done for novel genes that are induced in response to a candidate agent. After identifying a candidate agent based upon its ability to suppress a colorectal cancer expression pattern leading to a normal expression pattern, or

modulate a single colorectal cancer gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated colorectal cancer tissue reveals genes that are not
5 expressed in normal tissue or colorectal cancer tissue, but are expressed in agent treated tissue. These agent specific sequences can be identified and used by any of the methods described herein for colorectal cancer genes or proteins. In particular these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel
10 therapeutics to the treated colorectal cancer tissue sample.

[178] Thus, in one embodiment, a candidate agent is administered to a population of colorectal cancer cells, that thus has an associated colorectal cancer expression profile. By "administration" or "contacting" herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether
15 by uptake and intracellular action, or by action at the cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent (i.e. a peptide) may be put into a viral construct such as a retroviral construct and added to the cell, such that expression of the peptide agent is accomplished; see PCT US97/01019, hereby expressly incorporated by reference.

[179] Once the candidate agent has been administered to the cells, the cells can be washed if desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein.

[180] Thus, for example, colorectal cancer tissue may be screened for
25 agents that reduce or suppress the colorectal cancer phenotype. A change in at least one gene of the expression profile indicates that the agent has an effect on colorectal cancer activity. By defining such a signature for the colorectal cancer phenotype, screens for new drugs that alter the phenotype can be devised. With this approach, the drug target need not be known and need not be represented in the original expression screening platform, nor does
30 the level of transcript for the target protein need to change.

[181] In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of either the expression of the gene or the gene product itself can be done. The gene products of

differentially expressed genes are sometimes referred to herein as "colorectal cancer modulator proteins". The colorectal cancer modulator protein may be a fragment, or alternatively, be the full length protein to a fragment shown herein. Preferably, the colorectal cancer modulator protein is a fragment of approximately 14 to 24 amino acids long. More preferably the fragment is a soluble fragment.

[182] In a preferred embodiment, the fragment is charged and from the c-terminus. In one embodiment, the c-terminus of the fragment is kept as a free acid and the n-terminus is a free amine to aid in coupling, i.e., to cysteine. In another embodiment, the fragment is an internal peptide overlapping hydrophilic stretch the protein. In a preferred embodiment, the termini is blocked. In another preferred embodiment, the fragment is a novel fragment from the N-terminal. In one embodiment, the fragment excludes sequence outside of the N-terminal, in another embodiment, the fragment includes at least a portion of the N-terminal. "N-terminal" is used interchangeably herein with "N-terminus" which is further described above.

[183] In one embodiment the colorectal cancer proteins are conjugated to an immunogenic agent as discussed herein. In one embodiment the colorectal cancer protein is conjugated to BSA.

[184] Thus, in a preferred embodiment, screening for modulators of expression of specific genes can be done. This will be done as outlined above, but in general the expression of only one or a few genes are evaluated.

[185] In a preferred embodiment, screens are designed to first find candidate agents that can bind to differentially expressed proteins, and then these agents may be used in assays that evaluate the ability of the candidate agent to modulate differentially expressed activity. Thus, as will be appreciated by those in the art, there are a number of different assays which may be run; binding assays and activity assays.

[186] In a preferred embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more differentially expressed nucleic acids are made. In general, this is done as is known in the art. For example, antibodies are generated to the protein gene products, and standard immunoassays are run to determine the amount of protein present. Alternatively, cells comprising the colorectal cancer proteins can be used in the assays.

[187] Thus, in a preferred embodiment, the methods comprise combining a colorectal cancer protein and a candidate bioactive agent, and determining the binding of the candidate agent to the colorectal cancer protein. Preferred embodiments utilize the human

colorectal cancer protein, although other mammalian proteins may also be used, for example for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative colorectal cancer proteins may be used.

[188] Generally, in a preferred embodiment of the methods herein, the colorectal cancer protein or the candidate agent is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g. a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflon, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.

[189] In a preferred embodiment, the colorectal cancer protein is bound to the support, and a candidate bioactive agent is added to the assay. Alternatively, the candidate agent is bound to the support and the colorectal cancer protein is added. Novel binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

[190] The determination of the binding of the candidate bioactive agent to the colorectal cancer protein may be done in a number of ways. In a preferred embodiment, the candidate bioactive agent is labeled, and binding determined directly. For example, this

may be done by attaching all or a portion of the colorectal cancer protein to a solid support, adding a labeled candidate agent (for example a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as is known in the art.

5 **[191]** By "labeled" herein is meant that the compound is either directly or indirectly labeled with a label which provides a detectable signal, e.g. radioisotope, fluorescers, enzyme, antibodies, particles such as magnetic particles, chemiluminescers, or specific binding molecules, etc. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc. For the specific binding members, the
10 complementary member would normally be labeled with a molecule which provides for detection, in accordance with known procedures, as outlined above. The label can directly or indirectly provide a detectable signal.

[192] In some embodiments, only one of the components is labeled. For example, the proteins (or proteinaceous candidate agents) may be labeled at tyrosine
15 positions using ^{125}I , or with fluorophores. Alternatively, more than one component may be labeled with different labels; using ^{125}I for the proteins, for example, and a fluorophor for the candidate agents.

[193] In a preferred embodiment, the binding of the candidate bioactive agent is determined through the use of competitive binding assays. In this embodiment, the
20 competitor is a binding moiety known to bind to the target molecule (i.e. colorectal cancer), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding as between the bioactive agent and the binding moiety, with the binding moiety displacing the bioactive agent.

[194] In one embodiment, the candidate bioactive agent is labeled. Either
25 the candidate bioactive agent, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at any temperature which facilitates optimal activity, typically between 4 and 40°C. Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high through put screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is
30 generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

[195] In a preferred embodiment, the competitor is added first, followed by the candidate bioactive agent. Displacement of the competitor is an indication that the candidate bioactive agent is binding to the colorectal cancer protein and thus is capable of

binding to, and potentially modulating, the activity of the colorectal cancer protein. In this embodiment, either component can be labeled. Thus, for example, if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the candidate bioactive agent is labeled, the presence of the label on the support indicates displacement.

[196] In an alternative embodiment, the candidate bioactive agent is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the bioactive agent is bound to the colorectal cancer protein with a higher affinity. Thus, if the candidate bioactive agent is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate that the candidate agent is capable of binding to the colorectal cancer protein.

[197] In a preferred embodiment, the methods comprise differential screening to identify bioactive agents that are capable of modulating the activity of the colorectal cancer proteins. In this embodiment, the methods comprise combining a colorectal cancer protein and a competitor in a first sample. A second sample comprises a candidate bioactive agent, a colorectal cancer protein and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the colorectal cancer protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the colorectal cancer protein.

[198] Alternatively, a preferred embodiment utilizes differential screening to identify drug candidates that bind to the native colorectal cancer protein, but cannot bind to modified colorectal cancer proteins. The structure of the colorectal cancer protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect colorectal cancer bioactivity are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.

[199] Positive controls and negative controls may be used in the assays. Preferably all control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, all samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.

[200] A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in any order that provides for the requisite binding.

[201] Screening for agents that modulate the activity of colorectal cancer proteins may also be done. In a preferred embodiment, methods for screening for a bioactive agent capable of modulating the activity of colorectal cancer proteins comprise the steps of adding a candidate bioactive agent to a sample of colorectal cancer proteins, as above, and determining an alteration in the biological activity of colorectal cancer proteins.

"Modulating the activity of colorectal cancer " includes an increase in activity, a decrease in activity, or a change in the type or kind of activity present. Thus, in this embodiment, the candidate agent should both bind to colorectal cancer proteins (although this may not be necessary), and alter its biological or biochemical activity as defined herein. The methods include both in vitro screening methods, as are generally outlined above, and in vivo screening of cells for alterations in the presence, distribution, activity or amount of colorectal cancer proteins.

[202] Thus, in this embodiment, the methods comprise combining a colorectal cancer sample and a candidate bioactive agent, and evaluating the effect on colorectal cancer activity. By "colorectal cancer activity" or grammatical equivalents herein is meant one of the colorectal cancer 's biological activities, including, but not limited to, cell division, preferably in colon tissue, cell proliferation, tumor growth, transformation of cells. In one embodiment, colorectal cancer activity includes activation of a gene identified by a nucleic acid of Table 1. An inhibitor of colorectal cancer activity is the inhibition of any one or more colorectal cancer activities.

[203] In a preferred embodiment, the activity of the colorectal cancer protein is increased; in another preferred embodiment, the activity of the colorectal cancer protein is decreased. Thus, bioactive agents that are antagonists are preferred in some embodiments, and bioactive agents that are agonists may be preferred in other embodiments.

[204] In a preferred embodiment, the invention provides methods for screening for bioactive agents capable of modulating the activity of a colorectal cancer protein. The methods comprise adding a candidate bioactive agent, as defined above, to a cell comprising colorectal cancer proteins. Preferred cell types include almost any cell. The

cells contain a recombinant nucleic acid that encodes a colorectal cancer protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.

[205] In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, for example hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (i.e. cell-cell contacts). In another example, the determinations are determined at different stages of the cell cycle process.

[206] In this way, bioactive agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the colorectal cancer protein. In one embodiment, "colorectal cancer protein activity" as used herein includes at least one of the following: colorectal cancer activity, binding to the colorectal cancer protein, activation of the colorectal cancer protein or activation of substrates of the colorectal cancer protein by the colorectal cancer protein. In one embodiment, colorectal cancer activity is defined as the unregulated proliferation of colon tissue, or the growth of cancer in colon tissue. In one aspect, colorectal cancer activity as defined herein is related to the activity of the colorectal cancer protein in the upregulation of the colorectal cancer protein in colon cancer tissue.

[207] In another embodiment, colorectal cancer protein activity includes at least one of the following: colorectal cancer activity, binding to the CBF9 nucleic acid or poly peptide of Table 2 or binding to a nucleic acid of Table 1, or a peptide encoded by a nucleic acid of Table 1 or activation of substrates of the gene products identified by a nucleic acid of Table 1 or substrates of CBF9, which is shown in Table 2. In one aspect, colorectal cancer activity as defined herein is related to the activity of genes defined by the nucleic acids of Table 1 or of CBF9 as defined in Table 2, in colon cancer tissue.

[208] In one embodiment, a method of inhibiting colon cancer cell division is provided. The method comprises administration of a colorectal cancer inhibitor.

[209] In another embodiment, a method of inhibiting tumor growth is provided. The method comprises administration of a colorectal cancer inhibitor.

[210] In a further embodiment, methods of treating cells or individuals with cancer are provided. The method comprises administration of a colorectal cancer inhibitor.

[211] In one embodiment, a colorectal cancer inhibitor is an antibody as discussed above. In another embodiment, the colorectal cancer inhibitor is an antisense molecule. Antisense molecules as used herein include antisense or sense oligonucleotides

comprising a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for colorectal cancer molecules. A preferred antisense molecule is for the colorectal cancer sequences referenced in Table 1 or Table 2, or for a ligand or activator thereof. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, for example, Stein and Cohen (Cancer Res. 48:2659, 1988) and van der Krol et al. (BioTechniques 6:958, 1988).

[212] Antisense molecules may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a sense or an antisense oligonucleotide may be introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.

[213] The compounds having the desired pharmacological activity may be administered in a physiologically acceptable carrier to a host, as previously described. The agents may be administered in a variety of ways, orally, parenterally e.g., subcutaneously, intraperitoneally, intravascularly, etc. Depending upon the manner of introduction, the compounds may be formulated in a variety of ways. The concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt.%. The agents may be administered alone or in combination with other treatments, i.e., radiation.

[214] The pharmaceutical compositions can be prepared in various forms, such as granules, tablets, pills, suppositories, capsules, suspensions, salves, lotions and the like. Pharmaceutical grade organic or inorganic carriers and/or diluents suitable for oral and topical use can be used to make up compositions containing the therapeutically-active compounds. Diluents known to the art include aqueous media, vegetable and animal oils and fats. Stabilizing agents, wetting and emulsifying agents, salts for varying the osmotic

pressure or buffers for securing an adequate pH value, and skin penetration enhancers can be used as auxiliary agents.

[215] Without being bound by theory, it appears that the various colorectal cancer sequences are important in colorectal cancer. Accordingly, disorders based on mutant or variant colorectal cancer genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant colorectal cancer genes comprising determining all or part of the sequence of at least one endogeneous colorectal cancer genes in a cell. As will be appreciated by those in the art, this may be done using any number of sequencing techniques. In a preferred embodiment, the invention provides methods of identifying the colorectal cancer genotype of an individual comprising determining all or part of the sequence of at least one colorectal cancer gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced colorectal cancer gene to a known colorectal cancer gene, i.e. a wild-type gene.

[216] The sequence of all or part of the colorectal cancer gene can then be compared to the sequence of a known colorectal cancer gene to determine if any differences exist. This can be done using any number of known homology programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the colorectal cancer gene of the patient and the known colorectal cancer gene is indicative of a disease state or a propensity for a disease state, as outlined herein.

[217]

[218] In a preferred embodiment, the colorectal cancer genes are used as probes to determine the number of copies of the colorectal cancer gene in the genome.

[219] In another preferred embodiment colorectal cancer genes are used as probed to determine the chromosomal localization of the colorectal cancer genes. Information such as chromosomal localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in colorectal cancer gene loci.

[220] Thus, in one embodiment, methods of modulating colorectal cancer in cells or organisms are provided. In one embodiment, the methods comprise administering to a cell an anti-colorectal cancer antibody that reduces or eliminates the biological activity of an endogeneous colorectal cancer protein. Alternatively, the methods comprise administering to a cell or organism a recombinant nucleic acid encoding a colorectal cancer

protein. As will be appreciated by those in the art, this may be accomplished in any number of ways. In a preferred embodiment, for example when the colorectal cancer sequence is down-regulated in colorectal cancer, the activity of the colorectal cancer gene is increased by increasing the amount of colorectal cancer in the cell, for example by overexpressing the endogenous colorectal cancer or by administering a gene encoding the colorectal cancer sequence, using known gene-therapy techniques, for example. In a preferred embodiment, the gene therapy techniques include the incorporation of the endogenous gene using enhanced homologous recombination (EHR), for example as described in PCT/US93/03868, hereby incorporated by reference in its entirety. Alternatively, for example when the colorectal cancer sequence is up-regulated in colorectal cancer, the activity of the endogenous colorectal cancer gene is decreased, for example by the administration of a colorectal cancer antisense nucleic acid.

[221] In one embodiment, the colorectal cancer proteins of the present invention may be used to generate polyclonal and monoclonal antibodies to colorectal cancer proteins, which are useful as described herein. Similarly, the colorectal cancer proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify colorectal cancer antibodies. In a preferred embodiment, the antibodies are generated to epitopes unique to a colorectal cancer protein; that is, the antibodies show little or no cross-reactivity to other proteins. These antibodies find use in a number of applications. For example, the colorectal cancer antibodies may be coupled to standard affinity chromatography columns and used to purify colorectal cancer proteins. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the colorectal cancer protein.

[222] In one embodiment, a therapeutically effective dose of a colorectal cancer or modulator thereof is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces the effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. As is known in the art, adjustments for colorectal cancer degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art.

[223] A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals, and organisms. Thus the methods are

applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, and in the most preferred embodiment the patient is human.

[224] The administration of the colorectal cancer proteins and modulators of the present invention can be done in a variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, for example, in the treatment of wounds and inflammation, the colorectal cancer proteins and modulators may be directly applied as a solution or spray.

[225] The pharmaceutical compositions of the present invention comprise a colorectal cancer protein in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

[226] The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol. Additives are well known in the art, and are used in a variety of formulations.

[227] In a preferred embodiment, colorectal cancer proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above. Similarly,

colorectal cancer genes (including both the full-length sequence, partial sequences, or regulatory sequences of the colorectal cancer coding regions) can be administered in gene therapy applications, as is known in the art. These colorectal cancer genes can include antisense applications, either as gene therapy (i.e. for incorporation into the genome) or as antisense compositions, as will be appreciated by those in the art.

[228] In a preferred embodiment, colorectal cancer genes are administered as DNA vaccines, either single genes or combinations of colorectal cancer genes. Naked DNA vaccines are generally known in the art. Brower, Nature Biotechnology, 16:1304-1305 (1998).

[229] In one embodiment, colorectal cancer genes of the present invention are used as DNA vaccines. Methods for the use of genes as DNA vaccines are well known to one of ordinary skill in the art, and include placing a colorectal cancer gene or portion of a colorectal cancer gene under the control of a promoter for expression in a colorectal cancer patient. The colorectal cancer gene used for DNA vaccines can encode full-length colorectal cancer proteins, but more preferably encodes portions of the colorectal cancer proteins including peptides derived from the colorectal cancer protein. In a preferred embodiment a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from a colorectal cancer gene. Similarly, it is possible to immunize a patient with a plurality of colorectal cancer genes or portions thereof as defined herein. Without being bound by theory, expression of the polypeptide encoded by the DNA vaccine, cytotoxic T-cells, helper T-cells and antibodies are induced which recognize and destroy or eliminate cells expressing colorectal cancer proteins.

[230] In a preferred embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the colorectal cancer polypeptide encoded by the DNA vaccine. Additional or alternative adjuvants are known to those of ordinary skill in the art and find use in the invention.

[231] In another preferred embodiment colorectal cancer genes find use in generating animal models of colorectal cancer. As is appreciated by one of ordinary skill in the art, when the colorectal cancer gene identified is repressed or diminished in colorectal cancer tissue, gene therapy technology wherein antisense RNA directed to the colorectal cancer gene will also diminish or repress expression of the gene. An animal generated as such serves as an animal model of colorectal cancer that finds use in screening bioactive drug candidates. Similarly, gene knockout technology, for example as a result of

homologous recombination with an appropriate gene targeting vector, will result in the absence of the colorectal cancer protein. When desired, tissue-specific expression or knockout of the colorectal cancer protein may be necessary.

[232] It is also possible that the colorectal cancer protein is overexpressed in colorectal cancer. As such, transgenic animals can be generated that overexpress the colorectal cancer protein. Depending on the desired expression level, promoters of various strengths can be employed to express the transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the transgene. Animals generated by such methods find use as animal models of colorectal cancer and are additionally useful in screening for bioactive molecules to treat colorectal cancer.

EXAMPLES

[233] It is understood that the examples described herein in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All references and sequences of accession numbers cited herein are incorporated by reference in their entirety.

[234] Example 1

Tissue Preparation, Labeling Chips, and Fingerprints

[235] Purify total RNA from tissue using TRIzol Reagent

[236] Estimate tissue weight. Homogenize tissue samples in 1ml of TRIzol per 50mg of tissue using a Polytron 3100 homogenizer. The generator/probe used depends upon the tissue size. A generator that is too large for the amount of tissue to be homogenized will cause a loss of sample and lower RNA yield. Use the 20mm generator for tissue weighing more than 0.6g. If the working volume is greater than 2ml, then homogenize tissue in a 15ml polypropylene tube (Falcon 2059). Fill tube no greater than 10ml.

HOMOGENIZATION

[237] Before using generator, it should have been cleaned after last usage by running it through soapy H2O and rinsing thoroughly. Run through with EtOH to sterilize. Keep tissue frozen until ready. Add TRIzol directly to frozen tissue then homogenize.

[238] Following homogenization, remove insoluble material from the homogenate by centrifugation at 7500 x g for 15 min. in a Sorvall superspeed or 12,000 x g for 10 min. in an Eppendorf centrifuge at 4oC. Transfer the cleared homogenate to a new tube(s). The samples may be frozen now at -60 to -70oC (and kept for at least one month) or you may continue with the purification.

PHASE SEPARATION

[239] Incubate the homogenized samples for 5 minutes at room temperature.

[240] Add 0.2ml of chloroform per 1ml of TRIzol reagent used in the original homogenization.

[241] Cap tubes securely and shake tubes vigorously by hand (do not vortex) for 15 seconds.

[242] Incubate samples at room temp. for 2-3 minutes. Centrifuge samples at 6500rpm in a Sorvall superspeed for 30 min. at 4oC. (You may spin at up to 12,000 x g for 10 min. but you risk breaking your tubes in the centrifuge.)

RNA PRECIPITATION

[243] Transfer the aqueous phase to a fresh tube. Save the organic phase if isolation of DNA or protein is desired. Add 0.5ml of isopropyl alcohol per 1ml of TRIzol reagent used in the original homogenization. Cap tubes securely and invert to mix. Incubate samples at room temp. for 10 minutes. Centrifuge samples at 6500rpm in Sorvall for 20min. at 4oC.

RNA WASH

[244] Pour off the supernate. Wash pellet with cold 75% ethanol. Use 1ml of 75% ethanol per 1ml of TRIzol reagent used in the initial homogenization. Cap tubes securely and invert several times to loosen pellet. (Do not vortex). Centrifuge at <8000rpm (<7500 x g) for 5 minutes at 4oC.

[245] Pour off the wash. Carefully transfer pellet to an eppendorf tube (let it slide down the tube into the new tube and use a pipet tip to help guide it in if necessary). Depending on the volumes you are working with, you can decide what size tube(s) you want to precipitate the RNA in. When I tried leaving the RNA in the large 15ml tube, it took so long to dry (i.e. it did not dry) that I eventually had to transfer it to a smaller tube. Let pellet

dry in hood. Resuspend RNA in an appropriate volume of DEPC H₂O. Try for 2-5ug/ul.
Take absorbance readings.

5 [246] Purify poly A+ mRNA from total RNA or clean up total RNA with
Qiagen's RNeasy kit

10 [247] Purification of poly A+ mRNA from total RNA. Heat oligotex
suspension to 37oC and mix immediately before adding to RNA. Incubate Elution Buffer at
70oC. Warm up 2 x Binding Buffer at 65oC if there is precipitate in the buffer. Mix total
RNA with DEPC-treated water, 2 x Binding Buffer, and Oligotex according to Table 2 on
page 16 of the Oligotex Handbook. Incubate for 3 minutes at 65oC. Incubate for 10 minutes
at room temperature.

15 [248] Centrifuge for 2 minutes at 14,000 to 18,000 g. If centrifuge has a
"soft setting," then use it. Remove supernatant without disturbing Oligotex pellet. A little bit
of solution can be left behind to reduce the loss of Oligotex. Save sup until certain that
satisfactory binding and elution of poly A+ mRNA has occurred.

20 [249] Gently resuspend in Wash Buffer OW2 and pipet onto spin column.
Centrifuge the spin column at full speed (soft setting if possible) for 1 minute.

[250] Transfer spin column to a new collection tube and gently resuspend in
Wash Buffer OW2 and centrifuge as describe herein.

25 [251] Transfer spin column to a new tube and elute with 20 to 100 ul of
preheated (70oC) Elution Buffer. Gently resuspend Oligotex resin by pipetting up and down.
Centrifuge as above. Repeat elution with fresh elution buffer or use first eluate to keep the
elution volume low.

30 [252] Read absorbance, using diluted Elution Buffer as the blank.

[253] Before proceeding with cDNA synthesis, the mRNA must be
precipitated. Some component leftover or in the Elution Buffer from the Oligotex
purification procedure will inhibit downstream enzymatic reactions of the mRNA.

Ethanol Precipitation

[254] Add 0.4 vol. of 7.5 M NH₄OAc + 2.5 vol. of cold 100% ethanol. Precipitate at -20°C 1 hour to overnight (or 20-30 min. at -70°C). Centrifuge at 14,000-16,000 x g for 30 minutes at 4°C. Wash pellet with 0.5ml of 80% ethanol (-20°C) then centrifuge at 14,000-16,000 x g for 5 minutes at room temperature. Repeat 80% ethanol wash. Dry the last bit of ethanol from the pellet in the hood. (Do not speed vacuum). Suspend pellet in DEPC H₂O at 1µg/ul concentration.

Clean up total RNA using Qiagen's RNeasy kit

[255] Add no more than 100µg to an RNeasy column. Adjust sample to a volume of 100ul with RNase-free water. Add 350ul Buffer RLT then 250ul ethanol (100%) to the sample. Mix by pipetting (do not centrifuge) then apply sample to an RNeasy mini spin column. Centrifuge for 15 sec at >10,000rpm. If concerned about yield, re-apply flowthrough to column and centrifuge again.

[256] Transfer column to a new 2-ml collection tube. Add 500ul Buffer RPE and centrifuge for 15 sec at >10,000rpm. Discard flowthrough. Add 500ul Buffer RPE and centrifuge for 15 sec at >10,000rpm. Discard flowthrough then centrifuge for 2 min at maximum speed to dry column membrane. Transfer column to a new 1.5-ml collection tube and apply 30-50ul of RNase-free water directly onto column membrane. Centrifuge 1 min at >10,000rpm. Repeat elution.

[257] Take absorbance reading. If necessary, ethanol precipitate with ammonium acetate and 2.5X volume 100% ethanol.

[258] Make cDNA using Gibco's "SuperScript Choice System for cDNA Synthesis" kit

First Strand cDNA Synthesis

[259] Use 5µg of total RNA or 1µg of polyA+ mRNA as starting material. For total RNA, use 2ul of SuperScript RT. For polyA+ mRNA, use 1ul of SuperScript RT. Final volume of first strand synthesis mix is 20ul. RNA must be in a volume no greater than 10ul. Incubate RNA with 1ul of 100pmol T7-T24 oligo for 10 min at 70°C. On ice, add 7 ul of: 4ul 5X 1st Strand Buffer, 2ul of 0.1M DTT, and 1 ul of 10mM dNTP mix. Incubate at 37°C for 2 min then add SuperScript RT

Incubate at 37°C for 1 hour.

Second Strand Synthesis

Place 1st strand reactions on ice.

Add: 91ul DEPC H₂O

30ul 5X 2nd Strand Buffer

3ul 10mM dNTP mix

1ul 10U/ul E.coli DNA Ligase

4ul 10U/ul E.coli DNA Polymerase

1ul 2U/ul RNase H

5
10 [260] Make the above into a mix if there are more than 2 samples. Mix and incubate 2 hours at 16C.

[261] Add 2ul T4 DNA Polymerase. Incubate 5 min at 16C. Add 10ul of 0.5M EDTA

[262] Clean up cDNA

15 [263] Phenol:Chloroform:Isoamyl Alcohol (25:24:1) purification using Phase-Lock gel tubes:

[264] Centrifuge PLG tubes for 30 sec at maximum speed. Transfer cDNA mix to PLG tube. Add equal volume of phenol:chloroform:isamyl alcohol and shake vigorously (do not vortex). Centrifuge 5 minutes at maximum speed. Transfer top aqueous solution to a new tube. Ethanol precipitate: add 7.5X 5M NH₄Oac and 2.5X volume of 100% ethanol. Centrifuge immediately at room temp. for 20 min, maximum speed. Remove sup then wash pellet 2X with cold 80% ethanol. Remove as much ethanol wash as possible then let pellet air dry. Resuspend pellet in 3ul RNase-free water.

25 In vitro Transcription (IVT) and labeling with biotin

Pipet 1.5ul of cDNA into a thin-wall PCR tube.

Make NTP labeling mix:

Combine at room temperature: 2ul T7 10xATP (75mM) (Ambion)

30 2ul T7 10xGTP (75mM) (Ambion)

1.5ul T7 10xCTP (75mM) (Ambion)

1.5ul T7 10xUTP (75mM) (Ambion)

3.75ul 10mM Bio-11-UTP (Boehringer-Mannheim/Roche or Enzo)

3.75ul 10mM Bio-16-CTP (Enzo)

2ul 10x T7 transcription buffer (Ambion)

2ul 10x T7 enzyme mix (Ambion)

5 [265] Final volume of total reaction is 20ul. Incubate 6 hours at 37C in a PCR machine.

RNeasy clean-up of IVT product

[266] Follow previous instructions for RNeasy columns or refer to Qiagen's RNeasy protocol handbook.

10

[267] cRNA will most likely need to be ethanol precipitated. Resuspend in a volume compatible with the fragmentation step.

Fragmentation

15

[268] 15 ug of labeled RNA is usually fragmented. Try to minimize the fragmentation reaction volume; a 10 ul volume is recommended but 20 ul is all right. Do not go higher than 20 ul because the magnesium in the fragmentation buffer contributes to precipitation in the hybridization buffer.

20

[269] Fragment RNA by incubation at 94 C for 35 minutes in 1 x Fragmentation buffer.

25

5 x Fragmentation buffer:

200 mM Tris-acetate, pH 8.1

500 mM KOAc

150 mM MgOAc

30

[270] The labeled RNA transcript can be analyzed before and after fragmentation. Samples can be heated to 65C for 15 minutes and electrophoresed on 1% agarose/TBE gels to get an approximate idea of the transcript size range

Hybridization

[271] 200 ul (10ug cRNA) of a hybridization mix is put on the chip. If multiple hybridizations are to be done (such as cycling through a 5 chip set), then it is recommended that an initial hybridization mix of 300 ul or more be made.

Hybrization Mix: fragment labeled RNA (50ng/ul final conc.)

50 pM 948-b control oligo

1.5 pM BioB

5

5 pM BioC

25 pM BioD

100 pM CRE

0.1mg/ml herring sperm DNA

0.5mg/ml acetylated BSA

10

to 300 ul with 1xMES hyb. buffer

[272] The instruction manuals for the products used herein are incorporated herein in their entirety.

15

Labeling Protocol Provided Herein

Hybridization reaction:

Start with non-biotinylated IVT (purified by RNeasy columns)

(see example 1 for steps from tissue to IVT)

IVT antisense RNA; 4 µg: µl

20

Random Hexamers (1 µg/µl): 4 µl

H2O: µl

14 µl

25

- Incubate 70°C, 10 min. Put on ice.

Reverse transcription:

5X First Strand (BRL) buffer: 6 µl

0.1 M DTT: 3 µl

30

50X dNTP mix: 0.6 µl

H2O: 2.4 µl

Cy3 or Cy5 dUTP (1mM): 3 µl

SS RT II (BRL): 1 µl

16 µl

- Add to hybridization reaction.
 - Incubate 30 min., 42°C.
 - Add 1 µl SSII and let go for another hour.
- Put on ice.

5 - 50X dNTP mix (25mM of cold dATP, dCTP, and dGTP, 10mM of dTTP: 25 µl each of 100mM dATP, dCTP, and dGTP; 10 µl of 100mM dTTP to 15 µl H₂O. dNTPs from Pharmacia)

RNA degradation:

10 86 µl H₂O

 - Add 1.5 µl 1M NaOH/ 2mM EDTA, incubate at 65°C, 10 min.

 10 µl 10N NaOH

 4 µl 50mM EDTA

 U-Con 30

15 500 µl TE/sample spin at 7000g for 10 min, save flow through for purification

Qiagen purification:

- suspend u-con recovered material in 500µl buffer PB
- proceed w/ normal Qiagen protocol
- 20 DNase digest:
- Add 1 µl of 1/100 dil of DNase/30µl Rx and incubate at 37°C for 15 min.
- 5 min 95°C to denature enzyme

Sample preparation:

25 - Add:

 Cot-1 DNA: 10 µl

 50X dNTPs: 1 µl

 Na pyro phosphate: 7.5 µl

 10mg/ml Herring sperm DNA 1ul of 1/10 dilution

30 21.8 final vol.

 - Dry down in speed vac.

 - Resuspend in 15 µl H₂O.

 - Add 0.38 µl 10% SDS.

 - Heat 95°C, 2 min.

- Slow cool at room temp. for 20 min.
Put on slide and hybridize overnight at 64°C.

5 **Washing after the hybridization:**

3X SSC/0.03% SDS: 2 min. 37.5 ml 20X SSC+0.75ml 10% SDS in 250ml H2O

1X SSC: 5 min. 12.5 ml 20X SSC in 250ml H2O

0.2X SSC: 5 min. 2.5 ml 20X SSC in 250ml H2O

10 Dry slides in centrifuge, 1000 RPM, 1min.

[273] Scan using appropriate Photomultiplier tube (PMT) and fluorescent excitation and emission channels.

[274] The results are shown in Table 1 and Table 2. The lists of genes come from colorectal tumors from a variety of stages of the disease. The genes that are up regulated in the tumors (overall) were also found to be expressed at a limited amount or not at all in the body map. The body map consists of at least 28 tissue types, including Adrenal Gland, Bladder, Bone Marrow, Brain, Breast, Cervix, Colon, Diaphragm, Heart, Kidney, Liver, Lung, Lymph Node, Muscle, Pancreas, Prostate, Rectum, Salivary Gland, Skin, Small Intestine, Spinal Cord, Spleen, Stomach, Testis, Thymus, Thyroid Trachea and Uterus. As indicated, some of the Accession numbers include expression sequence tags (ESTs). Thus, in one embodiment herein, genes within an expression profile, also termed expression profile genes, include ESTs and are not necessarily full length.

[275] Table 1 shows Accession numbers for 1747 genes upregulated in colon tumor tissue. The table provides the exemplar accession numbers, Unigene ID numbers, unique Eos codes, descriptions of the genes encoded, and relative amount of expression as compared with expression in other normal body tissue.

TABLE 1. GENES INVOLVED IN COLORECTAL CANCER

		PKey	Primekey(unique probeset identifier)			
		Ex. Accn.	Exemplar accession number			
		Probeset	Eos Code number			
		Unigene#	Unigene number			
Pkey	Probeset	Ex Accn	UniG ID	UniGene Title		Ratio TumMet/Body
332264	EOS32195	N72849	Hs.115263	eptregulin		17.6
332716	EOS32647	L00058	Hs.79070	v-myc avian myelocytomatosis viral oncogene homolog		15.0
312845	EOS12776	AJ911215	Hs.186555	ESTs		14.3
310257	EOS10188	AW389247	Hs.148826	ESTs		11.6

5	322567	EOS22498	AF155108	EST cluster (not in UniGene)	11.5
	331060	EOS30991	N75081	ESTs	10.3
	322303	EOS22234	W07459	EST cluster (not in UniGene)	9.6
	301891	EOS01822	AF131855	Hs.106127 Homo sapiens clone 25056 mRNA sequence	9.5
	318524	EOS18455	AW291511	Hs.253687 ESTs	8.9
	314001	EOS13932	AW168495	Hs.8750 ESTs	7.8
	331183	EOS31114	T40769	Hs.8469 EST	7.3
10	315429	EOS15360	AW009951	Hs.206892 ESTs	7.3
	303344	EOS03275	AA255977	Hs.250646 ESTs; Highly similar to ubiquitin-conjugating enzyme [M.musculus]	6.7
	313625	EOS13556	AW468402	Hs.254020 ESTs	6.7
	307084	EOS07015	AI160527	EST singleton (not in UniGene) with exon hit	6.1
	314943	EOS14874	AI476797	Hs.184572 cell division cycle 2; G1 to S and G2 to M	6.1
	303753	EOS03684	AW503733	Hs.170315 ESTs	5.7
15	315593	EOS15524	AW198103	Hs.158154 ESTs	5.3
	313604	EOS13535	AI745325	Hs.182286 ESTs; Moderately similar to !!!! ALU SUBFAMILY SB2 WARNING ENTRY !!!! [H.sapiens]	5.1
	312319	EOS12250	AA216698	Hs.180780 Homo sapiens agrin precursor mRNA; partial cds	5.1
	312614	EOS12545	AI766732	Hs.201194 ESTs	4.8
	323176	EOS23107	AW071648	Hs.123199 ESTs	4.8
20	317916	EOS17847	AI565071	Hs.159983 ESTs	4.7
	301846	EOS01777	R20002	Hs.6823 ESTs; Weakly similar to intrinsic factor-B12 receptor precursor [H.sapiens]	4.6
	311157	EOS11088	AI990122	Hs.196988 ESTs	4.6
	332640	EOS32571	AA417152	Hs.5101 protein regulator of cytokinesis 1	4.6
	311728	EOS11659	AW083000	Hs.184776 ribosomal protein L23a	4.5
25	313774	EOS13705	AW136836	Hs.144583 ESTs	4.5
	312339	EOS12270	AA524394	Hs.256531 EST cluster (not in UniGene)	4.4
	315369	EOS15300	AA764918	Hs.115838 ESTs	4.3
	303756	EOS03687	AI738488	Hs.144475 ESTs; Weakly similar to mitogen inducible gene mig-2 [H.sapiens]	4.3
30	301050	EOS00981	AW136973	Hs.153506 ESTs; Weakly similar to microtubule-actin crosslinking factor [M.musculus]	4.3
	300319	EOS00250	AW157646	Hs.256809 ESTs	4.3
	300664	EOS00595	AI444628	Hs.152530 EST cluster (not in UniGene) with exon hit	4.1
	302655	EOS02586	AJ227892	Hs.152530 ESTs	4.1
	315175	EOS15106	AI025842	Hs.258712 EST	4.1
35	330786	EOS30717	D60374	Hs.132917 ESTs	4.1
	310875	EOS10806	T47764	Hs.186838 ESTs; Weakly similar to similar to zinc finger 5 protein from Gallus gallus; U51640 [H.sapiens]	4.0
	313425	EOS13356	AA745689	Hs.102082 EST cluster (not in UniGene) with exon hit	4.0
	301804	EOS01735	AA581004	Hs.102082 EST	3.9
	332203	EOS32134	H49388	EST cluster (not in UniGene)	3.8
	322968	EOS22899	AI905228	EST cluster (not in UniGene)	3.8
40	321524	EOS21455	N79126	EST cluster (not in UniGene) with exon hit	3.8
	302476	EOS02407	AF182294	Hs.208067 ESTs	3.8
	303295	EOS03226	AA205625	Hs.152475 ESTs	3.7
	310016	EOS09947	AW449612	Hs.148832 ESTs	3.7
45	324871	EOS24802	AW297755	Hs.233460 ESTs; Weakly similar to KIAA0969 protein [H.sapiens]	3.7
	322887	EOS22818	AI986306	Hs.157695 ESTs	3.7
	313171	EOS13102	N67879	Hs.108932 ESTs	3.7
	321638	EOS21569	AI356352	EST cluster (not in UniGene)	3.6
50	320445	EOS20376	R33916	protein arginine N-methyltransferase 3 (hnRNP methyltransferase S. cerevisiae)-like 3	3.6
	302149	EOS02080	AI383794	Hs.210846 ESTs	3.6
	316905	EOS16836	AW138241	Hs.151500 ESTs	3.6
	313166	EOS13097	AI801098	Hs.23348 S-phase kinase-associated protein 2 (p45)	3.5
	323338	EOS23269	R74219	Hs.201582 ESTs	3.5
55	311434	EOS11365	AW016607	Hs.116462 ESTs	3.4
	312742	EOS12673	AI650363	Hs.141901 ESTs; Moderately similar to !!!! ALU SUBFAMILY SP WARNING ENTRY !!!! [H.sapiens]	3.4
	323587	EOS23518	AI905527	Hs.181245 ESTs	3.4
	317390	EOS17321	AW136551	Hs.144923 ESTs	3.4
	315282	EOS15213	AI222165	Hs.164989 ESTs	3.4
	318565	EOS18496	AI440137	Hs.240770 EST singleton (not in UniGene) with exon hit	3.4
60	307586	EOS07517	AI285499	nuclear cap binding protein subunit 2; 20kD	3.3
	321052	EOS20983	AW372884	Hs.247514 ESTs	3.3
	324338	EOS24269	AI138357	Hs.164989 ESTs	3.3
	307517	EOS07448	AI275055	Hs.137527 ESTs; Weakly similar to X-linked retinopathy protein [H.sapiens]	3.2
	314852	EOS14783	AI903735	Hs.255628 ESTs	3.2
65	324657	EOS24588	AW451142	Hs.161784 ESTs	3.2
	314912	EOS14843	AI431345	Hs.159337 ESTs	3.2
	324790	EOS24721	AI334367	Hs.116252 ESTs; Moderately similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]	3.2
	315498	EOS15429	AA628539	Hs.126914 ESTs	3.2
	312857	EOS12788	AA772279	Hs.168053 ESTs	3.2
70	300762	EOS00693	AI497778	c12_hs gjl6682462[ref] gn 1 + 126724 126967 ex 7 7 CDSI 2.44 244 3099	3.2
	325587	EOS25518	CH.12_hs gjl6682462	ESTs	3.2
	320654	EOS20585	AW263086	Hs.118112 ESTs	3.1
	316715	EOS16646	AI440266	Hs.170673 ESTs	3.1
75	333279	EOS33210	CH22_522FG_126_1_LINK	EM:AC005500.GENSCAN.8-1	3.1
	309689	EOS09620	AW236171	Hs.181357 CH22_FGENES.126_1	3.1
	323846	EOS23777	AA337621	Hs.137635 laminin receptor 1 (67kD; ribosomal protein SA)	3.1
	324678	EOS24609	AI990739	Hs.236511 ESTs	3.1
	308362	EOS08293	AI613519	ESTs; Moderately similar to RNA splicing-related protein [R.norvegicus]	3.1
80	308615	EOS08546	AI738593	EST singleton (not in UniGene) with exon hit	3.0
	315397	EOS15328	AA218940	Hs.137516 EST singleton (not in UniGene) with exon hit	3.0
	302236	EOS02167	AI128606	Hs.167558 ESTs	3.0
	321693	EOS21624	AA700017	Hs.173737 zinc finger protein 161	3.0
	330814	EOS30745	AA015730	Hs.247277 ras-related C3 botulinum toxin substrate 1 (rho family; small GTP binding protein Rac1)	3.0
	302977	EOS02908	AW263124	ESTs; Weakly similar to transformation-related protein [H.sapiens]	3.0
85	327516	EOS27447	c_2_hs gjl6117815[ref] gn 6 + 199078 199216 ex 4 4 CDSI 9.15 139 1551	EST cluster (not in UniGene) with exon hit	3.0
			CH.02_hs gjl6117815		2.9

	302099	EOS02030	AL021397	Hs.137576	ribosomal protein L34 pseudogene 1	2.4
	314092	EOS14023	AI984040	Hs.226946	ESTs	2.4
	318587	EOS18518	AA779704	Hs.168830	ESTs	2.4
5	303702	EOS03633	AW500748	Hs.224961	ESTs; Weakly similar to 73 kDa subunit of cleavage and polyadenylation specificity factor [H.sapiens]	2.4
	301822	EOS01753	X17033	Hs.1142	integrin; alpha 2 (CD49B; alpha 2 subunit of VLA-2 receptor)	2.4
	322694	EOS22625	AI110872		EST cluster (not in UniGene)	2.4
	323333	EOS23264	AA228883		EST cluster (not in UniGene)	2.4
10	301954	EOS01885	AJ009936	Hs.118138	nuclear receptor subfamily 1; group I; member 2	2.4
	331363	EOS31294	AA421562	Hs.91011	anterior gradient 2 (Xenopus laevis) homolog	2.4
	303811	EOS03742	AW182340	Hs.246155	ESTs; Weakly similar to DNA TOPOISOMERASE I [H.sapiens]	2.4
	308243	EOS08174	AI560037		EST singleton (not in UniGene) with exon hit	2.4
	336021	EOS35952	CH22_3404FG_669_10_LINK_DJ32110.GENSCAN.9-15		CH22_FGENES.669_10	2.4
15	334789	EOS34720	CH22_2101FG_432_14_LINK_EM.AC005500.GENSCAN.293-17		CH22_FGENES.432_14	2.4
	320807	EOS20738	AA086110	Hs.188536	Homo sapiens clone 24838 mRNA sequence	2.4
	328903	EOS28834	c_8_hs_gij5868514[ref] gn 1 + 23625 24468 ex 3 5 CDSi 91.18 844 219		CH.08_hs_gij5868514	2.4
20	338759	EOS38690	CH22_7581FG_LINK_EM.AC005500.GENSCAN.517-6		CH22_EM.AC005500.GENSCAN.517-6	2.3
	333769	EOS33700	CH22_1036FG_271_8_LINK_EM.AC005500.GENSCAN.127-8		CH22_FGENES.271_8	2.3
25	303597	EOS03528	AI792141	Hs.143560	ESTs; Weakly similar to brain mitochondrial carrier protein-1 [H.sapiens]	2.3
	305898	EOS05829	AA872838	Hs.242463	keratin 8	2.3
	304439	EOS04370	AA398882		EST singleton (not in UniGene) with exon hit	2.3
	301604	EOS01535	AA373124	Hs.105837	ESTs; Weakly similar to C17G10.1 [C.elegans]	2.3
	315071	EOS15002	AA552690	Hs.152423	ESTs	2.3
	330565	EOS30496	U51095	Hs.1545	caudal type homeo box transcription factor 1	2.3
30	331589	EOS31520	N71027	Hs.41856	ESTs	2.3
	303216	EOS03147	AA581439	Hs.152328	ESTs	2.3
	324988	EOS24919	T06997		EST cluster (not in UniGene)	2.3
	312996	EOS12927	AA249018		EST cluster (not in UniGene)	2.3
	332314	EOS32245	T25862	Hs.101774	ESTs	2.3
35	313325	EOS13256	AJ420611	Hs.127832	ESTs	2.3
	322991	EOS22922	C18965	Hs.159473	ESTs	2.3
	335496	EOS35427	CH22_2848FG_571_4_LINK_EM.AC005500.GENSCAN.460-25		CH22_FGENES.571_4	2.3
40	315135	EOS15066	AA627561	Hs.192446	ESTs	2.3
	319488	EOS19419	AW250340		EST cluster (not in UniGene)	2.3
	323571	EOS23502	AA984133	Hs.153260	c-Cbl-interacting protein	2.3
	322826	EOS22757	AI807883	Hs.156932	ESTs	2.3
	322221	EOS22152	AI890619	Hs.179662	nucleosome assembly protein 1-like 1	2.3
	312242	EOS12173	AJ380207	Hs.125276	ESTs	2.3
45	315238	EOS15169	AA593867	Hs.170890	ESTs	2.3
	315168	EOS15099	AA622130	Hs.152524	ESTs	2.3
	300504	EOS00435	AW204624	Hs.192927	ESTs; Weakly similar to Lim kinase [H.sapiens]	2.3
	323243	EOS23174	W44372		EST cluster (not in UniGene)	2.3
50	331628	EOS31559	R80965	Hs.204079	ESTs	2.3
	320746	EOS20677	AA128302		EST cluster (not in UniGene)	2.3
	324598	EOS24529	AA502659	Hs.163986	ESTs	2.3
	308667	EOS08598	AJ758754		EST singleton (not in UniGene) with exon hit	2.2
	302944	EOS02875	AA340708	Hs.256204	ESTs; Weakly similar to cyclic nucleotide-gated channel beta subunit [R.norvegicus]	2.2
55	316291	EOS16222	AW375974	Hs.156704	ESTs	2.2
	315296	EOS15227	AA876905	Hs.125286	ESTs	2.2
	334150	EOS34081	CH22_1429FG_339_1_LINK_EM.AC005500.GENSCAN.189-1		CH22_FGENES.339_1	2.2
60	331380	EOS31311	AA453266	Hs.246131	ESTs	2.2
	321795	EOS21728	AI796896	Hs.222448	ESTs	2.2
	331493	EOS31424	N34357	Hs.44571	ESTs	2.2
	312890	EOS12821	AI813654	Hs.127478	ESTs	2.2
	315583	EOS15514	AW003622	Hs.126555	ESTs	2.2
	314306	EOS14237	AI697901	Hs.192425	ESTs	2.2
65	314138	EOS14069	AA740616		EST cluster (not in UniGene)	2.2
	302656	EOS02587	AW293005	Hs.220905	ESTs	2.2
	313564	EOS13495	AA810141	Hs.192182	ESTs	2.2
	332792	EOS32723	CH22_8FG_3_2_LINK_C4G1.GENSCAN.3-2		CH22_FGENES.3_2	2.2
70	332020	EOS31951	AA488895	Hs.105219	ESTs	2.2
	315143	EOS15074	AA878324	Hs.192734	ESTs	2.2
	313385	EOS13316	AJ032087	Hs.176711	ESTs	2.2
	323835	EOS23766	AI042005		EST cluster (not in UniGene)	2.2
	314014	EOS13945	AW291847	Hs.121715	ESTs; Weakly similar to HP protein [H.sapiens]	2.2
75	336016	EOS35947	CH22_3399FG_669_5_LINK_DJ32110.GENSCAN.9-10		CH22_FGENES.669_5	2.2
	323218	EOS23149	AF131846	Hs.13396	Homo sapiens clone 25028 mRNA sequence	2.2
	338059	EOS37990	CH22_6561FG_LINK_EM.AC005500.GENSCAN.160-4		CH22_EM.AC005500.GENSCAN.160-4	2.2
80	302613	EOS02544	AA371059	Hs.251636	ubiquitin specific protease 3	2.2
	304852	EOS04783	AA588595		EST singleton (not in UniGene) with exon hit	2.2
	308457	EOS08388	AI669859		EST singleton (not in UniGene) with exon hit	2.2
	311736	EOS11667	AA765897		EST cluster (not in UniGene)	2.2
	334183	EOS34114	CH22_1464FG_350_13_LINK_EM.AC005500.GENSCAN.209-16		CH22_FGENES.350_13	2.2
85	315021	EOS14952	AA533447		EST cluster (not in UniGene)	2.2
	303013	EOS02944	F07898	Hs.214190	interleukin enhancer binding factor 1	2.2
	315006	EOS14937	AI538613	Hs.135657	ESTs	2.2

	337534	EOS37465	CH22_5803FG_828_3_	CH22_FGENES.828-3	
	303276	EOS03207	AA431599	Hs.132799	ESTs
	318617	EOS18548	AW247252	Hs.75514	nucleoside phosphorylase
5	330760	EOS30691	AA448663	Hs.30469	ESTs
	319545	EOS19476	R83716	Hs.14355	ESTs
	312252	EOS12183	AI128388	Hs.143655	ESTs
	322882	EOS22813	AW248508	Hs.2491	DiGeorge syndrome critical region gene 2
	312684	EOS12615	AW294020	Hs.117721	ESTs
10	315782	EOS15713	AW515455	Hs.115558	ESTs; Weakly similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]
	320076	EOS20007	AI653733	Hs.204079	ESTs
	300566	EOS00497	H86709	Hs.21371	son of sevenless (Drosophila) homolog 1
	300908	EOS00839	AA618335	Hs.148137	ESTs; Weakly similar to putative [C.elegans]
	314778	EOS14709	AW079559	Hs.152258	ESTs
15	319233	EOS19164	R21054	Hs.211522	ESTs
	335488	EOS35419	CH22_2840FG_570_20_LINK_EM:AC005500.GENSCAN.460-15		2.1
			CH22_FGENES.570_20		2.1
	334616	EOS34547	CH22_1923FG_411_15_LINK_EM:AC005500.GENSCAN.274-22		2.1
			CH22_FGENES.411_15		2.1
20	306792	EOS06723	AI042426		EST singleton (not in UniGene) with exon hit
	301661	EOS01592	AI815558		EST cluster (not in UniGene) with exon hit
	311332	EOS11263	AW292247	Hs.255052	ESTs
	314785	EOS14716	AI538226	Hs.135184	ESTs
	301460	EOS01391	AW196758	Hs.165998	DKFZP564M2423 protein
25	332015	EOS31946	AA487910	Hs.208800	ESTs; Weakly similar to !!!! ALU CLASS B WARNING ENTRY !!!! [H.sapiens]
	321529	EOS21460	AI269506	Hs.146066	ESTs
	323740	EOS23671	AA324643	Hs.246106	ESTs
	336019	EOS35950	CH22_3402FG_669_8_LINK_DJ32110.GENSCAN.9-13		2.1
			CH22_FGENES.669_8		2.1
30	314954	EOS14885	AA521381	Hs.187726	ESTs
	303037	EOS02968	AF118395		EST cluster (not in UniGene) with exon hit
	302056	EOS01987	AI457532	Hs.126082	ESTs; Moderately similar to ROSA26AS [M.musculus]
	315178	EOS15109	AW362945	Hs.162459	ESTs
	332246	EOS32177	N57927	Hs.120777	ESTs; Weakly similar to RNA POLYMERASE II ELONGATION FACTOR ELL2 [H.sapiens]
35	334288	EOS34219	CH22_1577FG_369_18_LINK_EM:AC005500.GENSCAN.229-18		2.0
			CH22_FGENES.369_18		2.0
	324690	EOS24621	N88286	Hs.132808	ESTs; Weakly similar to Similar to S.pombe -rad4+/cut5+product [H.sapiens]
	305257	EOS05188	AA679005		EST singleton (not in UniGene) with exon hit
40	311315	EOS11246	AW450536	Hs.209260	ESTs
	311988	EOS11919	AW016096	Hs.13801	ESTs
	302638	EOS02569	AA463798	Hs.102696	ESTs; Weakly similar to C11D2.4 [C.elegans]
	320531	EOS20462	W03691	Hs.24884	ESTs; Moderately similar to RNA polymerase I associated factor [M.musculus]
	323604	EOS23535	AI751438	Hs.182827	ESTs; Weakly similar to !!!! ALU SUBFAMILY SQ WARNING ENTRY !!!! [H.sapiens]
45	308852	EOS08783	AI829848	Hs.182937	peptidylprolyl isomerase A (cyclophilin A)
	320521	EOS20452	N31464	Hs.24743	ESTs
	331306	EOS31237	AA252079	Hs.63931	dachshund (Drosophila) homolog
	314941	EOS14872	AA515902	Hs.130650	ESTs
	336684	EOS36615	CH22_4167FG_46_1_		CH22_FGENES.46-1
	301137	EOS01068	AF049569	Hs.137096	ESTs
50	338454	EOS38385	CH22_7128FG_LINK_EM:AC005500.GENSCAN.360-4		2.0
			CH22_EM:AC005500.GENSCAN.360-4		2.0
	309700	EOS09631	AW241170	Hs.179661	Homo sapiens clone 24703 beta-tubulin mRNA; complete cds
55	330262	EOS30193	c_5_p2 gi 6671884 gb a gn 1 + 67913 68053 ex 3 3 CDSI 5.41 141 597		2.0
			CH.05_p2 gi 6671884		2.0
	324163	EOS24094	AL046827	Hs.134651	ESTs
	316493	EOS16424	AA766142	Hs.131810	ESTs; Weakly similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]
	311873	EOS11804	AA730045	Hs.187866	ESTs
	326757	EOS26688	c20_hs gi 6249610 ref gn 3 + 74531 74597 ex 1 3 CDSI 9.52 67 1416		2.0
			CH.20_hs gi 6249610		2.0
60	319167	EOS19098	F05984	Hs.250138	protein phosphatase 2C; magnesium-dependent; catalytic subunit
	316011	EOS15942	AW516953	Hs.201372	ESTs
	313635	EOS13566	AA507227	Hs.6390	ESTs
	310027	EOS09958	AW449009	Hs.126647	ESTs
	336662	EOS36593	CH22_4138FG_41_1_		CH22_FGENES.41-1
65	334648	EOS34579	CH22_1956FG_417_15_LINK_EM:AC005500.GENSCAN.278-15		2.0
			CH22_FGENES.417_15		2.0
	308876	EOS08607	AI761036		EST singleton (not in UniGene) with exon hit
	312047	EOS11978	AA588275	Hs.14258	ESTs
	324826	EOS24757	AA704806	Hs.143842	ESTs
70	322889	EOS22820	AA081924	Hs.211417	ESTs
	316345	EOS16278	AW139408	Hs.152940	ESTs
	313922	EOS13853	AI702038	Hs.100057	ESTs
	319423	EOS19354	T83024	Hs.15119	ESTs
	320244	EOS20175	AA296922	Hs.129778	gastrintestinal peptide
75	308957	EOS08888	AI869642		EST singleton (not in UniGene) with exon hit
	334223	EOS34154	CH22_1507FG_360_4_LINK_EM:AC005500.GENSCAN.218-4		2.0
			CH22_FGENES.360_4		2.0
	302980	EOS02911	W93435		EST cluster (not in UniGene) with exon hit
	312153	EOS12084	AA759250	Hs.153028	cytochrome b-561
80	326460	EOS26391	c19_hs gi 5867400 ref gn 3 - 142633 142935 ex 1 2 CDSI 19.03 303 1731		1.9
			CH.19_hs gi 5867400		1.9
	319962	EOS19893	H06350	Hs.135056	ESTs
	307064	EOS06995	AI149335		EST singleton (not in UniGene) with exon hit
	331608	EOS31539	N89861	Hs.44182	ESTs; Weakly similar to cDNA EST yk342h12.5 comes from this gene [C.elegans]
85	328142	EOS28073	c_6_hs gi 5868050 ref gn 1 - 9656 9778 ex 2 6 CDSI 11.11 123 3339		1.9
			CH.06_hs gi 5868050		1.9
	312527	EOS12458	AI695522	Hs.191271	ESTs

	318581	EOS18512	AA769058		EST cluster (not in UniGene)		1.9
	319979	EOS19910	AB018281	Hs.107479	KIAA0738 gene product		1.9
	336107	EOS36038	CH22_3496FG_696_3_LINK_DA59H18	GENSCAN.4-3	CH22_FGENES.696_3		1.9
5	305232	EOS05163	AA670052	Hs.195188	glyceraldehyde-3-phosphate dehydrogenase		1.9
	315043	EOS14974	AA806538	Hs.130732	ESTs		1.9
	323377	EOS23308	AA133260	Hs.8454	protein kinase; cAMP-dependent; regulatory; type II; alpha		1.9
	338260	EOS38191	CH22_6863FG_LINK_EM:AC005500	GENSCAN.279-10	CH22_EM:AC005500.GENSCAN.279-10		1.9
10	334891	EOS34822	CH22_2208FG_452_5_LINK_EM:AC005500	GENSCAN.341-8	CH22_FGENES.452_5		1.9
	316055	EOS15986	AA693880		EST cluster (not in UniGene)		1.9
	312414	EOS12345	AI915014	Hs.164235	ESTs; Weakly similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]		1.9
15	300225	EOS00156	AI989963	Hs.197505	ESTs		1.9
	332607	EOS32538	RA1791	Hs.36566	LIM domain kinase 1		1.9
	312405	EOS12336	AI523875		EST cluster (not in UniGene)		1.9
	313605	EOS13536	AI761786	Hs.204674	ESTs		1.9
	337755	EOS37686	CH22_6105FG_LINK_EM:AC000097	GENSCAN.109-2	CH22_EM:AC000097.GENSCAN.109-2		1.9
20	323216	EOS23147	AA332145		EST cluster (not in UniGene)		1.9
	334872	EOS34803	CH22_2186FG_450_2_LINK_EM:AC005500	GENSCAN.339-2	CH22_FGENES.450_2		1.9
	332034	EOS13965	AA489847	Hs.112019	ESTs; Moderately similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]		1.9
25	332103	EOS32034	AA609161	Hs.112657	ESTs; Weakly similar to ORF YOR243c [S.cerevisiae]		1.9
	318196	EOS18127	AI056776	Hs.133397	ESTs		1.9
	329141	EOS29072	c_x_hs gi 6017060 ref gn 1 + 343924 343997 ex 2 3 CDSi	8.53 74 1715	CH.X_hs gi 6017060		1.9
	321539	EOS21470	N98619	Hs.62461	ARP2 (actin-related protein 2; yeast) homolog		1.9
	313881	EOS13812	AA535580	Hs.16331	ESTs		1.9
30	314046	EOS13977	AW021917	Hs.181878	ESTs		1.9
	336045	EOS35976	CH22_3430FG_679_7_LINK_DJ32I10	GENSCAN.18-8	CH22_FGENES.679_7		1.9
	324799	EOS24730	AW272262	Hs.250468	ESTs		1.9
35	312656	EOS12587	AW152449	Hs.226469	ESTs		1.9
	324662	EOS24593	AW504689		EST cluster (not in UniGene)		1.9
	323930	EOS23861	AA570698	Hs.193203	ESTs		1.9
	314465	EOS14396	AA602917	Hs.156974	ESTs		1.9
	335897	EOS35828	CH22_3274FG_635_5_LINK_EM:AC005500	GENSCAN.525-7	CH22_FGENES.635_5		1.9
40	321746	EOS21677	AI806500	Hs.102652	ESTs; Weakly similar to KIAA0437 [H.sapiens]		1.9
	335687	EOS35618	CH22_3048FG_596_2_LINK_EM:AC005500	GENSCAN.488-2	CH22_FGENES.596_2		1.9
	330731	EOS30662	AA278816	Hs.177204	ESTs		1.9
45	315542	EOS15473	AA079476	Hs.109857	ESTs; Highly similar to CGI-89 protein [H.sapiens]		1.9
	336379	EOS36310	CH22_3791FG_821_7_LINK_BA232E17	GENSCAN.4-19	CH22_FGENES.821_7		1.9
	305691	EOS05622	AA813590	Hs.119500	karyopherin alpha 4 (importin alpha 3)		1.9
	310639	EOS10570	AW269082	Hs.175162	ESTs		1.9
50	327481	EOS27412	c_2_hs gi 5867783 ref gn 3 + 104472 104673 ex 1 4 CDSi	14.33 202 1308	CH.02_hs gi 5867783		1.9
	301910	EOS01841	T84852	Hs.98370	cytochrome P540 family member predicted from ESTs		1.9
	335478	EOS35409	CH22_2830FG_569_1_LINK_EM:AC005500	GENSCAN.456-1	CH22_FGENES.569_1		1.9
55	331135	EOS31066	R61398	Hs.4197	ESTs		1.9
	335690	EOS35621	CH22_3051FG_596_5_LINK_EM:AC005500	GENSCAN.488-5	CH22_FGENES.596_5		1.9
	308047	EOS07978	AI459633		EST singleton (not in UniGene) with exon hit		1.9
	334500	EOS34431	CH22_1800FG_397_16_LINK_EM:AC005500	GENSCAN.260-18	CH22_FGENES.397_16		1.9
60	338250	EOS38181	CH22_6848FG_LINK_EM:AC005500	GENSCAN.269-2	CH22_EM:AC005500.GENSCAN.269-2		1.8
	320618	EOS20549	AI220276	Hs.235228	EST		1.8
	335044	EOS34975	CH22_2367FG_480_1_LINK_EM:AC005500	GENSCAN.374-1	CH22_FGENES.480_1		1.8
65	313789	EOS13720	AI167810	Hs.217743	ESTs		1.8
	311911	EOS11842	AI087123	Hs.114434	ESTs; Weakly similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]		1.8
	320180	EOS20111	AA846203	Hs.193974	ESTs; Weakly similar to alternatively spliced product using exon 13A [H.sapiens]		1.8
	311036	EOS10967	AI539227	Hs.214039	ESTs		1.8
	323903	EOS23834	AA773580	Hs.193598	ESTs		1.8
70	318676	EOS18607	T57448	Hs.15467	ESTs; Moderately similar to putative phosphoinositide 5-phosphatase type II [M.musculus]		1.8
	303007	EOS02938	AA478876	Hs.7037	pallid (mouse) homolog; pallidin		1.8
	334806	EOS34737	CH22_2119FG_435_7_LINK_EM:AC005500	GENSCAN.296-6	CH22_FGENES.435_7		1.8
75	311767	EOS11698	AI076686	Hs.190068	ESTs		1.8
	331750	EOS31681	AA284372	Hs.111471	ESTs		1.8
	314872	EOS14803	AI144254	Hs.239726	ESTs		1.8
	314071	EOS14002	AA192455	Hs.188690	ESTs		1.8
	328450	EOS28381	c_7_hs gi 5868425 ref gn 2 - 209192 209321 ex 2 3 CDSi	10.41 130 1407	CH.07_hs gi 5868425		1.8
80	328857	EOS28788	c_7_hs gi 6381927 ref gn 3 - 80557 81051 ex 1 1 CDSi	41.51 495 6090	CH.07_hs gi 6381927		1.8
	313781	EOS13712	AA078836		EST cluster (not in UniGene)		1.8
	336953	EOS36884	CH22_4746FG_361_22		CH22_FGENES.361-22		1.8
	300233	EOS00164	AI380777	Hs.189402	ESTs		1.8
85	326862	EOS26793	c20_hs gi 6552465 ref gn 2 + 107702 107782 ex 12 13 CDSi	3.62 81 2149	CH.20_hs gi 6552465		1.8

	312364	EOS12295	R40111	Hs.187618	ESTs	1.8
	321541	EOS21472	AI220292	Hs.254467	ESTs	1.8
	307432	EOS07363	AI244259	Hs.181165	eukaryotic translation elongation factor 1 alpha 1	1.8
5	320921	EOS20852	R94038	Hs.199538	inhibin; beta C	1.8
	333110	EOS33041	CH22_338FG_79_16_LINK_EM:AC000097.GENSCAN.59-15			
			CH22_FGENES.79_16			1.8
	324914	EOS24845	AA847510	Hs.161292	ESTs	1.8
10	312681	EOS12612	AI028149	Hs.193124	pyruvate dehydrogenase kinase; isoenzyme 3	1.8
	335697	EOS35628	CH22_3058FG_596_12_LINK_EM:AC005500.GENSCAN.488-13			
			CH22_FGENES.596_12			1.8
	308462	EOS08393	AI671311		EST singleton (not in UniGene) with exon hit	1.8
	312138	EOS12069	T89405	Hs.218851	ESTs; Weakly similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]	1.8
	309116	EOS09047	AI927149	Hs.29797	ribosomal protein L10	1.8
15	320730	EOS20661	AA534539	Hs.151072	ESTs	1.8
	300844	EOS00775	AL042759	Hs.191762	ESTs	1.8
	337570	EOS37501	CH22_5856FG_LINK_C65E1.GENSCAN.4-2			
			CH22_C65E1.GENSCAN.4-2			1.8
	332756	EOS32687	D63479	Hs.115907	diacylglycerol kinase; delta (130kD)	1.8
20	332161	EOS32092	AA621523	Hs.165464	ESTs	1.8
	300942	EOS00873	AW275006	Hs.195969	ESTs	1.8
	300680	EOS00611	AW468066	Hs.257712	ESTs; Weakly similar to KIAA0986 protein [H.sapiens]	1.8
	328783	EOS328714	c_7_hs_gi 5868309 ref gn 5		73658 73822 ex 2 5 CDSI 0.78 165 5371	
			CH.07_hs_gi 5868309			1.8
25	307542	EOS07473	AI280859		EST singleton (not in UniGene) with exon hit	1.8
	331975	EOS31906	AA464972	Hs.99624	ESTs	1.8
	321532	EOS21463	T77886	Hs.83428	nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)	1.8
	318721	EOS18652	Z28504		EST cluster (not in UniGene)	1.8
	302124	EOS02055	AB023967	Hs.145078	regulator of differentiation (in S. pombe) 1	1.8
30	323541	EOS23472	AI185116	Hs.104613	ESTs; Weakly similar to Similar to S.cerevisiae hypothetical protein L3111 [H.sapiens]	1.8
	331057	EOS30988	N71399	Hs.28143	ESTs	1.8
	316860	EOS16791	AW139099	Hs.127489	ESTs	1.8
	330601	EOS30532	U90916	Hs.82845	Human clone 23815 mRNA sequence	1.8
	307334	EOS07265	AI214811	Hs.220615	ESTs; Weakly similar to TFII-I protein [H.sapiens]	1.8
35	323195	EOS23126	AI064982	Hs.117950	multifunctional polypeptide similar to SAICAR synthetase and AIR carboxylase	1.8
	303856	EOS03787	AA968589	Hs.944	glucose phosphate isomerase	1.8
	321553	EOS21484	H92449	Hs.116406	ESTs	1.8
	332705	EOS32636	T59161	Hs.76293	thymosin; beta 10	1.8
40	333139	EOS33070	CH22_368FG_83_16_LINK_EM:AC000097.GENSCAN.67-19			
			CH22_FGENES.83_16			1.8
	338997	EOS38928	CH22_7881FG_LINK_DA59H18.GENSCAN.8-22			
			CH22_DA59H18.GENSCAN.8-22			1.8
	301509	EOS01440	AI025435	Hs.117532	ESTs	1.8
	314522	EOS14453	AI732331	Hs.187750	ESTs; Moderately similar to !!!! ALU CLASS C WARNING ENTRY !!!! [H.sapiens]	1.8
45	303072	EOS03003	AF157833		EST cluster (not in UniGene) with exon hit	1.8
	305271	EOS05202	AA679895		EST singleton (not in UniGene) with exon hit	1.8
	335287	EOS35218	CH22_2629FG_526_11_LINK_EM:AC005500.GENSCAN.420-4			
			CH22_FGENES.526_11			1.8
	321286	EOS21217	AI380940		EST cluster (not in UniGene)	1.8
50	318740	EOS18671	NM_002543		EST cluster (not in UniGene)	1.8
	323465	EOS23396	AA287406		EST cluster (not in UniGene)	1.8
	300611	EOS00542	N75450		EST cluster (not in UniGene) with exon hit	1.8
	306235	EOS06166	AA932299		EST singleton (not in UniGene) with exon hit	1.8
	336721	EOS36652	CH22_4244FG_83_17_LINK_EM:AC005500.GENSCAN.420-4			
			CH22_FGENES.83-17			1.8
55	311291	EOS11222	AA782601	Hs.122684	ESTs	1.8
	310247	EOS10178	AI224982	Hs.211454	ESTs	1.8
	316564	EOS16495	AI743571	Hs.168799	ESTs; Weakly similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]	1.8
	328170	EOS28101	c_6_hs_gi 5868071 ref gn 1		+ 93170 93295 ex 9 9 CDSI 13.31 126 3591	
			CH.06_hs_gi 5868071			1.8
60	300909	EOS00840	AW295479	Hs.154903	ESTs; Weakly similar to Abl substrate ena [D.melanogaster]	1.8
	330869	EOS30800	AA115197	Hs.183702	ESTs	1.8
	311048	EOS10979	AA506952	Hs.210508	ESTs	1.8
	333764	EOS33695	CH22_1031FG_271_3_LINK_EM:AC005500.GENSCAN.127-3			
			CH22_FGENES.271_3			1.8
65	338862	EOS38793	CH22_7715FG_LINK_DJ32110.GENSCAN.1-6			
			CH22_DJ32110.GENSCAN.1-6			1.8
	331487	EOS31398	N22206	Hs.43112	ESTs	1.8
	327742	EOS27673	c_5_hs_gi 5867944 ref gn 3		143307 143512 ex 1 3 CDSI 11.07 206 172	
			CH.05_hs_gi 5867944			1.8
70	320955	EOS20886	AL049415	Hs.204290	Homo sapiens mRNA; cDNA DKFZp586N2119 (from clone DKFZp586N2119)	1.8
	323589	EOS23520	AW390054	Hs.192843	ESTs	1.8
	319951	EOS19882	AA307665	Hs.14559	ESTs	1.8
	333763	EOS33694	CH22_1030FG_271_2_LINK_EM:AC005500.GENSCAN.127-2			
			CH22_FGENES.271_2			1.7
75	331046	EOS30977	N66563	Hs.191358	ESTs	1.7
	320001	EOS19932	AA873350		EST cluster (not in UniGene)	1.7
	316869	EOS16800	AI954880	Hs.134604	ESTs	1.7
	310774	EOS10705	AW134483	Hs.164371	ESTs	1.7
	319379	EOS19310	T91443	Hs.193963	ESTs	1.7
	321549	EOS21480	AA470984	Hs.161947	ESTs	1.7
80	300823	EOS00754	AI863068	Hs.222665	ESTs; Weakly similar to putative zinc finger protein NY-REN-34 antigen [H.sapiens]	1.7
	324228	EOS24159	AI798146	Hs.207780	ESTs	1.7
	313902	EOS13833	AI308165	Hs.156242	ESTs	1.7
	308928	EOS08859	AI863908		EST singleton (not in UniGene) with exon hit	1.7
85	333770	EOS33701	CH22_1037FG_272_1_LINK_EM:AC005500.GENSCAN.127-10			
			CH22_FGENES.272_1			1.7
	316934	EOS16865	AI571647	Hs.146170	ESTs	1.7

	313219	EOS13150	N74924	Hs.182099	ESTs	1.7
	317360	EOS17291	AI125252	Hs.126419	ESTs	1.7
	303530	EOS03461	AI274851	Hs.258744	ESTs	1.7
5	334739	EOS34670	CH22_2051FG_424_14_LINK_EM:AC005500.GENSCAN.285-16			
			CH22_FGENES.424_14			1.7
	337670	EOS37601	CH22_5996FG_LINK_EM:AC000097.GENSCAN.57-2			
			CH22_EM:AC000097.GENSCAN.57-2			1.7
	312079	EOS12010	T79745	Hs.189717	ESTs	1.7
10	320211	EOS20142	AL039402	Hs.125783	DEME-6 protein	1.7
	316218	EOS16149	AW207642	Hs.174021	ESTs	1.7
	335682	EOS35613	CH22_3043FG_595_2_LINK_EM:AC005500.GENSCAN.487-11			
			CH22_FGENES.595_2			1.7
	330698	EOS30627	AA022632	Hs.15825	ESTs	1.7
15	314449	EOS14380	AL042667	Hs.225539	ESTs	1.7
	311972	EOS11903	N51511	Hs.188449	ESTs	1.7
	307691	EOS07622	AI318285	Hs.182371	prothymosin; alpha (gene sequence 28)	1.7
	338249	EOS38180	CH22_6847FG_LINK_EM:AC005500.GENSCAN.269-1			
			CH22_EM:AC005500.GENSCAN.269-1			1.7
20	326399	EOS26330	c19_hs gjl5867353[ref] gn 1 + 6385 6536 ex 6 6 CDSI 10.69 152 684			
			CH.19_hs gjl5867353			1.7
	313290	EOS13221	AI753247	Hs.206454	ESTs	1.7
	301615	EOS01546	W39477		EST cluster (not in UniGene) with exon hit	1.7
	307034	EOS06965	AI142526		EST singleton (not in UniGene) with exon hit	1.7
25	313577	EOS13508	AA565051	Hs.155029	ESTs	1.7
	324703	EOS24634	AB009282	Hs.31086	Homo sapiens mRNA for cytochrome b5; partial cds	1.7
	321317	EOS21248	AI937060	Hs.202040	ESTs; Weakly similar to KIAA0938 protein [H.sapiens]	1.7
	312278	EOS12209	AW205234	Hs.201587	ESTs	1.7
	333358	EOS33289	CH22_604FG_141_9_LINK_EM:AC005500.GENSCAN.21-9			
			CH22_FGENES.141_9			1.7
30	322735	EOS22666	AA086123		EST cluster (not in UniGene)	1.7
	326752	EOS26683	c20_hs gjl5867615[ref] gn 1 - 1214 1562 ex 2 2 CDSI 33.07 349 1366			
			CH.20_hs gjl5867615			1.7
	314733	EOS14664	AW452355	Hs.256037	ESTs	1.7
35	312902	EOS12833	AW292797	Hs.130316	ESTs	1.7
	322653	EOS22584	AI828854	Hs.171891	ESTs	1.7
	336015	EOS35946	CH22_3398FG_669_4_LINK_DJ32110.GENSCAN.9-9			
			CH22_FGENES.669_4			1.7
40	324500	EOS24431	AW269819	Hs.169905	ESTs	1.7
	310900	EOS10831	AI922728	Hs.165803	ESTs; Weakly similar to !!!! ALU SUBFAMILY SB WARNING ENTRY !!!! [H.sapiens]	1.7
	337908	EOS37839	CH22_6323FG_LINK_EM:AC005500.GENSCAN.57-1			
			CH22_EM:AC005500.GENSCAN.57-1			1.7
	304084	EOS04015	T91986		EST singleton (not in UniGene) with exon hit	1.7
45	332539	EOS32470	AA412528	Hs.20183	ESTs; Weakly similar to cDNA EST EMBL:T01421 comes from this gene [C.elegans]	1.7
	314332	EOS14263	AL037551	Hs.95612	ESTs	1.7
	321412	EOS21343	AW366305		EST cluster (not in UniGene)	1.7
	312187	EOS12118	AA700439	Hs.188490	ESTs	1.7
	314147	EOS14078	AI656135	Hs.129805	ESTs	1.7
	303131	EOS03062	AW081061	Hs.103180	actin-like 6	1.7
50	331341	EOS31272	AA303125	Hs.119009	ESTs; Weakly similar to !!!! ALU SUBFAMILY SB2 WARNING ENTRY !!!! [H.sapiens]	1.7
	313615	EOS13546	AW295194	Hs.25264	DKFZP434N126 protein	1.7
	329598	EOS29529	c10_p2 gjl3962482[gb]A gn 4 + 39924 40220 ex 2 3 CDSi 8.71 297 420			
			CH.10_p2 gjl3962482			1.7
	303579	EOS03510	AA381124	Hs.193353	ESTs; Weakly similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]	1.7
55	331692	EOS31623	W93592	Hs.47343	ESTs	1.7
	323977	EOS23908	AW328177	Hs.234713	ESTs	1.7
	332930	EOS32861	CH22_151FG_38_4_LINK_C20H12.GENSCAN.29-4			
			CH22_FGENES.38_4			1.7
60	326596	EOS26527	c19_hs gjl6138928[ref] gn 4 + 133386 133563 ex 7 9 CDSi -1.32 178 3520			
			CH.19_hs gjl6138928			1.7
	314946	EOS14877	AI097229	Hs.217484	ESTs; Weakly similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]	1.7
	315357	EOS15288	AA608684	Hs.121705	ESTs; Moderately similar to !!!! ALU CLASS C WARNING ENTRY !!!! [H.sapiens]	1.7
	324728	EOS24659	AA303024		EST cluster (not in UniGene)	1.7
	317501	EOS17432	AA931245	Hs.137097	ESTs	1.7
65	332219	EOS32150	N22508	Hs.139315	ESTs	1.7
	335369	EOS35300	CH22_2718FG_543_7_LINK_EM:AC005500.GENSCAN.432-9			
			CH22_FGENES.543_7			1.7
	322417	EOS22348	W36286	Hs.171873	ESTs; Weakly similar to PUTATIVE STEROID DEHYDROGENASE KIK-1 [M.musculus]	1.7
	316100	EOS16031	AW203986	Hs.213003	ESTs	1.7
70	314866	EOS14797	AW305124	Hs.191682	ESTs	1.7
	300328	EOS00259	AW015860	Hs.224623	ESTs	1.7
	315676	EOS15607	AW002565	Hs.136590	ESTs	1.7
	314183	EOS14114	AA748600		EST cluster (not in UniGene)	1.7
	321354	EOS21285	AA078493		EST cluster (not in UniGene)	1.7
75	311904	EOS11835	T86907	Hs.119371	ESTs	1.7
	322890	EOS22821	AA082030		EST cluster (not in UniGene)	1.7
	302759	EOS02690	AI885815	Hs.184727	ESTs	1.7
	324600	EOS24531	AA503297	Hs.117108	ESTs	1.7
	314973	EOS14904	AW273128	Hs.254669	EST	1.7
80	324432	EOS24363	AA464510		EST cluster (not in UniGene)	1.7
	331520	EOS31451	N49068	Hs.93966	ESTs	1.7
	308380	EOS08311	AI623988		EST singleton (not in UniGene) with exon hit	1.7
	331010	EOS30941	H95039	Hs.32168	KIAA0442 protein	1.7
85	325363	EOS25294	c12_hs gjl5866920[ref] gn 7 + 700446 700516 ex 6 8 CDSi -6.58 71 113			
			CH.12_hs gjl5866920			1.7
	310470	EOS10401	AI281848	Hs.165547	ESTs	1.7
	330711	EOS30642	AA164687	Hs.177576	mannosyl (alpha-1,3)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase; isoenzyme A	1.7

	332074	EOS32005	AA599012	Hs.22826	ESTs	1.7
	309732	EOS09663	AW262211	Hs.5662	guanine nucleotide binding protein (G protein); beta polypeptide 2-like 1	1.6
	306337	EOS06268	AA954221	Hs.73742	ribosomal protein; large; P0	1.6
5	335189	EOS35120	CH22_2525FG_507_4_LINK	EM:AC005500.GENSCAN.400-4	CH22_FGENES.507_4	1.6
	316253	EOS16184	AI919537	Hs.118056	ESTs	1.6
	332908	EOS32839	CH22_129FG_36_12_LINK	C20H12.GENSCAN.28-9	CH22_FGENES.36_12	1.6
10	310002	EOS09933	AI439096	Hs.25832	ESTs	1.6
	332258	EOS32189	N68670	Hs.103808	ESTs; Weakly similar to RanBPM [H.sapiens]	1.6
	336182	EOS36113	CH22_3576FG_715_2_LINK	DA59H18.GENSCAN.19-3	CH22_FGENES.715_2	1.6
15	328987	EOS28918	c_9_hs	gj 5868535 ref gn 1 - 25705 25764 ex 3 10 CDSi 9.90 60 438	CH.09_hs gj 5868535	1.6
	324481	EOS24412	AI916284	Hs.199671	ESTs	1.6
	331406	EOS31337	AA610064	Hs.23440	KIAA1105 protein	1.6
	332280	EOS32211	R38100	Hs.106294	ESTs	1.6
	332173	EOS32104	F09281	Hs.90424	ESTs	1.6
20	335739	EOS35670	CH22_3102FG_601_10_LINK	EM:AC005500.GENSCAN.491-10	CH22_FGENES.601_10	1.6
	332104	EOS32035	AA609177	Hs.109363	ESTs	1.6
	315033	EOS14964	AI493046	Hs.146133	ESTs	1.6
	334740	EOS34671	CH22_2052FG_424_15_LINK	EM:AC005500.GENSCAN.285-17	CH22_FGENES.424_15	1.6
25	334783	EOS34714	CH22_2095FG_432_8_LINK	EM:AC005500.GENSCAN.293-11	CH22_FGENES.432_8	1.6
	308010	EOS07941	AI439190	Hs.181165	eukaryotic translation elongation factor 1 alpha 1	1.6
	304521	EOS04452	AA464716		EST singleton (not in UniGene) with exon hit	1.6
30	318719	EOS18650	Z25900	Hs.18724	Homo sapiens mRNA; cDNA DKFZp564F093 (from clone DKFZp564F093)	1.6
	321920	EOS21851	N63915		EST cluster (not in UniGene)	1.6
	315019	EOS14950	AA532807	Hs.105822	ESTs	1.6
	320793	EOS20724	AL049980	Hs.184216	DKFZP564C152 protein	1.6
	305371	EOS05302	AA714180		EST singleton (not in UniGene) with exon hit	1.6
35	305054	EOS04985	AA634127	Hs.182426	ribosomal protein S2	1.6
	314643	EOS14574	AI587502	Hs.192088	ESTs	1.6
	308186	EOS08117	AI537940		EST singleton (not in UniGene) with exon hit	1.6
	319371	EOS19302	R00321	Hs.174928	ESTs	1.6
	331700	EOS31631	Z40011	Hs.180582	ESTs	1.6
40	316955	EOS16886	AW203959	Hs.149532	ESTs	1.6
	314961	EOS14892	AW008061	Hs.231994	ESTs	1.6
	336676	EOS36607	CH22_4154FG_43_4_LINK		CH22_FGENES.43_4	1.6
	322801	EOS22732	AI831910	Hs.163734	ESTs	1.6
	303363	EOS03294	AI964095	Hs.226801	ESTs; Weakly similar to DIA-156 protein [H.sapiens]	1.6
45	328105	EOS28036	c_6_hs	gj 5868020 ref gn 11 - 301705 301784 ex 4 7 CDSi 5.30 80 3147	CH.06_hs gj 5868020	1.6
	325481	EOS25412	c12_hs	gj 5866957 ref gn 3 + 47590 47672 ex 4 7 CDSi 2.69 83 1895	CH.12_hs gj 5866957	1.6
	315361	EOS15292	AI335229	Hs.122031	ESTs	1.6
50	324902	EOS24833	D31323	Hs.211188	ESTs	1.6
	336018	EOS35949	CH22_3401FG_669_7_LINK	DJ32110.GENSCAN.9-12	CH22_FGENES.669_7	1.6
	308747	EOS08678	AI804500	Hs.181165	eukaryotic translation elongation factor 1 alpha 1	1.6
55	328251	EOS28182	c_6_hs	gj 6381891 ref gn 4 + 124444 124557 ex 2 3 CDSi 0.40 114 4554	CH.06_hs gj 6381891	1.6
	303153	EOS03084	U09759	Hs.8325	mitogen-activated protein kinase 9	1.6
	327809	EOS27740	c_5_hs	gj 5867968 ref gn 3 + 54610 54761 ex 4 4 CDSi 0.78 152 993	CH.05_hs gj 5867968	1.6
	314107	EOS14038	AA806113	Hs.189025	ESTs	1.6
60	300304	EOS00235	AI837934	Hs.224978	ESTs	1.6
	313009	EOS12940	W52010	Hs.191379	ESTs	1.6
	331074	EOS31005	R08440		yf1919.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:127337 3' similar to contains Alu repetitive element; mRNA sequence	1.6
	335773	EOS35704	CH22_3142FG_607_9_LINK	EM:AC005500.GENSCAN.496-4	CH22_FGENES.607_9	1.6
65	334991	EOS34922	CH22_2312FG_469_11_LINK	EM:AC005500.GENSCAN.365-11	CH22_FGENES.469_11	1.6
	322959	EOS22890	AI267606		EST cluster (not in UniGene)	1.6
	323731	EOS23662	AA323414		EST cluster (not in UniGene)	1.6
70	331073	EOS31004	R07998	Hs.18628	ESTs; Weakly similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]	1.6
	313573	EOS13504	AI076259	Hs.190337	ESTs	1.6
	316949	EOS16880	AA856749	Hs.124620	ESTs	1.6
	328084	EOS28015	c_6_hs	gj 6469819 ref gn 3 - 155366 155459 ex 1 4 CDSi 1.23 94 2982	CH.06_hs gj 6469819	1.6
75	331526	EOS31457	N49967	Hs.46624	ESTs	1.6
	317987	EOS17918	AW138174	Hs.130651	ESTs	1.6
	325594	EOS25525	c13_hs	gj 5866992 ref gn 4 - 470474 470566 ex 2 3 CDSi 8.09 93 68	CH.13_hs gj 5866992	1.6
	310848	EOS10779	AI459554	Hs.161286	ESTs	1.6
80	309268	EOS09199	AI985821	Hs.62954	ferritin; heavy polypeptide 1	1.6
	304518	EOS04449	AA461438		EST singleton (not in UniGene) with exon hit	1.6
	331065	EOS30996	N90584	Hs.9167	Homo sapiens clone 25085 mRNA sequence	1.6
	306501	EOS06432	AA987294		EST singleton (not in UniGene) with exon hit	1.6
	323289	EOS23220	AL134235	Hs.222442	ESTs	1.6
85	334630	EOS34561	CH22_1938FG_416_6_LINK	EM:AC005500.GENSCAN.277-6	CH22_FGENES.416_6	1.6
	302025	EOS01956	AI091466	Hs.127241	DKFZP564F052 protein	1.6

	328998	EOS28929	c_9_hs	gi 5868538 ref	gn 1 + 40996 41104 ex 1 3 CDS	11.00 109 480	
					CH.09_hs	gi 5868538	1.6
	313197	EOS13128	A1738851	Hs.222487	ESTs		1.6
5	338763	EOS38694	CH22_7585FG	_LINK_EM:AC005500.GENSCAN.517-16			
					CH22_EM:AC005500.GENSCAN.517-16		1.6
	332247	EOS32178	N58172	Hs.109370	ESTs		1.6
	316724	EOS16655	AA810788	Hs.123337	ESTs		1.6
	303306	EOS03237	AA215297		EST cluster (not in UniGene) with exon hit		1.6
10	306336	EOS06267	AA954198		EST singleton (not in UniGene) with exon hit		1.6
	308256	EOS08187	AI565498		EST singleton (not in UniGene) with exon hit		1.6
	307056	EOS06987	AI148675		EST singleton (not in UniGene) with exon hit		1.6
	321370	EOS21301	AJ227900		EST cluster (not in UniGene)		1.6
	336262	EOS36193	CH22_3661FG_754_9	_LINK_DA59H18.GENSCAN.57-11			
15					CH22_FGENES.754_9		1.6
	335497	EOS35428	CH22_2849FG_571_5	_LINK_EM:AC005500.GENSCAN.460-26			
					CH22_FGENES.571_5		1.6
	309582	EOS09513	AW169657		EST singleton (not in UniGene) with exon hit		1.6
20	329563	EOS29494	c10_p2	gi 3962490 gb A	gn 1 - 410 635 ex 2 2 CDS	13.80 226 267	
					CH.10_p2	gi 3962490	1.6
	332504	EOS32435	AA053917	Hs.15106	chromosome 14 open reading frame 1		1.6
	308090	EOS08021	AI474601	Hs.2186	eukaryotic translation elongation factor 1 gamma		1.6
	331752	EOS31683	AA287312	Hs.191648	ESTs		1.6
	330881	EOS30812	AA132986	Hs.69321	ESTs; Weakly similar to Similar to mucin and several other Ser-Thr-rich proteins [S.cerevisiae]		1.6
25	315647	EOS15578	AA648983	Hs.212911	ESTs		1.6
	336766	EOS36697	CH22_4341FG_143_20		CH22_FGENES.143-20		1.6
	302592	EOS02523	AA294921	Hs.250811	v-ral simian leukemia viral oncogene homolog B (ras related; GTP binding protein)		1.6
	315076	EOS15007	AI623817	Hs.168457	ESTs		1.6
	337056	EOS36987	CH22_4946FG_441_4		CH22_FGENES.441-4		1.6
	322175	EOS22106	AF085975		EST cluster (not in UniGene)		1.6
30	336833	EOS36764	CH22_4504FG_242_2		CH22_FGENES.242-2		1.6
	334902	EOS34833	CH22_2219FG_452_16	_LINK_EM:AC005500.GENSCAN.341-19			
					CH22_FGENES.452_16		1.6
	318671	EOS18602	AA188823	Hs.212621	ESTs		1.6
35	308064	EOS07995	AI469273	Hs.181165	eukaryotic translation elongation factor 1 alpha 1		1.6
	320559	EOS20490	AB021981	Hs.159322	solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter); member 3		1.6
	317881	EOS17812	AI827248	Hs.224398	ESTs		1.6
	313078	EOS13009	N49730		EST cluster (not in UniGene)		1.6
	338689	EOS38620	CH22_7464FG	_LINK_EM:AC005500.GENSCAN.475-3			
					CH22_EM:AC005500.GENSCAN.475-3		1.6
40	311804	EOS11735	AA135159	Hs.203349	ESTs		1.6
	316359	EOS16290	AI472213	Hs.123415	ESTs		1.6
	330182	EOS30113	c_4_p2	gi 5123954 emb	gn 4 + 120156 120245 ex 2 2 CDS	4.69 90 11	
					CH.04_p2	gi 5123954	1.6
45	334718	EOS34649	CH22_2028FG_421_29	_LINK_EM:AC005500.GENSCAN.282-29			
					CH22_FGENES.421_29		1.6
	324196	EOS24127	AA405524	Hs.178000	ESTs		1.6
	305350	EOS05281	AA706676		EST singleton (not in UniGene) with exon hit		1.6
	331469	EOS31400	N22273	Hs.39140	ESTs		1.6
50	305715	EOS05646	AA826884		EST singleton (not in UniGene) with exon hit		1.6
	314460	EOS14391	AI263231	Hs.145607	ESTs		1.6
	317634	EOS17565	AA953088	Hs.127550	ESTs		1.6
	335293	EOS35224	CH22_2635FG_527_6	_LINK_EM:AC005500.GENSCAN.421-9			
					CH22_FGENES.527_6		1.6
55	305611	EOS05542	AA782331		EST singleton (not in UniGene) with exon hit		1.6
	310430	EOS10361	AI670843	Hs.200257	ESTs		1.6
	323696	EOS23627	AA641201	Hs.222051	ESTs		1.6
	300610	EOS00541	N72596	Hs.99120	DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide; Y chromosome		1.6
	327364	EOS27295	c_1_hs	gi 6552412 ref	gn 2 - 115235 115396 ex 1 9 CDS	2.77 162 3007	
60					CH.01_hs	gi 6552412	1.6
	324848	EOS24779	AW021857		EST cluster (not in UniGene)		1.6
	321491	EOS21422	H70665	Hs.183960	ESTs		1.6
	336367	EOS36298	CH22_3779FG_818_11	_LINK_BA232E17.GENSCAN.3-17			
					CH22_FGENES.818_11		1.6
65	331549	EOS31480	N56866	Hs.237507	EST		1.6
	328332	EOS28263	c_7_hs	gi 5868375 ref	gn 6 + 280154 280289 ex 3 5 CDS	-1.04 136 516	
					CH.07_hs	gi 5868375	1.5
	322817	EOS22748	C02420		EST cluster (not in UniGene)		1.5
70	303983	EOS03914	AW514111	Hs.181165	eukaryotic translation elongation factor 1 alpha 1		1.5
	329434	EOS29365	c_y_hs	gi 5868883 ref	gn 1 - 31124 31263 ex 3 20 CDS	6.38 140 241	
					CH.Y_hs	gi 5868883	1.5
	338196	EOS38127	CH22_6763FG	_LINK_EM:AC005500.GENSCAN.235-16			
					CH22_EM:AC005500.GENSCAN.235-16		1.5
75	308488	EOS08419	AI682148	Hs.179661	Homo sapiens clone 24703 beta-tubulin mRNA; complete cds		1.5
	314883	EOS14814	AW178807	Hs.246182	ESTs		1.5
	307095	EOS07026	AI167910		EST singleton (not in UniGene) with exon hit		1.5
	306953	EOS06884	AI124971		EST singleton (not in UniGene) with exon hit		1.5
	331786	EOS31717	AA398539	Hs.97369	EST		1.5
	303509	EOS03440	AW378236	Hs.256050	ESTs		1.5
80	324515	EOS24446	AW501686	Hs.163539	ESTs		1.5
	339323	EOS39254	CH22_8284FG	_LINK_BA354I12.GENSCAN.23-2			
					CH22_BA354I12.GENSCAN.23-2		1.5
	306563	EOS06494	AA995296		EST singleton (not in UniGene) with exon hit		1.5
	316076	EOS16007	AW297895	Hs.116424	ESTs		1.5
85	325622	EOS25553	c14_hs	gi 5867000 ref	gn 2 + 69994 70075 ex 6 8 CDS	9.40 82 194	
					CH.14_hs	gi 5867000	1.5
	309632	EOS09563	AW193261	Hs.156110	Immunoglobulin kappa variable 1D-8		1.5

5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85

314926	EOS14857	AI380838	Hs.124835	ESTs	1.5
314458	EOS14389	AI217440	Hs.143873	ESTs	1.5
335219	EOS35150	CH22_2558FG_513_2_LINK_EM:AC005500.GENSCAN.406-2		CH22_FGENES.513_2	1.5
301079	EOS01010	AA305047	Hs.183654	ESTs; Weakly similar to unknown [S.cerevisiae]	1.5
334122	EOS34053	CH22_1400FG_333_3_LINK_EM:AC005500.GENSCAN.185-27		CH22_FGENES.333_3	1.5
308139	EOS08070	AI494477		EST singleton (not in UniGene) with exon hit	1.5
317412	EOS17343	AI301528	Hs.132604	ESTs	1.5
315073	EOS15004	AW452948	Hs.257631	ESTs	1.5
313139	EOS13070	AA362113		EST cluster (not in UniGene)	1.5
307012	EOS06943	AI140212		EST singleton (not in UniGene) with exon hit	1.5
322895	EOS22826	AW470295	Hs.192152	ESTs	1.5
303779	EOS03710	AA897296	Hs.221266	ESTs	1.5
312344	EOS12275	AI742618	Hs.181733	ESTs; Weakly similar to nitrilase homolog 1 [H.sapiens]	1.5
323632	EOS23563	AL039950		EST cluster (not in UniGene)	1.5
332336	EOS32267	T96130	Hs.137551	ESTs	1.5
304547	EOS04478	AA486189		EST singleton (not in UniGene) with exon hit	1.5
335692	EOS35623	CH22_3053FG_596_7_LINK_EM:AC005500.GENSCAN.488-7		CH22_FGENES.596_7	1.5
328333	EOS28264	c_7_hs gj 5868375 ref gn 6 + 282506 282664 ex 4 5 CDSi 7.71 159 517		CH.07_hs gj 5868375	1.5
304143	EOS04074	R88737		EST singleton (not in UniGene) with exon hit	1.5
329625	EOS29556	c11_p2 gj 4567169 gb A gn 2 - 85893 85984 ex 3 5 CDSi 2.24 92 29		CH.11_p2 gj 4567169	1.5
329960	EOS29891	c16_p2 gj 5091594 gb A gn 1 - 1031 1162 ex 1 3 CDSi 10.75 132 415		CH.16_p2 gj 5091594	1.5
318975	EOS18906	Z44110		EST cluster (not in UniGene)	1.5
321875	EOS21806	N49122		EST cluster (not in UniGene)	1.5
320451	EOS20382	R26944	Hs.180777	Homo sapiens mRNA; cDNA DKFZp564M0264 (from clone DKFZp564M0264)	1.5
336020	EOS35951	CH22_3403FG_669_9_LINK_DJ32110.GENSCAN.9-14		CH22_FGENES.669_9	1.5
332581	EOS32512	T28799	Hs.2913	EphB3	1.5
338622	EOS38553	CH22_7384FG_LINK_EM:AC005500.GENSCAN.451-1		CH22_EM:AC005500.GENSCAN.451-1	1.5
330397	EOS30328	D14659	Hs.154387	KIAA0103 gene product	1.5
314359	EOS14290	AA205569	Hs.194193	ESTs	1.5
313456	EOS13387	AW380579	Hs.209657	ESTs	1.5
318486	EOS18417	H09123	Hs.139258	ESTs	1.5
318175	EOS18106	AA644624		EST cluster (not in UniGene)	1.5
335684	EOS35615	CH22_3045FG_595_4_LINK_EM:AC005500.GENSCAN.487-13		CH22_FGENES.595_4	1.5
327814	EOS27745	c_5_hs gj 5867968 ref gn 6 + 69377 70566 ex 1 2 CDSi 86.15 1190 999		CH.05_hs gj 5867968	1.5
322120	EOS22051	W84351	Hs.213846	ESTs	1.5
311749	EOS11680	R06249	Hs.13911	ESTs	1.5
329797	EOS29728	c14_p2 gj 6523160 emb gn 1 - 10616 10894 ex 3 6 CDSi 5.86 279 1549		CH.14_p2 gj 6523160	1.5
330630	EOS30561	X78669	Hs.79088	reticulocalbin 2; EF-hand calcium binding domain	1.5
303777	EOS03708	AA348491		EST cluster (not in UniGene) with exon hit	1.5
309656	EOS09587	AW197060	Hs.195188	glyceraldehyde-3-phosphate dehydrogenase	1.5
326165	EOS26096	c17_hs gj 5867208 ref gn 2 - 62787 62929 ex 1 10 CDSi 0.87 143 2037		CH.17_hs gj 5867208	1.5
308328	EOS08259	AI590571	Hs.186412	EST	1.5
300601	EOS00532	AI762130	Hs.165619	ESTs	1.5
303610	EOS03541	AA323288		EST cluster (not in UniGene) with exon hit	1.5
307856	EOS07787	AI366158		EST singleton (not in UniGene) with exon hit	1.5
319920	EOS19851	R54575	Hs.13337	ESTs; Weakly similar to similar to Phosphoglucosyltransferase and phosphomannomutase phosphoserine [C.elegans]	1.5
332167	EOS32098	D57389	Hs.75447	ralA binding protein 1	1.5
316427	EOS16358	AI241019	Hs.145644	ESTs	1.5
303888	EOS03817	AW365963		EST cluster (not in UniGene) with exon hit	1.5
314292	EOS14223	AA732590	Hs.134740	ESTs	1.5
315408	EOS15339	AW273261	Hs.216292	ESTs	1.5
335698	EOS35629	CH22_3059FG_597_1_LINK_EM:AC005500.GENSCAN.489-1		CH22_FGENES.597_1	1.5
315084	EOS15015	AI821085	Hs.187796	ESTs	1.5
302299	EOS02230	R64632	Hs.182167	hemoglobin; gamma A	1.5
306803	EOS06734	AI055860	Hs.193717	interleukin 10	1.5
315802	EOS15733	AA677540	Hs.117064	ESTs	1.5
326257	EOS26188	c17_hs gj 5867264 ref gn 6 + 222712 222819 ex 2 2 CDSi 4.46 108 3597		CH.17_hs gj 5867264	1.5
319599	EOS19530	H56112		EST cluster (not in UniGene)	1.5
321891	EOS21822	AW157424	Hs.165954	ESTs	1.5
335164	EOS35095	CH22_2500FG_502_8_LINK_EM:AC005500.GENSCAN.396-23		CH22_FGENES.502_8	1.5
327133	EOS27064	c21_hs gj 6682522 ref gn 1 + 38069 38938 ex 2 2 CDSi 63.42 870 1583		CH.21_hs gj 6682522	1.5
317460	EOS17391	AA926980	Hs.131347	ESTs	1.5
332344	EOS32275	W45574	Hs.252497	ESTs	1.5
328801	EOS28732	c_7_hs gj 5868321 ref gn 1 - 44492 44609 ex 2 3 CDSi 1.71 118 5525		CH.07_hs gj 5868321	1.5
321877	EOS21608	N44545	Hs.251865	ESTs	1.5
331858	EOS31789	AA421163	Hs.163848	ESTs	1.5
309243	EOS09174	AI972052		EST singleton (not in UniGene) with exon hit	1.5
326213	EOS26144	c17_hs gj 5867224 ref gn 3 - 60751 60927 ex 1 4 CDSi 2.06 177 2687			1.5

5	321632	EOS21563	AA419617	CH.17_hs gjl5867224	1.5
	321424	EOS21355	AA057301	EST cluster (not in UniGene)	1.5
	322465	EOS22396	AA137152 Hs.3784	ESTs; Highly similar to phosphoserine aminotransferase [H.sapiens]	1.5
	333391	EOS33322	CH22_637FG_144_6_LINK_EM:AC005500.GENSCAN.25-6		1.5
	333384	EOS33315	CH22_630FG_143_23_LINK_EM:AC005500.GENSCAN.24-17		1.5
10	334784	EOS34715	CH22_2096FG_432_9_LINK_EM:AC005500.GENSCAN.293-12		1.5
	334078	EOS34009	CH22_1356FG_327_33_LINK_EM:AC005500.GENSCAN.181-35		1.5
	335158	EOS35089	CH22_2494FG_502_2_LINK_EM:AC005500.GENSCAN.396-17		1.5
15	335062	EOS34993	CH22_2388FG_482_17_LINK_EM:AC005500.GENSCAN.376-16		1.5
	333243	EOS33174	CH22_482FG_111_7_LINK_EM:AC000097.GENSCAN.120-6		1.5
	306380	EOS06311	AA968861	EST singleton (not in UniGene) with exon hit	1.5
20	320809	EOS20740	AI540299	EST cluster (not in UniGene)	1.5
	332813	EOS32744	CH22_29FG_8_1_LINK_C65E1.GENSCAN.2-2		1.5
	335817	EOS35748	CH22_3189FG_618_5_LINK_EM:AC005500.GENSCAN.510-5		1.5
25	319551	EOS19482	AA761668	EST cluster (not in UniGene)	1.5
	334472	EOS34403	CH22_1771FG_394_3_LINK_EM:AC005500.GENSCAN.257-3		1.5
	333029	EOS32960	CH22_255FG_68_3_LINK_EM:AC000097.GENSCAN.40-3		1.5
30	308055	EOS07986	AI468091 Hs.119252	tumor protein; translationally-controlled 1	1.5
	302882	EOS02813	AW403330	EST cluster (not in UniGene) with exon hit	1.5
	314033	EOS13964	AA167125	EST cluster (not in UniGene)	1.5
35	324928	EOS24859	AI932285 Hs.160569	ESTs	1.5
	329524	EOS29455	c10_p2 gjl3983507[gblA gn 6 - 38025 38143 ex 3 3 CDSi 2.40 119 170		1.5
	333131	EOS33062	CH22_360FG_83_6_LINK_EM:AC000097.GENSCAN.67-10		1.5
40	332085	EOS32016	AA600353 Hs.173933	ESTs; Weakly similar to NUCLEAR FACTOR 1/X [H.sapiens]	1.5
	305369	EOS05300	AA714040	EST singleton (not in UniGene) with exon hit	1.5
	300344	EOS00275	AW291487 Hs.213659	ESTs	1.5
45	325071	EOS25002	H09693	EST cluster (not in UniGene)	1.5
	323693	EOS23624	AW297758 Hs.249721	ESTs	1.5
	321899	EOS21830	N55158 Hs.135252	ESTs	1.5
50	331857	EOS31788	AA421160 Hs.9456	SWI/SNF related; matrix associated; actin dependent regulator of chromatin; subfamily a; member 5	1.5
	334850	EOS34781	CH22_2164FG_439_36_LINK_EM:AC005500.GENSCAN.311-13		1.5
	322610	EOS22541	AF180919	EST cluster (not in UniGene)	1.5
55	335332	EOS35263	CH22_2677FG_535_6_LINK_EM:AC005500.GENSCAN.426-6		1.5
	307565	EOS07496	AI282468	EST singleton (not in UniGene) with exon hit	1.5
	314140	EOS14071	AI216473 Hs.154297	ESTs	1.5
60	323011	EOS22942	AA580288	EST cluster (not in UniGene)	1.5
	325366	EOS25297	c12_hs gjl5866920[ref] gn 9 - 920962 921713 ex 1 8 CDSi 15.95 752 167		1.5
	322306	EOS22237	W75935 Hs.146083	ESTs	1.5
65	311034	EOS10965	AI564023 Hs.171467	ESTs; Highly similar to NKG2-D TYPE II INTEGRAL MEMBRANE PROTEIN [H.sapiens]	1.5
	305081	EOS05012	AA641638	EST singleton (not in UniGene) with exon hit	1.5
	322933	EOS22864	AA099759	EST cluster (not in UniGene)	1.5
70	335221	EOS35152	CH22_2560FG_513_4_LINK_EM:AC005500.GENSCAN.406-4		1.5
	304948	EOS04879	AA613107	EST singleton (not in UniGene) with exon hit	1.5
	334900	EOS34831	CH22_2217FG_452_14_LINK_EM:AC005500.GENSCAN.341-17		1.5
75	318404	EOS18335	AI654108 Hs.135125	ESTs	1.5
	339358	EOS39289	CH22_8328FG_LINK_BA354112.GENSCAN.31-3		1.5
	327074	EOS27005	c21_hs gjl6531965[ref] gn 58 + 4039993 4040096 ex 3 4 CDSi 0.68 104 1284		1.5
80	326054	EOS25985	c17_hs gjl5867184[ref] gn 2 - 146342 146469 ex 3 4 CDSi 10.00 128 426		1.5
	326892	EOS26823	c20_hs gjl6682511[ref] gn 5 + 119424 119500 ex 29 30 CDSi 18.89 77 2313		1.5
	328767	EOS28698	c_7_hs gjl6017031[ref] gn 1 - 35625 35723 ex 4 4 CDSi 5.63 99 5262		1.5
85	337772	EOS37703	CH22_6125FG_LINK_EM:AC000097.GENSCAN.119-11		1.5
	312199	EOS12130	AW438602 Hs.191179	ESTs	1.5
	303506	EOS03437	AA340605 Hs.105887	ESTs	1.5
90	325176	EOS25107	T52843	EST cluster (not in UniGene)	1.5
	302023	EOS01954	AF060567 Hs.126782	sushi-repeat protein	1.5
	305833	EOS05764	AA857836 Hs.181165	eukaryotic translation elongation factor 1 alpha 1	1.5
95	309131	EOS09062	AI929175 Hs.119122	ribosomal protein L13a	1.5
	334184	EOS34115	CH22_1465FG_350_15_LINK_EM:AC005500.GENSCAN.209-17		1.5
	335188	EOS35119	CH22_2524FG_507_3_LINK_EM:AC005500.GENSCAN.400-3		1.5

	304813	EOS04744	AA584540		EST singleton (not in UniGene) with exon hit	1.5
	315359	EOS15290	AA608808	Hs.225118	ESTs	1.5
	324434	EOS24365	AA707249	Hs.98789	ESTs	1.5
5	327910	EOS27841	c_6_hs	gj 5868162 ref	gn 1 + 21622 21748 ex 6 7 CDSi 3.69 127 449	1.4
					CH.06_hs	gj 5868162
	335671	EOS35602	CH22_3031FG_592_3_LINK	EM:AC005500.GENSCAN.485-4		1.4
					CH22_FGENES.592_3	1.4
	334943	EOS34874	CH22_2264FG_465_8_LINK	EM:AC005500.GENSCAN.359-8		1.4
10					CH22_FGENES.465_8	1.4
	326393	EOS26324	c_19_hs	gj 5867341 ref	gn 2 + 41702 41841 ex 5 5 CDSi 20.15 140 504	1.4
					CH.19_hs	gj 5867341
	305296	EOS05227	AA687181		EST singleton (not in UniGene) with exon hit	1.4
	307243	EOS07174	AI199957		EST singleton (not in UniGene) with exon hit	1.4
15	320066	EOS19997	AW364885	Hs.112442	ESTs	1.4
	311465	EOS11396	AI758660	Hs.206132	ESTs	1.4
	302822	EOS02753	AW404176	Hs.111611	ribosomal protein L27	1.4
	304987	EOS04918	AA618044		EST singleton (not in UniGene) with exon hit	1.4
	330892	EOS30823	AA149579	Hs.118258	ESTs	1.4
20	333385	EOS33316	CH22_631FG_143_24_LINK	EM:AC005500.GENSCAN.24-18		1.4
					CH22_FGENES.143_24	1.4
	302626	EOS02557	AB021870		EST cluster (not in UniGene) with exon hit	1.4
	318042	EOS17973	AW294522	Hs.149991	ESTs	1.4
	339361	EOS39292	CH22_8331FG_LINK_BA354112	GENSCAN.32-3		1.4
					CH22_BA354112.GENSCAN.32-3	1.4
25	309000	EOS08931	AI880489		EST singleton (not in UniGene) with exon hit	1.4
	306004	EOS05935	AA889992		EST singleton (not in UniGene) with exon hit	1.4
	329539	EOS29470	c10_p2	gj 3983503 gb U	gn 1 - 1 326 ex 1 3 CDSi 41.66 326 212	1.4
					CH.10_p2	gj 3983503
	313663	EOS13594	AI953261	Hs.169813	ESTs	1.4
30	323538	EOS23469	AW247696		EST cluster (not in UniGene)	1.4
	337595	EOS37526	CH22_5884FG_LINK_C20H12	GENSCAN.8-1		1.4
					CH22_C20H12.GENSCAN.8-1	1.4
	303149	EOS03080	AA312995		EST cluster (not in UniGene) with exon hit	1.4
35	308484	EOS08415	AI679292		EST singleton (not in UniGene) with exon hit	1.4
	300912	EOS00843	AW138724	Hs.168974	ESTs	1.4
	315158	EOS15089	AA744438	Hs.142476	ESTs; Weakly similar to !!!! ALU CLASS D WARNING ENTRY !!!! [H.sapiens]	1.4
	300462	EOS00393	AA746501	Hs.14217	ESTs	1.4
	312730	EOS12661	AI804372	Hs.208661	ESTs	1.4
40	316868	EOS16799	AI660898	Hs.195602	ESTs	1.4
	337629	EOS37560	CH22_5933FG_LINK_C20H12	GENSCAN.28-35		1.4
					CH22_C20H12.GENSCAN.28-35	1.4
	332518	EOS32449	D16562	Hs.155433	ATP synthase; H+ transporting; mitochondrial F1 complex; gamma polypeptide 1	1.4
	337422	EOS37353	CH22_5624FG_760_2		CH22_FGENES.760-2	1.4
45	328835	EOS28766	c_7_hs	gj 5868339 ref	gn 5 + 88053 88461 ex 3 3 CDSi 13.78 409 5775	1.4
					CH.07_hs	gj 5868339
	338282	EOS38213	CH22_6897FG_LINK_EM:AC005500	GENSCAN.291-4		1.4
					CH22_EM:AC005500.GENSCAN.291-4	1.4
	337895	EOS37826	CH22_6303FG_LINK_EM:AC005500	GENSCAN.56-2		1.4
					CH22_EM:AC005500.GENSCAN.56-2	1.4
50	320330	EOS20261	AF026004	Hs.141660	chloride channel 2	1.4
	314302	EOS14233	AA813118	Hs.163230	ESTs	1.4
	313280	EOS13211	AI285537	Hs.222830	ESTs	1.4
	333222	EOS33153	CH22_459FG_105_2_LINK	EM:AC000097.GENSCAN.109-6		1.4
					CH22_FGENES.105_2	1.4
55	305726	EOS05657	AA828156		EST singleton (not in UniGene) with exon hit	1.4
	312674	EOS12605	AI762475	Hs.151327	ESTs; Moderately similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]	1.4
	315869	EOS15800	AI033547	Hs.132826	ESTs	1.4
	327010	EOS26941	c21_hs	gj 5867664 ref	gn 12 + 941057 941139 ex 9 9 CDSi 7.44 83 790	1.4
					CH.21_hs	gj 5867664
60	325892	EOS25823	c16_hs	gj 5867088 ref	gn 1 - 10498 10652 ex 2 3 CDSi 3.94 155 870	1.4
					CH.16_hs	gj 5867088
	302575	EOS02506	AF071164	Hs.249171	homeo box A11	1.4
	301970	EOS01901	AB028962	Hs.120245	KIAA1039 protein	1.4
65	332207	EOS32138	H61475	Hs.237353	EST	1.4
	316024	EOS15955	AA707141	Hs.193388	ESTs	1.4
	314599	EOS14530	AW206512	Hs.186996	ESTs	1.4
	333585	EOS33516	CH22_846FG_203_4_LINK	EM:AC005500.GENSCAN.74-6		1.4
					CH22_FGENES.203_4	1.4
	324670	EOS24601	AI525557		EST cluster (not in UniGene)	1.4
70	321307	EOS21238	R85409		EST cluster (not in UniGene)	1.4
	335170	EOS35101	CH22_2506FG_503_1_LINK	EM:AC005500.GENSCAN.397-1		1.4
					CH22_FGENES.503_1	1.4
	328274	EOS28205	c_7_hs	gj 5868219 ref	gn 2 - 31244 31439 ex 1 11 CDSi 13.06 196 9	1.4
					CH.07_hs	gj 5868219
75	336880	EOS36811	CH22_4619FG_318_8		CH22_FGENES.318-8	1.4
	313825	EOS13756	AA215470		EST cluster (not in UniGene)	1.4
	318410	EOS18341	AI138418	Hs.144935	ESTs	1.4
	335361	EOS35292	CH22_2710FG_541_11_LINK	EM:AC005500.GENSCAN.431-16		1.4
					CH22_FGENES.541_11	1.4
80	319802	EOS19733	AI701489	Hs.202501	ESTs	1.4
	334769	EOS34700	CH22_2081FG_429_4_LINK	EM:AC005500.GENSCAN.290-9		1.4
					CH22_FGENES.429_4	1.4
	312709	EOS12640	AW069181	Hs.141146	ESTs; Weakly similar to transformation-related protein [H.sapiens]	1.4
85	330004	EOS29935	c16_p2	gj 6623963 gb A	gn 5 - 78672 78999 ex 2 6 CDSi 19.93 128 728	1.4
					CH.16_p2	gj 6623963
	313103	EOS13034	AI184303	Hs.143806	ESTs	1.4

	326359	EOS26290	c18_hs gi 5867293 ref gn 1 + 9436 9494 ex 2 3 CDSi 2.16 59 88		
			CH.18_hs gi 5867293		1.4
	305211	EOS05142	AA668563	EST singleton (not in UniGene) with exon hit	1.4
5	334628	EOS34559	CH22_1936FG_416_4_LINK_EM:AC005500.GENSCAN.277-4		
			CH22_FGENES.416_4		1.4
	326919	EOS26850	c21_hs gi 6456782 ref gn 2 - 40486 41046 ex 1 5 CDSi 17.70 561 157		
			CH.21_hs gi 6456782		1.4
	315527	EOS15458	A1791138 Hs.116768	ESTs	1.4
10	306090	EOS06021	AA908609	EST singleton (not in UniGene) with exon hit	1.4
	303316	EOS03247	AF033122 Hs.14125	p53 regulated PA26 nuclear protein	1.4
	303642	EOS03573	AW299459	EST cluster (not in UniGene) with exon hit	1.4
	314357	EOS14288	AA781795 Hs.122587	ESTs	1.4
	337102	EOS37033	CH22_5033FG_472_7_	CH22_FGENES.472-7	1.4
15	304384	EOS04315	AA235482 Hs.62954	ferritin; heavy polypeptide 1	1.4
	315117	EOS15048	AA828609 Hs.192044	ESTs	1.4
	305750	EOS05681	AA835250	EST singleton (not in UniGene) with exon hit	1.4
	311726	EOS11657	AW081766 Hs.253920	ESTs	1.4
	326996	EOS26927	c21_hs gi 5867660 ref gn 4 - 63212 63404 ex 2 6 CDSi 15.70 193 622		
20			CH.21_hs gi 5867660		1.4
	330257	EOS30188	c_5_p2 gi 6671881 gb A gn 2 - 143228 143393 ex 1 9 CDSi 11.31 166 586		
			CH.05_p2 gi 6671881		1.4
	323864	EOS23795	AA340724 Hs.214028	ESTs	1.4
	338204	EOS38135	CH22_6773FG__LINK_EM:AC005500.GENSCAN.241-3		
25			CH22_EM:AC005500.GENSCAN.241-3		1.4
	314025	EOS13956	A1983981 Hs.189114	ESTs	1.4
	315974	EOS15905	AW029203 Hs.191952	ESTs	1.4
	335599	EOS35530	CH22_2957FG_581_39_LINK_EM:AC005500.GENSCAN.476-37		
			CH22_FGENES.581_39		1.4
30	335364	EOS35295	CH22_2713FG_543_2_LINK_EM:AC005500.GENSCAN.432-4		
			CH22_FGENES.543_2		1.4
	303634	EOS03565	A1953377 Hs.169425	ESTs; Weakly similar to predicted using Genefinder [C.elegans]	1.4
	315626	EOS15557	AA808598 Hs.35353	ESTs; Weakly similar to H21P03.2 [C.elegans]	1.4
	329936	EOS29867	c16_p2 gi 6165200 gb A gn 4 - 82761 82920 ex 3 4 CDSi 1.15 160 199		
35			CH.16_p2 gi 6165200		1.4
	328632	EOS28563	c_7_hs gi 5868247 ref gn 1 + 76734 76853 ex 1 4 CDSi 13.95 120 3764		
			CH.07_hs gi 5868247		1.4
	330207	EOS30138	c_5_p2 gi 6013606 gb A gn 3 - 109912 110004 ex 2 4 CDSi 6.54 93 174		
			CH.05_p2 gi 6013606		1.4
40	329919	EOS29850	c16_p2 gi 6223624 gb A gn 6 - 103492 103681 ex 1 8 CDSi 6.18 190 93		
			CH.16_p2 gi 6223624		1.4
	331916	EOS31847	AA446131 Hs.124918	ESTs	1.4
	317617	EOS17548	T58194	EST cluster (not in UniGene)	1.4
	331943	EOS31874	AA453418 Hs.178272	ESTs	1.4
45	306413	EOS06344	AA973288	EST singleton (not in UniGene) with exon hit	1.4
	313607	EOS13538	N94169 Hs.194258	ESTs; Moderately similar to !!!! ALU SUBFAMILY SC WARNING ENTRY !!!! [H.sapiens]	1.4
	336292	EOS36223	CH22_3691FG_783_3_LINK_BA354112.GENSCAN.4-7		
			CH22_FGENES.783_3		1.4
	330453	EOS30384	HG3976-HT4246	Pou-Domain Dna Binding Factor Pit1, Pituitary-Specific	1.4
50	324602	EOS24533	AA503620 Hs.213239	ESTs	1.4
	332183	EOS32114	H08225 Hs.177181	ESTs	1.4
	320032	EOS19963	A1699772 Hs.202361	ESTs; Weakly similar to X-linked retinopathy protein [H.sapiens]	1.4
	333156	EOS33087	CH22_387FG_89_6_LINK_EM:AC000097.GENSCAN.84-8		
			CH22_FGENES.89_6		1.4
55	334156	EOS34087	CH22_1435FG_340_6_LINK_EM:AC005500.GENSCAN.190-7		
			CH22_FGENES.340_6		1.4
	334303	EOS34234	CH22_1594FG_373_6_LINK_EM:AC005500.GENSCAN.233-5		
			CH22_FGENES.373_6		1.4
60	325513	EOS25444	c12_hs gi 6017035 ref gn 1 - 34295 34490 ex 2 7 CDSi 6.49 196 2471		
			CH.12_hs gi 6017035		1.4
	302758	EOS02689	AA984563	EST cluster (not in UniGene) with exon hit	1.4
	329557	EOS29488	c10_p2 gi 3962492 gb A gn 6 - 53197 53647 ex 2 2 CDSi 37.68 451 247		
			CH.10_p2 gi 3962492		1.4
	331717	EOS31648	AA190888 Hs.153881	ESTs; Highly similar to NY-REN-62 antigen [H.sapiens]	1.4
65	325885	EOS25816	c16_hs gi 5867087 ref gn 11 + 193212 193377 ex 1 3 CDSi 43.19 166 792		
			CH.16_hs gi 5867087		1.4
	312160	EOS12091	AA805903 Hs.184371	ESTs	1.4
	328882	EOS28813	c_7_hs gi 6552423 ref gn 2 - 157669 157826 ex 4 6 CDSi 4.91 158 6200		
			CH.07_hs gi 6552423		1.4
70	339028	EOS38959	CH22_7925FG__LINK_DA59H18.GENSCAN.22-8		
			CH22_DA59H18.GENSCAN.22-8		1.4
	323497	EOS23428	A1523613 Hs.221544	ESTs	1.4
	316897	EOS16828	AA838114	EST cluster (not in UniGene)	1.4
	312479	EOS12410	A1950844 Hs.128738	ESTs; Weakly similar to non-lens beta gamma-crystallin like protein [H.sapiens]	1.4
75	338535	EOS38466	CH22_7251FG__LINK_EM:AC005500.GENSCAN.404-3		
			CH22_EM:AC005500.GENSCAN.404-3		1.4
	312754	EOS12685	R99834 Hs.250383	ESTs	1.4
	327527	EOS27458	c_2_hs gi 6381882 ref gn 2 - 98950 99040 ex 4 8 CDSi 5.78 91 1768		
			CH.02_hs gi 6381882		1.4
	324714	EOS24645	AA574312 Hs.245737	ESTs	1.4
80	302347	EOS02278	AF039400 Hs.194659	chloride channel; calcium activated; family member 1	1.4
	338008	EOS37939	CH22_6490FG__LINK_EM:AC005500.GENSCAN.127-9		
			CH22_EM:AC005500.GENSCAN.127-9		1.4
	315590	EOS15521	AA640637 Hs.225817	ESTs	1.4
	320825	EOS20756	NM_004751	EST cluster (not in UniGene)	1.4
85	300930	EOS00861	A1289481 Hs.136371	ESTs	1.4
	335225	EOS35156	CH22_2564FG_513_10_LINK_EM:AC005500.GENSCAN.406-9		

				CH22_FGENES.513_10	1.4
	337303	EOS37234	CH22_5442FG_681_5_	CH22_FGENES.681-5	1.4
	317198	EOS17129	AI810384 Hs.128025	ESTs	1.4
5	308991	EOS08922	AI879831	EST singleton (not in UniGene) with exon hit	1.4
	325472	EOS25403	c12_hs gj 6017034 ref gn 7 - 289581 289657 ex 2 6 CDSi 4.74 77 1786	CH.12_hs gj 6017034	1.4
	301266	EOS01197	AA829774	EST cluster (not in UniGene) with exon hit	1.4
	330901	EOS30832	AA157818 Hs.238380	Human endogenous retroviral protease mRNA; complete cds	1.4
10	313406	EOS13337	AI248314 Hs.132932	ESTs	1.4
	301454	EOS01385	AI751738	EST cluster (not in UniGene) with exon hit	1.4
	317269	EOS17200	AA906411 Hs.127378	ESTs	1.4
	338876	EOS38807	CH22_7733FG_LINK_DJ32110.GENSCAN.4-2	CH22_DJ32110.GENSCAN.4-2	1.4
15	328481	EOS28412	c_7_hs gj 5868449 ref gn 1 - 8987 9180 ex 4 31 CDSi 10.00 194 2103	CH.07_hs gj 5868449	1.4
	314022	EOS13953	AW452420 Hs.248678	ESTs	1.4
	307640	EOS07571	AI301992	EST singleton (not in UniGene) with exon hit	1.4
	315541	EOS15472	AI168233 Hs.123159	ESTs; Weakly similar to KIAA0668 protein [H.sapiens]	1.4
20	315489	EOS15420	AA628245 Hs.191847	ESTs	1.4
	327815	EOS27746	c_5_hs gj 5867968 ref gn 6 + 70804 71401 ex 2 2 CDSi 27.99 598 1000	CH.05_hs gj 5867968	1.4
	339319	EOS39250	CH22_8280FG_LINK_BA354112.GENSCAN.22-19	CH22_BA354112.GENSCAN.22-19	1.4
25	322564	EOS22495	W86440 Hs.118344	ESTs	1.4
	323812	EOS23743	AW081373 Hs.199199	ESTs	1.4
	303540	EOS03471	AA355607 Hs.173590	ESTs; Weakly similar to MMSET type I [H.sapiens]	1.4
	337902	EOS37833	CH22_6314FG_LINK_EM:AC005500.GENSCAN.56-13	CH22_EM:AC005500.GENSCAN.56-13	1.4
30	335289	EOS35220	CH22_2631FG_527_2_LINK_EM:AC005500.GENSCAN.421-2	CH22_FGENES.527_2	1.4
	327919	EOS27850	c_6_hs gj 5868165 ref gn 6 + 547701 547800 ex 14 14 CDSi -0.20 100 505	CH.06_hs gj 5868165	1.4
35	337674	EOS37605	CH22_6005FG_LINK_EM:AC000097.GENSCAN.67-4	CH22_EM:AC000097.GENSCAN.67-4	1.4
	320087	EOS20018	AF032387 Hs.113265	small nuclear RNA activating complex; polypeptide 4; 190kD	1.4
	334939	EOS34870	CH22_2259FG_465_3_LINK_EM:AC005500.GENSCAN.359-3	CH22_FGENES.465_3	1.3
40	303443	EOS03374	AA320525	EST cluster (not in UniGene) with exon hit	1.3
	325929	EOS25860	c16_hs gj 5867125 ref gn 2 - 51715 51996 ex 1 1 CDSi 29.05 282 1594	CH.16_hs gj 5867125	1.3
	327745	EOS27676	c_5_hs gj 6531959 ref gn 1 - 229066 229124 ex 3 6 CDSi 3.01 59 177	CH.05_hs gj 6531959	1.3
45	335166	EOS35097	CH22_2502FG_502_10_LINK_EM:AC005500.GENSCAN.396-25	CH22_FGENES.502_10	1.3
	324497	EOS24428	AW152624 Hs.136340	ESTs	1.3
	338374	EOS38305	CH22_7017FG_LINK_EM:AC005500.GENSCAN.327-1	CH22_EM:AC005500.GENSCAN.327-1	1.3
50	313601	EOS13532	R32458 Hs.257711	ESTs	1.3
	321415	EOS21346	AI377596 Hs.3337	transmembrane 4 superfamily member 1	1.3
	305309	EOS05240	AA699717	EST singleton (not in UniGene) with exon hit	1.3
	330447	EOS30378	HG3546-HT3744	Pre-Mma Splicing Factor S12p33, Alt. Splice Form 1	1.3
55	308578	EOS08509	AI708573	EST singleton (not in UniGene) with exon hit	1.3
	315344	EOS15275	AW292176 Hs.245834	ESTs	1.3
	330503	EOS30434	M55024	Human cell surface glycoprotein P3.58 mRNA, partial cds	1.3
	308227	EOS08158	AI559126 Hs.195188	glyceraldehyde-3-phosphate dehydrogenase	1.3
	332222	EOS32153	N28271 Hs.176618	ESTs	1.3
	323961	EOS23892	AL044428 Hs.207345	ESTs	1.3
	314530	EOS14461	AI052358 Hs.131741	ESTs	1.3
60	320503	EOS20434	NM_005897	EST cluster (not in UniGene)	1.3
	306820	EOS06751	AI074408	EST singleton (not in UniGene) with exon hit	1.3
	304165	EOS04096	H73265	EST singleton (not in UniGene) with exon hit	1.3
	324302	EOS24233	AA543008 Hs.136806	ESTs; Weakly similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]	1.3
65	319128	EOS19059	AA393820	EST cluster (not in UniGene)	1.3
	317092	EOS17023	AI286162 Hs.125657	ESTs	1.3
	304998	EOS04929	AA621203	EST singleton (not in UniGene) with exon hit	1.3
	331433	EOS31364	H68097 Hs.161023	EST	1.3
	333348	EOS33279	CH22_594FG_140_2_LINK_EM:AC005500.GENSCAN.20-2	CH22_FGENES.140_2	1.3
70	333619	EOS33550	CH22_880FG_219_3_LINK_EM:AC005500.GENSCAN.87-2	CH22_FGENES.219_3	1.3
	335903	EOS35834	CH22_3280FG_635_11_LINK_EM:AC005500.GENSCAN.525-14	CH22_FGENES.635_11	1.3
75	326219	EOS26150	c17_hs gj 5867226 ref gn 11 - 264008 264274 ex 3 5 CDSi 5.74 267 2847	CH.17_hs gj 5867226	1.3
	324456	EOS24387	AW500954	EST cluster (not in UniGene)	1.3
	316405	EOS16336	AA757900 Hs.202624	ESTs	1.3
	314361	EOS14292	AL038765 Hs.161304	ESTs	1.3
	328546	EOS28477	c_7_hs gj 5868487 ref gn 1 - 17547 17722 ex 2 3 CDSi 9.96 176 3284	CH.07_hs gj 5868487	1.3
80	335871	EOS35802	CH22_3246FG_629_19_LINK_EM:AC005500.GENSCAN.519-18	CH22_FGENES.629_19	1.3
	303735	EOS03666	AA707750 Hs.202616	ESTs; Weakly similar to cis-Golgi matrix protein GM130 [R.norvegicus]	1.3
	324048	EOS23979	AA378739	EST cluster (not in UniGene)	1.3
85	326720	EOS26651	c20_hs gj 6552456 ref gn 1 + 84525 84677 ex 5 7 CDSi 11.78 153 1031	CH.20_hs gj 6552456	1.3
	322309	EOS22240	AF086372	EST cluster (not in UniGene)	1.3

	322136	EOS22067	AF075083		EST cluster (not in UniGene)	1.3
	313460	EOS13391	AW028655	Hs.136033	ESTs	1.3
	306275	EOS06206	AA936312		EST singleton (not in UniGene) with exon hit	1.3
5	321974	EOS21905	N76794		EST cluster (not in UniGene)	1.3
	327600	EOS27531	c_3_hs_gij6004462 ref	gn 1 - 2621 2862 ex 1 4 CDSi -4.01 242 1407		
				CH.03_hs_gij6004462		1.3
	329086	EOS29017	c_x_hs_gij5868604 ref	gn 1 - 35489 35588 ex 2 9 CDSi 2.55 100 719		
				CH.X_hs_gij5868604		1.3
10	336919	EOS36850	CH22_4690FG_346_6		CH22_FGENES.346-6	1.3
	302767	EOS02698	H94900	Hs.17882	ESTs	1.3
	334786	EOS34717	CH22_2098FG_432_11_LINK_EM:AC005500.GENSCAN.293-14			
				CH22_FGENES.432_11		1.3
	302472	EOS02403	AA317451	Hs.241451	SW/ISNF related; matrix associated; actin dependent regulator of chromatin; subfamily e; member 1	1.3
15	333033	EOS32964	CH22_259FG_68_8_LINK_EM:AC000097.GENSCAN.40-8			
				CH22_FGENES.68_8		1.3
	330493	EOS30424	M27826	Hs.238380	Human endogenous retroviral protease mRNA; complete cds	1.3
	330506	EOS30437	M61906	Hs.6241	phosphoinositide-3-kinase; regulatory subunit; polypeptide 1 (p85 alpha)	1.3
	313932	EOS13863	AI147601	Hs.154087	ESTs	1.3
20	314394	EOS14325	AI380563	Hs.130816	ESTs	1.3
	323033	EOS22964	AI744284	Hs.221727	ESTs	1.3
	326431	EOS26362	c19_hs_gij5867371 ref	gn 1 + 15855 15971 ex 4 6 CDSi 7.79 117 1108		
				CH.19_hs_gij5867371		1.3
	335547	EOS35478	CH22_2902FG_576_8_LINK_EM:AC005500.GENSCAN.467-8			
25				CH22_FGENES.576_8		1.3
	300548	EOS00479	AI026836	Hs.114689	ESTs	1.3
	316504	EOS16435	AW135854	Hs.132458	ESTs	1.3
	335756	EOS35687	CH22_3123FG_604_5_LINK_EM:AC005500.GENSCAN.493-10			
				CH22_FGENES.604_5		1.3
30	301209	EOS01140	AI809912	Hs.159354	ESTs	1.3
	306610	EOS06541	AI000635		EST singleton (not in UniGene) with exon hit	1.3
	314439	EOS14370	AI539443	Hs.137447	ESTs	1.3
	315396	EOS15327	AW296107	Hs.152686	ESTs	1.3
	335914	EOS35845	CH22_3291FG_636_10_LINK_EM:AC005500.GENSCAN.526-10			
35				CH22_FGENES.636_10		1.3
	333734	EOS33665	CH22_1000FG_260_2_LINK_EM:AC005500.GENSCAN.119-7			
				CH22_FGENES.260_2		1.3
	312370	EOS12301	AA744692	Hs.166539	ESTs	1.3
	304636	EOS04567	AA524031		EST singleton (not in UniGene) with exon hit	1.3
40	323166	EOS23097	AA291001		EST cluster (not in UniGene)	1.3
	338702	EOS38633	CH22_7482FG_LINK_EM:AC005500.GENSCAN.480-1			
				CH22_EM:AC005500.GENSCAN.480-1		1.3
	322331	EOS22262	AF086467		EST cluster (not in UniGene)	1.3
	318706	EOS18637	AI383593	Hs.159148	ESTs	1.3
45	331186	EOS31117	T41159	Hs.8418	ESTs	1.3
	334764	EOS34695	CH22_2076FG_428_13_LINK_EM:AC005500.GENSCAN.289-13			
				CH22_FGENES.428_13		1.3
	327565	EOS27496	c_3_hs_gij5867811 ref	gn 1 + 32516 32778 ex 2 3 CDSi 0.20 263 368		
				CH.03_hs_gij5867811		1.3
50	335524	EOS35455	CH22_2879FG_572_4_LINK_EM:AC005500.GENSCAN.461-4			
				CH22_FGENES.572_4		1.3
	308050	EOS07981	AI460004		EST singleton (not in UniGene) with exon hit	1.3
	334172	EOS34103	CH22_1452FG_349_5_LINK_EM:AC005500.GENSCAN.208-6			
				CH22_FGENES.349_5		1.3
55	315674	EOS15605	AA651923	Hs.191850	ESTs	1.3
	334876	EOS34807	CH22_2190FG_450_6_LINK_EM:AC005500.GENSCAN.339-6			
				CH22_FGENES.450_6		1.3
	315606	EOS15537	AW298724	Hs.202639	ESTs	1.3
	338779	EOS38710	CH22_7610FG_LINK_EM:AC005500.GENSCAN.526-15			
60				CH22_EM:AC005500.GENSCAN.526-15		1.3
	333511	EOS33442	CH22_766FG_171_5_LINK_EM:AC005500.GENSCAN.51-5			
				CH22_FGENES.171_5		1.3
	329254	EOS29185	c_x_hs_gij5868733 ref	gn 1 + 4133 4214 ex 1 2 CDSi -0.36 82 2833		
				CH.X_hs_gij5868733		1.3
65	319510	EOS19441	W88633	Hs.254562	ESTs	1.3
	339418	EOS39349	CH22_8411FG_LINK_DJ579N16.GENSCAN.11-4			
				CH22_DJ579N16.GENSCAN.11-4		1.3
	321012	EOS20943	AA737314		EST cluster (not in UniGene)	1.3
	333217	EOS33148	CH22_454FG_104_9_LINK_EM:AC000097.GENSCAN.108-8			
70				CH22_FGENES.104_9		1.3
	338561	EOS38492	CH22_7294FG_LINK_EM:AC005500.GENSCAN.421-5			
				CH22_EM:AC005500.GENSCAN.421-5		1.3
	335742	EOS35673	CH22_3105FG_601_13_LINK_EM:AC005500.GENSCAN.491-14			
				CH22_FGENES.601_13		1.3
75	334993	EOS34924	CH22_2314FG_469_14_LINK_EM:AC005500.GENSCAN.365-18			
				CH22_FGENES.469_14		1.3
	323430	EOS23361	AW062479		EST cluster (not in UniGene)	1.3
	306069	EOS06000	AA906983		EST singleton (not in UniGene) with exon hit	1.3
80	331681	EOS31612	W85712	Hs.119571	collagen; type III; alpha 1 (Ehlers-Danlos syndrome type IV; autosomal dominant)	1.3
	337986	EOS37917	CH22_6441FG_LINK_EM:AC005500.GENSCAN.110-7			
				CH22_EM:AC005500.GENSCAN.110-7		1.3
	313204	EOS13135	AI800518	Hs.118158	ESTs	1.3
	323189	EOS23120	AL121194	Hs.120589	ESTs	1.3
	318171	EOS18102	AA381202		EST cluster (not in UniGene)	1.3
	307156	EOS07087	AI186762		EST singleton (not in UniGene) with exon hit	1.3
85	332713	EOS32644	AA349792	Hs.78489	mutY (E. coli) homolog	1.3
	312828	EOS12759	AI865455	Hs.211818	ESTs; Moderately similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]	1.3

	301127	EOS01058	AA758109	Hs.121072	ESTs	1.3
	311260	EOS11191	AI672509	Hs.196582	ESTs	1.3
	338364	EOS38295	CH22_7007FG_LINK_EM:AC005500.GENSCAN.323-7			1.3
5	337904	EOS37835	CH22_6318FG_LINK_EM:AC005500.GENSCAN.56-17			1.3
	329347	EOS29278	c_x_hs gj 6456785 ref gn 1 + 18433 18897 ex 4 4 CDSI 43.39 465 3718			1.3
10	313329	EOS13260	AW293704	Hs.122658	ESTs	1.3
	314367	EOS14298	AA535749		EST cluster (not in UniGene)	1.3
	317098	EOS17029	AI123513	Hs.125456	ESTs	1.3
	306462	EOS06393	AA983397		EST singleton (not in UniGene) with exon hit	1.3
	301254	EOS01185	AI049624		EST cluster (not in UniGene) with exon hit	1.3
15	335504	EOS35435	CH22_2856FG_571_15_LINK_EM:AC005500.GENSCAN.460-34			1.3
	334270	EOS34201	CH22_1559FG_368_2_LINK_EM:AC005500.GENSCAN.228-3			1.3
	334324	EOS34255	CH22_1616FG_375_1_LINK_EM:AC005500.GENSCAN.235-1			1.3
20	304254	EOS04185	AA046273	Hs.111334	ferritin; light polypeptide	1.3
	305731	EOS05662	AA829363		EST singleton (not in UniGene) with exon hit	1.3
	323284	EOS23215	AA279381	Hs.190010	ESTs	1.3
	322007	EOS21938	AW410646	Hs.165739	ESTs	1.3
25	334537	EOS34468	CH22_1839FG_403_2_LINK_EM:AC005500.GENSCAN.268-2			1.3
	302360	EOS02291	AJ010901	Hs.198267	mucin 4; tracheobronchial	1.3
	311641	EOS11572	AJ948829	Hs.213786	ESTs	1.3
	324643	EOS24574	AI436356	Hs.130729	ESTs	1.3
30	327554	EOS27485	c_3_hs gj 5867801 ref gn 2 - 23092 23191 ex 2 6 CDSI 10.44 100 107			1.3
	312165	EOS12096	AW292139	Hs.115789	ESTs	1.3
	304679	EOS04610	AA548741		EST singleton (not in UniGene) with exon hit	1.3
	319564	EOS19495	AA026777	Hs.169732	ESTs	1.3
	310860	EOS10791	AW015920	Hs.161359	ESTs	1.3
35	337161	EOS37092	CH22_5180FG_561_3		CH22_FGENES.561-3	1.3
	311155	EOS11086	AI634410	Hs.197608	EST	1.3
	336846	EOS36777	CH22_4540FG_263_5		CH22_FGENES.263-5	1.3
	310985	EOS10916	T51842		EST cluster (not in UniGene)	1.3
40	329499	EOS29430	c10_p2 gj 3983518 gb A gn 5 + 33463 33789 ex 1 1 CDSO 34.50 327 97			1.3
	334924	EOS34855	CH22_2244FG_459_2_LINK_EM:AC005500.GENSCAN.351-2			1.3
	330861	EOS30792	AA084064	Hs.185747	ESTs	1.3
	324658	EOS24589	AI694767	Hs.129179	ESTs	1.3
45	323362	EOS23293	AL135067	Hs.117182	ESTs	1.3
	330468	EOS30399	L10343	Hs.112341	protease inhibitor 3; skin-derived (SKALP)	1.3
	314198	EOS14129	AA897581	Hs.128773	ESTs	1.3
50	339436	EOS39367	CH22_8431FG_LINK_DJ579N16.GENSCAN.19-1			1.3
	312483	EOS12414	AI417526	Hs.184636	ESTs	1.3
	321505	EOS21436	H73183	Hs.129885	ESTs	1.3
	332254	EOS32185	N64702	Hs.194140	ESTs	1.3
	328253	EOS28184	c_6_hs gj 6381894 ref gn 1 - 4411 4509 ex 1 5 CDSI 4.20 99 4561			1.3
55	332357	EOS32288	W73417	Hs.103183	EST	1.3
	329017	EOS28948	c_x_hs gj 6682532 ref gn 7 - 255591 255672 ex 3 3 CDSI 12.94 82 22			1.3
	337504	EOS37435	CH22_5739FG_803_2		CH22_FGENES.803-2	1.3
60	316625	EOS16556	AA780307	Hs.122156	ESTs	1.3
	335389	EOS35320	CH22_2739FG_545_1_LINK_EM:AC005500.GENSCAN.436-1			1.3
	310017	EOS09948	AI188739	Hs.148488	ESTs	1.3
	314354	EOS14285	AL037984	Hs.208982	ESTs; Weakly similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]	1.3
65	324641	EOS24572	AI732515	Hs.189218	ESTs	1.3
	335207	EOS35138	CH22_2546FG_510_4_LINK_EM:AC005500.GENSCAN.402-3			1.3
	333673	EOS33604	CH22_934FG_246_5_LINK_EM:AC005500.GENSCAN.101-3			1.3
70	334370	EOS34301	CH22_1664FG_378_18_LINK_EM:AC005500.GENSCAN.240-1			1.3
	328690	EOS28621	c_7_hs gj 6588001 ref gn 7 - 571207 571274 ex 1 3 CDSI 3.34 68 4325			1.3
	323208	EOS23139	AA203415	Hs.136200	ESTs	1.3
75	307010	EOS06941	AI140014		EST singleton (not in UniGene) with exon hit	1.3
	316563	EOS16494	AI587083	Hs.200558	ESTs; Weakly similar to !!!! ALU SUBFAMILY SP WARNING ENTRY !!!! [H.sapiens]	1.3
	312219	EOS12150	H73505	Hs.117874	ESTs	1.3
	319884	EOS19815	T73234		EST cluster (not in UniGene)	1.3
80	334720	EOS34651	CH22_2030FG_421_31_LINK_EM:AC005500.GENSCAN.282-31			1.3
	335836	EOS35767	CH22_3210FG_621_3_LINK_EM:AC005500.GENSCAN.513-3			1.3
	305448	EOS05379	AA737894	Hs.29797	ribosomal protein L10	1.3
85	314885	EOS14816	AI049878	Hs.133032	ESTs	1.3
	320130	EOS20061	AI820675	Hs.203804	ESTs	1.3
	310567	EOS10498	AI691065	Hs.155780	ESTs	1.3
	323898	EOS23829	AA347566		EST cluster (not in UniGene)	1.3

				CH.07_hs gj 5868363	1.2
	328662	EOS28593	c_7_hs gj 6004473 ref	gn 22 + 1184773 1184855 ex 7 8 CDSi 12.72 83 3916	
				CH.07_hs gj 6004473	1.2
5	319808	EOS19739	T58960	EST cluster (not in UniGene)	1.2
	303929	EOS03860	AW470753	EST singleton (not in UniGene) with exon hit	1.2
	315712	EOS15643	AI950133 Hs.120882	ESTs; Moderately similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]	1.2
	307391	EOS07322	AI225058	EST singleton (not in UniGene) with exon hit	1.2
	335499	EOS35430	CH22_2851FG_571_8_LINK	EM:AC005500.GENSCAN.460-28	
10				CH22_FGENES.571_8	1.2
	303792	EOS03723	C75094 Hs.199839	ESTs; Highly similar to NG22 [H.sapiens]	1.2
	327287	EOS27218	c_1_hs gj 5867479 ref	gn 1 - 62838 63024 ex 4 5 CDSi 11.66 187 1628	
				CH.01_hs gj 5867479	1.2
	317713	EOS17644	AI733306 Hs.128071	ESTs	1.2
15	330137	EOS30068	c21_p2 gj 4210430 emb	gn 1 - 21220 21377 ex 2 3 CDSi 1.89 158 104	
				CH.21_p2 gj 4210430	1.2
	308157	EOS08088	AI510824 Hs.75968	thymosin; beta 4; X chromosome	1.2
	314452	EOS14383	AL042699 Hs.209222	ESTs	1.2
	308268	EOS08199	AI567509 Hs.172928	collagen; type I; alpha 1	1.2
20	321467	EOS21398	X13075	EST cluster (not in UniGene)	1.2
	320993	EOS20924	AL050145 Hs.225986	Homo sapiens mRNA; cDNA DKFZp586C2020 (from clone DKFZp586C2020)	1.2
	336778	EOS36709	CH22_4367FG_159_4_	CH22_FGENES.159-4	1.2
	319827	EOS19758	T62778	EST cluster (not in UniGene)	1.2
	308249	EOS08180	AI560998	EST singleton (not in UniGene) with exon hit	1.2
25	310094	EOS10025	AW450967 Hs.235240	ESTs	1.2
	336902	EOS36833	CH22_4655FG_331_2_	CH22_FGENES.331-2	1.2
	339044	EOS38975	CH22_7944FG_LINK_DA59H18	GENSCAN.27-5	
				CH22_DA59H18.GENSCAN.27-5	1.2
	336675	EOS36606	CH22_4153FG_43_3_	CH22_FGENES.43-3	1.2
30	303563	EOS03494	AA367699 Hs.118787	transforming growth factor; beta-induced; 68kD	1.2
	330673	EOS30604	D57823 Hs.92962	Sec23 (S. cerevisiae) homolog A	1.2
	311814	EOS11745	AW377113 Hs.119640	ESTs; Moderately similar to zinc finger protein [H.sapiens]	1.2
	335481	EOS35412	CH22_2833FG_570_10_LINK	EM:AC005500.GENSCAN.460-4	
				CH22_FGENES.570_10	1.2
	314775	EOS14706	AI149880 Hs.188809	ESTs	1.2
35	324961	EOS24892	AA613792	EST cluster (not in UniGene)	1.2
	313458	EOS13389	AA007259 Hs.255853	ESTs	1.2
	307074	EOS07005	AI150989	EST singleton (not in UniGene) with exon hit	1.2
	337964	EOS37895	CH22_6410FG_LINK	EM:AC005500.GENSCAN.100-9	
40				CH22_EM:AC005500.GENSCAN.100-9	1.2
	326519	EOS26450	c19_hs gj 5867439 ref	gn 4 + 166004 166243 ex 4 5 CDSi 4.49 240 2534	
				CH.19_hs gj 5867439	1.2
	337366	EOS37297	CH22_5551FG_736_1_	CH22_FGENES.736-1	1.2
	322340	EOS22271	AF088076	EST cluster (not in UniGene)	1.2
45	307954	EOS07885	AI419692	EST singleton (not in UniGene) with exon hit	1.2
	328615	EOS28546	c_7_hs gj 5868239 ref	gn 2 + 35214 35347 ex 3 4 CDSi 11.49 134 3651	
				CH.07_hs gj 5868239	1.2
	317787	EOS17718	AW339612 Hs.249364	ESTs	1.2
	335288	EOS35219	CH22_2630FG_527_1_LINK	EM:AC005500.GENSCAN.421-1	
50				CH22_FGENES.527_1	1.2
	323175	EOS23106	AI827137 Hs.184023	ESTs	1.2
	330893	EOS30824	AA149620 Hs.71999	ESTs	1.2
	306810	EOS06741	AI057294	EST singleton (not in UniGene) with exon hit	1.2
	338239	EOS38170	CH22_6833FG_LINK	EM:AC005500.GENSCAN.264-5	
55				CH22_EM:AC005500.GENSCAN.264-5	1.2
	332347	EOS32278	W60326 Hs.221716	ESTs	1.2
	309782	EOS09713	AW275156 Hs.156110	Immunoglobulin kappa variable 1D-8	1.2
	322518	EOS22449	AI133446	EST cluster (not in UniGene)	1.2
	301187	EOS01118	AA806542	EST cluster (not in UniGene) with exon hit	1.2
60	312129	EOS12060	AW300867	EST cluster (not in UniGene)	1.2
	334714	EOS34645	CH22_2024FG_421_25_LINK	EM:AC005500.GENSCAN.282-25	
				CH22_FGENES.421_25	1.2
	316586	EOS16517	AI205077 Hs.144689	ESTs	1.2
	320488	EOS20419	R31386	EST cluster (not in UniGene)	1.2
65	327458	EOS27389	c_2_hs gj 6004455 ref	gn 3 + 173257 173378 ex 5 7 CDSi 4.03 122 1184	
				CH.02_hs gj 6004455	1.2
	336707	EOS36638	CH22_4212FG_64_3_	CH22_FGENES.64-3	1.2
	313561	EOS13492	AA040155	EST cluster (not in UniGene)	1.2
	330906	EOS30837	AA169498 Hs.72804	ESTs	1.2
70	330987	EOS30918	H40988 Hs.131965	ESTs; Weakly similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]	1.2
	325041	EOS24972	AI809182 Hs.130907	ESTs	1.2
	313225	EOS13156	AA502384 Hs.151529	ESTs	1.2
	305295	EOS05226	AA687131	EST singleton (not in UniGene) with exon hit	1.2
	306896	EOS06827	AI093383	EST singleton (not in UniGene) with exon hit	1.2
75	326981	EOS26912	c21_hs gj 6588016 ref	gn 3 + 105091 106038 ex 1 1 CDSi 122.69 948 567	
				CH.21_hs gj 6588016	1.2
	332225	EOS32156	N33213 Hs.100425	ESTs	1.2
	318802	EOS18733	R19443 Hs.92414	ESTs	1.2
	318413	EOS18344	AI138592 Hs.144936	ESTs	1.2
80	312292	EOS12223	AW451893 Hs.151124	ESTs	1.2
	323753	EOS23684	AA327102	EST cluster (not in UniGene)	1.2
	313582	EOS13513	AW207684 Hs.13583	ESTs	1.2
	317836	EOS17767	AA983913 Hs.128929	ESTs	1.2
	332868	EOS32799	CH22_86FG_28_8_LINK	C20H12.GENSCAN.18-8	
85				CH22_FGENES.28_8	1.2
	336924	EOS36855	CH22_4699FG_347_9_	CH22_FGENES.347-9	1.2
	327791	EOS27722	c_5_hs gj 5867977 ref	gn 1 + 22491 22610 ex 6 7 CDSi 11.29 120 658	

	332961	EOS32892	CH22_185FG_48_18_LINK_EM:AC000097.GENSCAN.2-14		
			CH22_FGENES.48_18	1.1	
	314703	EOS14634	AI791249	EST cluster (not in UniGene)	1.1
	317791	EOS17722	AI801500 Hs.128457	ESTs	1.1
5	333680	EOS33611	CH22_942FG_247_7_LINK_EM:AC005500.GENSCAN.102-7		
			CH22_FGENES.247_7	1.1	
	322419	EOS22350	AA248987 Hs.14084	ESTs; Highly similar to zinc RING finger protein SAG [M.musculus]	1.1
	338124	EOS38055	CH22_6661FG_LINK_EM:AC005500.GENSCAN.196-2		
			CH22_EM:AC005500.GENSCAN.196-2	1.1	
10	308884	EOS08815	AI833131 Hs.179100	ESTs	1.1
	333349	EOS33280	CH22_595FG_140_3_LINK_EM:AC005500.GENSCAN.20-3		
			CH22_FGENES.140_3	1.1	
	313150	EOS13081	AA824410 Hs.165003	ESTs	1.1
15	339208	EOS39139	CH22_8146FG_LINK_FF113D11.GENSCAN.6-3		
			CH22_FF113D11.GENSCAN.6-3	1.1	
	335653	EOS35584	CH22_3013FG_590_4_LINK_EM:AC005500.GENSCAN.484-4		
			CH22_FGENES.590_4	1.1	
	319524	EOS19455	AA682865 Hs.194441	ESTs	1.1
20	301576	EOS01507	AI682905 Hs.146875	ESTs; Weakly similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]	1.1
	317598	EOS17529	AW206035 Hs.192123	ESTs	1.1
	333473	EOS33404	CH22_724FG_162_3_LINK_EM:AC005500.GENSCAN.42-10		
			CH22_FGENES.162_3	1.1	
	333949	EOS33880	CH22_1225FG_303_5_LINK_EM:AC005500.GENSCAN.162-9		
			CH22_FGENES.303_5	1.1	
25	339256	EOS39187	CH22_8207FG_LINK_BA354I12.GENSCAN.7-11		
			CH22_BA354I12.GENSCAN.7-11	1.1	
	332884	EOS32815	CH22_104FG_33_5_LINK_C20H12.GENSCAN.22-7		
			CH22_FGENES.33_5	1.1	
	314660	EOS14591	AA436007 Hs.188780	ESTs	1.1
30	333220	EOS33151	CH22_457FG_104_12_LINK_EM:AC000097.GENSCAN.108-11		
			CH22_FGENES.104_12	1.1	
	308108	EOS08037	AI476803	EST singleton (not in UniGene) with exon hit	1.1
	320709	EOS20640	AA456660 Hs.154165	ESTs	1.1
35	307612	EOS07543	AI290787	EST singleton (not in UniGene) with exon hit	1.1
	330286	EOS30217	c_5_p2 gj[6671913]gb[A gn 2 - 31050 31171 ex 2 7 CDSi 8.84 122 791		
			CH.05_p2 gj[6671913	1.1	
	304495	EOS04428	AA446448	EST singleton (not in UniGene) with exon hit	1.1
	310583	EOS10514	AW205632 Hs.211198	ESTs	1.1
40	332896	EOS32827	CH22_117FG_35_10_LINK_C20H12.GENSCAN.24-9		
			CH22_FGENES.35_10	1.1	
	337602	EOS37533	CH22_5895FG_LINK_C20H12.GENSCAN.15-1		
			CH22_C20H12.GENSCAN.15-1	1.1	
	307626	EOS07557	AI300035	EST singleton (not in UniGene) with exon hit	1.1
45	334696	EOS34627	CH22_2006FG_421_5_LINK_EM:AC005500.GENSCAN.282-5		
			CH22_FGENES.421_5	1.1	
	318652	EOS18583	T53259	EST cluster (not in UniGene)	1.1
	337844	EOS37775	CH22_6229FG_LINK_EM:AC005500.GENSCAN.30-9		
			CH22_EM:AC005500.GENSCAN.30-9	1.1	
50	334823	EOS34754	CH22_2137FG_437_5_LINK_EM:AC005500.GENSCAN.301-7		
			CH22_FGENES.437_5	1.1	
	333928	EOS33859	CH22_1201FG_299_2_LINK_EM:AC005500.GENSCAN.158-5		
			CH22_FGENES.299_2	1.1	
	337503	EOS37434	CH22_5738FG_803_1_	CH22_FGENES.803-1	1.1
55	323044	EOS22975	AA148725 Hs.154190	ESTs	1.1
	329164	EOS29095	c_x_hs gj[5868691]ref[gn 1 + 62305 62517 ex 2 2 CDSi 17.51 213 1868		
			CH.X_hs gj[5868691	1.1	
	335468	EOS35399	CH22_2819FG_567_4_LINK_EM:AC005500.GENSCAN.454-12		
			CH22_FGENES.567_4	1.1	
60	338962	EOS38893	CH22_7838FG_LINK_DJ32I10.GENSCAN.23-39		
			CH22_DJ32I10.GENSCAN.23-39	1.1	
	323570	EOS23501	AL038623 Hs.208752	ESTs; Weakly similar to !!!! ALU SUBFAMILY SX WARNING ENTRY !!!! [H.sapiens]	1.1
	333568	EOS33499	CH22_826FG_185_1_LINK_EM:AC005500.GENSCAN.64-1		
			CH22_FGENES.185_1	1.1	
65	331865	EOS31796	AA425756 Hs.98445	ESTs	1.1
	336246	EOS36177	CH22_3644FG_746_5_LINK_DA59H18.GENSCAN.48-4		
			CH22_FGENES.746_5	1.1	
	337238	EOS37169	CH22_5343FG_641_3_	CH22_FGENES.641-3	1.1
	305089	EOS05020	AA642622	EST singleton (not in UniGene) with exon hit	1.1
70	300097	EOS00028	AI918973 Hs.213603	ESTs	1.1
	313134	EOS13065	N63406 Hs.258697	ESTs	1.1
	337452	EOS37383	CH22_5665FG_775_1_	CH22_FGENES.775-1	1.1
	325433	EOS25364	c12_hs gj[5866936]ref[gn 4 - 480708 480826 ex 3 4 CDSi 1.99 121 818		
			CH.12_hs gj[5866936	1.1	
75	335999	EOS35930	CH22_3380FG_657_1_LINK_DJ246D7.GENSCAN.11-1		
			CH22_FGENES.657_1	1.1	
	333580	EOS33511	CH22_840FG_199_2_LINK_EM:AC005500.GENSCAN.71-2		
			CH22_FGENES.199_2	1.1	
	336836	EOS36767	CH22_4512FG_247_11_	CH22_FGENES.247-11	1.1
80	334677	EOS34608	CH22_1986FG_418_30_LINK_EM:AC005500.GENSCAN.279-31		
			CH22_FGENES.418_30	1.1	
	329062	EOS28993	c_x_hs gj[5868590]ref[gn 3 - 58977 59094 ex 4 11 CDSi -6.19 118 627		
			CH.X_hs gj[5868590	1.1	
	333671	EOS33602	CH22_932FG_245_5_LINK_EM:AC005500.GENSCAN.100-12		
			CH22_FGENES.245_5	1.1	
85	304941	EOS04872	AA612612	EST singleton (not in UniGene) with exon hit	1.1
	315772	EOS15703	AW515373 Hs.158893	ESTs	1.1

	301281	EOS01212	AA843986	Hs.190586	ESTs	1.1
	333520	EOS33451	CH22_777FG_174_3_LINK_EM:AC005500.GENSCAN.53-6			1.1
			CH22_FGENES.174_3			1.1
5	315203	EOS15134	AI559820	Hs.199438	ESTs	1.1
	315927	EOS15858	AW025517	Hs.133250	ESTs	1.1
	317161	EOS17092	AA972165	Hs.150308	ESTs	1.1
	337692	EOS37623	CH22_6028FG_LINK_EM:AC000097.GENSCAN.78-12			1.1
			CH22_EM:AC000097.GENSCAN.78-12			1.1
10	331472	EOS31403	N24830	yx70a02.s1 Soares melanocyte 2NbHM Homo sapiens cDNA clone IMAGE:267050 3' similar to gb M87912 HUMALNE562 Human carcinoma cell-derived Alu RNA transcript, (rRNA);contains Alu repetitive element; mRNA sequence.		1.1
	336439	EOS36370	CH22_3859FG_827_4_LINK_DJ579N16.GENSCAN.1-3			1.1
			CH22_FGENES.827_4			1.1
15	326882	EOS26813	c20_hs gj 6682509 ref gn 2 - 167988 168179 ex 4 4 CDSI 18.69 192 2238			1.1
			CH.20_hs gj 6682509			1.1
	336977	EOS36908	CH22_4793FG_380_9			1.1
	333983	EOS33914	CH22_1260FG_310_7_LINK_EM:AC005500.GENSCAN.167-5			1.1
			CH22_FGENES.310_7			1.1
20	328878	EOS28809	c_7_hs gj 6552423 ref gn 1 + 105580 105774 ex 6 7 CDSI 2.91 195 6195			1.1
			CH.07_hs gj 6552423			1.1
	330415	EOS30346	D83777	Hs.75137	KIAA0193 gene product	1.1
	324824	EOS24755	AI826999	Hs.224624	ESTs	1.1
	325815	EOS25746	c14_hs gj 6682483 ref gn 1 - 129273 130754 ex 1 1 CDSI 11.82 1482 2225			1.1
			CH.14_hs gj 6682483			1.1
25	300463	EOS00394	N52510	Hs.186470	ESTs	1.1
	335708	EOS35639	CH22_3069FG_599_8_LINK_EM:AC005500.GENSCAN.490-11			1.1
			CH22_FGENES.599_8			1.1
	324575	EOS24506	AW502257		EST cluster (not in UniGene)	1.1
	337951	EOS37882	CH22_6391FG_LINK_EM:AC005500.GENSCAN.94-1			1.1
			CH22_EM:AC005500.GENSCAN.94-1			1.1
30	335935	EOS35866	CH22_3313FG_646_6_LINK_DJ246D7.GENSCAN.1-5			1.1
			CH22_FGENES.646_6			1.1
	334914	EOS34845	CH22_2233FG_457_3_LINK_EM:AC005500.GENSCAN.346-2			1.1
			CH22_FGENES.457_3			1.1
35	309527	EOS09458	AW150648	Hs.75621	protease inhibitor 1 (anti-elastase); alpha-1-antitrypsin	1.1
	318901	EOS18832	AW368520	Hs.24639	ESTs	1.1
	320484	EOS20415	AA094436	Hs.155712	folistatin-like 1	1.1
	333665	EOS33596	CH22_926FG_244_1_LINK_EM:AC005500.GENSCAN.99-1			1.1
			CH22_FGENES.244_1			1.1
40	335860	EOS35791	CH22_3235FG_629_5_LINK_EM:AC005500.GENSCAN.519-4			1.1
			CH22_FGENES.629_5			1.1
	313339	EOS13270	AI682536	Hs.163495	ESTs	1.1
	300149	EOS00080	AW448916	Hs.149018	ESTs	1.1
	318112	EOS18043	AI028162	Hs.132307	ESTs	1.1
45	337807	EOS37738	CH22_6178FG_LINK_EM:AC005500.GENSCAN.9-4			1.1
			CH22_EM:AC005500.GENSCAN.9-4			1.1
	336917	EOS36848	CH22_4688FG_346_4			1.1
	337489	EOS37420	CH22_5722FG_799_2			1.1
	320112	EOS20043	T92107	Hs.188489	ESTs	1.1
50	332975	EOS32906	CH22_199FG_51_10_LINK_EM:AC000097.GENSCAN.4-12			1.1
			CH22_FGENES.51_10			1.1
	327805	EOS27736	c_5_hs gj 5867968 ref gn 2 + 19952 20019 ex 1 2 CDSI 9.47 68 988			1.1
			CH.05_hs gj 5867968			1.1
55	339215	EOS39146	CH22_8153FG_LINK_FF113D11.GENSCAN.6-10			1.1
			CH22_FF113D11.GENSCAN.6-10			1.1
	311965	EOS11896	T69279		EST cluster (not in UniGene)	1.1
	314043	EOS13974	AA827082		EST cluster (not in UniGene)	1.1
	333447	EOS33378	CH22_697FG_154_5_LINK_EM:AC005500.GENSCAN.35-6			1.1
			CH22_FGENES.154_5			1.1
60	333242	EOS33173	CH22_481FG_111_6_LINK_EM:AC000097.GENSCAN.120-5			1.1
			CH22_FGENES.111_6			1.1
	338596	EOS38527	CH22_7343FG_LINK_EM:AC005500.GENSCAN.437-2			1.1
			CH22_EM:AC005500.GENSCAN.437-2			1.1
65	329989	EOS29920	c16_p2 gj 4567166 gb A gn 2 + 72861 73052 ex 1 3 CDSI 18.02 192 590			1.1
			CH.16_p2 gj 4567166			1.1
	315675	EOS15606	AA652272	Hs.197320	ESTs	1.1
	336722	EOS36653	CH22_4245FG_84_2			1.1
	334220	EOS34151	CH22_1503FG_359_4_LINK_EM:AC005500.GENSCAN.217-7			1.1
			CH22_FGENES.359_4			1.1
70	336703	EOS36634	CH22_4201FG_56_3			1.1
	336397	EOS36328	CH22_3812FG_823_12_LINK_BA232E17.GENSCAN.6-11			1.1
			CH22_FGENES.823_12			1.1
	316105	EOS16036	AW295687	Hs.254420	ESTs	1.1
75	334661	EOS34592	CH22_1969FG_418_9_LINK_EM:AC005500.GENSCAN.279-13			1.1
			CH22_FGENES.418_9			1.1
	307783	EOS07714	AI347274		EST singleton (not in UniGene) with exon hit	1.1
	333997	EOS33928	CH22_1275FG_310_22_LINK_EM:AC005500.GENSCAN.167-21			1.1
			CH22_FGENES.310_22			1.1
80	331903	EOS31834	AA436673	Hs.29417	Homo sapiens mRNA; cDNA DKFZp586B0323 (from clone DKFZp586B0323)	1.1
	328249	EOS28180	c_6_hs gj 6381891 ref gn 2 - 96352 96527 ex 2 3 CDSI 6.19 176 4550			1.1
			CH.06_hs gj 6381891			1.1
	338251	EOS38182	CH22_6849FG_LINK_EM:AC005500.GENSCAN.270-1			1.1
			CH22_EM:AC005500.GENSCAN.270-1			1.1
85	323561	EOS23492	AA825426	Hs.238832	ESTs; Weakly similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]	1.1
	301464	EOS01395	AA991519	Hs.253324	ESTs	1.1
	335916	EOS35847	CH22_3293FG_636_12_LINK_EM:AC005500.GENSCAN.526-12			1.1

				CH22_FGENES.636_12	1.1
	321828	EOS21759	X56197	EST cluster (not in UniGene)	1.1
	327413	EOS27344	c_2_hs gj 5867750 ref gn 3 + 101410 101508 ex 4 5 CDSi 4.34 99 587	CH.02_hs gj 5867750	1.1
5	334474	EOS34405	CH22_1773FG_394_5_LINK_EM:AC005500.GENSCAN.257-5	CH22_FGENES.394_5	1.1
	336739	EOS36670	CH22_4291FG_117_3_	CH22_FGENES.117-3	1.1
	316517	EOS16448	AI784315 Hs.123163	ESTs	1.1
10	325519	EOS25450	c12_hs gj 6017036 ref gn 5 - 186804 186915 ex 1 3 CDSi 8.36 112 2508	CH.12_hs gj 6017036	1.1
	333875	EOS33806	CH22_1145FG_291_11_LINK_EM:AC005500.GENSCAN.149-6	CH22_FGENES.291_11	1.1
	338221	EOS38152	CH22_6797FG_LINK_EM:AC005500.GENSCAN.246-10	CH22_EM:AC005500.GENSCAN.246-10	1.1
15	336878	EOS36809	CH22_4617FG_318_5_	CH22_FGENES.318-5	1.1
	337919	EOS37850	CH22_6338FG_LINK_EM:AC005500.GENSCAN.66-5	CH22_EM:AC005500.GENSCAN.66-5	1.1
	309828	EOS09759	AW293999	EST singleton (not in UniGene) with exon hit	1.1
20	305259	EOS05190	AA679225	EST singleton (not in UniGene) with exon hit	1.1
	333922	EOS33853	CH22_1195FG_296_13_LINK_EM:AC005500.GENSCAN.155-16	CH22_FGENES.296_13	1.1
	322092	EOS22023	AF085833	EST cluster (not in UniGene)	1.1
	313356	EOS13287	AI266254 Hs.132929	ESTs	1.1
25	318847	EOS18778	Z42908 Hs.12308	ESTs	1.1
	337175	EOS37106	CH22_5195FG_567_1_	CH22_FGENES.567-1	1.1
	336979	EOS36910	CH22_4802FG_385_4_	CH22_FGENES.385-4	1.1
	312169	EOS12100	AI064824 Hs.193385	ESTs	1.1
	336198	EOS36129	CH22_3595FG_719_2_LINK_DA59H18.GENSCAN.21-2	CH22_FGENES.719_2	1.1
30	321948	EOS21879	AA309612 Hs.118797	ubiquitin-conjugating enzyme E2D 3 (homologous to yeast UBC4/5)	1.1
	324692	EOS24623	AA557952	EST cluster (not in UniGene)	1.1
	330395	EOS30326	D10923 Hs.137555	putative chemokine receptor, GTP-binding protein	1.1
	333119	EOS33050	CH22_347FG_80_4_LINK_EM:AC000097.GENSCAN.65-4	CH22_FGENES.80_4	1.1
35	316012	EOS15943	AA764950 Hs.119898	ESTs	1.1
	300142	EOS00073	AI743419 Hs.205707	ESTs	1.1
	317215	EOS17146	AW014242 Hs.159998	ESTs	1.1
	329526	EOS29457	c10_p2 gj 3983506 gb U gn 2 + 12251 12325 ex 3 3 CDSi 7.37 75 178	CH.10_p2 gj 3983506	1.1
40	317409	EOS17340	AA764968 Hs.4864	KIAA0892 protein	1.1
	339230	EOS39161	CH22_8171FG_LINK_BA354I12.GENSCAN.1-6	CH22_BA354I12.GENSCAN.1-6	1.1
	311598	EOS11529	AW023595 Hs.232048	ESTs	1.1
45	339164	EOS39095	CH22_8091FG_LINK_DA59H18.GENSCAN.69-4	CH22_DA59H18.GENSCAN.69-4	1.1
	326725	EOS26656	c20_hs gj 6552456 ref gn 2 - 223005 223125 ex 5 6 CDSi 6.10 121 1038	CH.20_hs gj 6552456	1.1
	330952	EOS30883	H02855 Hs.29567	ESTs	1.1
50	334621	EOS34552	CH22_1928FG_412_4_LINK_EM:AC005500.GENSCAN.275-4	CH22_FGENES.412_4	1.1
	301685	EOS01616	W67730	EST cluster (not in UniGene) with exon hit	1.1
	308781	EOS08712	AI811707	EST singleton (not in UniGene) with exon hit	1.1
55	323413	EOS23344	AA248828 Hs.225676	ESTs	1.1
	306723	EOS06654	AI026151	EST singleton (not in UniGene) with exon hit	1.1
	331258	EOS31189	Z41777 Hs.27413	ESTs	1.1
	313028	EOS12959	AI355433 Hs.190856	ESTs	1.1
	333002	EOS32933	CH22_226FG_59_3_LINK_EM:AC000097.GENSCAN.21-3	CH22_FGENES.59_3	1.1
60	303011	EOS02942	AF090405	EST cluster (not in UniGene) with exon hit	1.1
	317687	EOS17618	AA972990 Hs.127904	ESTs	1.1
	328779	EOS28710	c_7_hs gj 5868309 ref gn 4 + 41570 41639 ex 1 5 CDSi 2.65 70 5365	CH.07_hs gj 5868309	1.1
	338707	EOS38638	CH22_7487FG_LINK_EM:AC005500.GENSCAN.482-2	CH22_EM:AC005500.GENSCAN.482-2	1.1
65	337974	EOS37905	CH22_6427FG_LINK_EM:AC005500.GENSCAN.106-3	CH22_EM:AC005500.GENSCAN.106-3	1.1
	332854	EOS32785	CH22_71FG_22_1_LINK_C20H12.GENSCAN.15-2	CH22_FGENES.22_1	1.1
70	311225	EOS11156	AW451982 Hs.248613	ESTs	1.1
	337094	EOS37025	CH22_5018FG_465_19_	CH22_FGENES.465-19	1.1
	319357	EOS19288	F13425 Hs.26229	ESTs	1.1
	332958	EOS32889	CH22_182FG_48_15_LINK_EM:AC000097.GENSCAN.2-11	CH22_FGENES.48_15	1.1
75	309634	EOS09565	AW193825	EST singleton (not in UniGene) with exon hit	1.1
	321171	EOS21102	AI769410 Hs.221461	ESTs	1.1
	316440	EOS16371	AI954795 Hs.156135	ESTs	1.1
	311665	EOS11596	AW294254 Hs.223742	ESTs	1.1
	327548	EOS27479	c_3_hs gj 5867797 ref gn 2 - 81067 81130 ex 3 7 CDSi 6.42 64 12	CH.03_hs gj 5867797	1.1
80	314940	EOS14871	AW452768 Hs.162045	ESTs	1.1
	326401	EOS26332	c19_hs gj 5867355 ref gn 1 + 35165 35332 ex 9 11 CDSi 0.41 168 788	CH.19_hs gj 5867355	1.1
	336347	EOS36278	CH22_3759FG_815_3_LINK_BA232E17.GENSCAN.1-24	CH22_FGENES.815_3	1.1
85	322297	EOS22228	W76548 Hs.136026	ESTs; Moderately similar to !!!! ALU SUBFAMILY SC WARNING ENTRY !!!! [H.sapiens]	1.1
	309977	EOS09908	AW451663	EST singleton (not in UniGene) with exon hit	1.1

	310026	EOS09957	T24895	Hs.100691	ESTs	1.1
	330153	EOS30084	c21_p2	gi 4325335 gb A	gn 2 + 146951 147475 ex 2 2 CDSi 25.45 525 233 CH.21_p2 gi 4325335	1.1
5	334118	EOS34049	CH22_1396FG_330_19_LINK	EM:AC005500.GENSCAN.185-20 CH22_FGENES.330_19	1.1	
	324795	EOS24726	A1494481	Hs.141579	ESTs	1.1
	332530	EOS32461	M31682	Hs.1735	inhibin; beta B (activin AB beta polypeptide)	1.1
	332048	EOS31979	AA496019	Hs.201591	ESTs	1.1
10	334532	EOS34463	CH22_1834FG_402_13_LINK	EM:AC005500.GENSCAN.266-13 CH22_FGENES.402_13	1.1	
	329762	EOS29693	c14_p2	gi 6048280 emb	gn 3 + 127744 127878 ex 2 4 CDSi 11.66 135 1054 CH.14_p2 gi 6048280	1.1
	332909	EOS32840	CH22_130FG_36_13_LINK	C20H12.GENSCAN.28-10 CH22_FGENES.36_13	1.1	
15	321253	EOS21184	A1699484		EST cluster (not in UniGene)	1.1
	336572	EOS36503	CH22_4007FG_843_12_LINK	DJ579N16.GENSCAN.15-13 CH22_FGENES.843_12	1.1	
	328768	EOS28699	c_7_hs	gi 6017031 ref	gn 5 - 223741 224238 ex 1 1 CDSi 30.00 498 5285 CH.07_hs gi 6017031	1.1
20	334335	EOS34266	CH22_1627FG_375_12_LINK	EM:AC005500.GENSCAN.235-12 CH22_FGENES.375_12	1.1	
	334063	EOS33994	CH22_1341FG_327_17_LINK	EM:AC005500.GENSCAN.181-20 CH22_FGENES.327_17	1.1	
25	333011	EOS32942	CH22_235FG_61_3_LINK	EM:AC000097.GENSCAN.23-3 CH22_FGENES.61_3	1.1	
	304677	EOS04608	AA548071		EST singleton (not in UniGene) with exon hit	1.1
	313948	EOS13879	AW452823	Hs.135268	ESTs	1.1
	334358	EOS34289	CH22_1652FG_378_1_LINK	EM:AC005500.GENSCAN.239-1 CH22_FGENES.378_1	1.1	
30	328479	EOS28410	c_7_hs	gi 5868449 ref	gn 1 - 331 560 ex 1 31 CDSi 18.51 230 2100 CH.07_hs gi 5868449	1.1
	335813	EOS35744	CH22_3185FG_618_1_LINK	EM:AC005500.GENSCAN.510-1 CH22_FGENES.618_1	1.1	
35	312430	EOS12361	AW139117	Hs.117494	ESTs	1.1
	324783	EOS24714	AA640770		EST cluster (not in UniGene)	1.1
	337776	EOS37707	CH22_6132FG_LINK	EM:AC000097.GENSCAN.119-18 CH22_EM:AC000097.GENSCAN.119-18	1.1	
	327205	EOS27136	c_1_hs	gi 5867447 ref	gn 5 + 167335 167576 ex 9 9 CDSi 15.50 242 259 CH.01_hs gi 5867447	1.1
40	315198	EOS15129	A1741506	Hs.186753	ESTs; Weakly similar to !!!! ALU SUBFAMILY J WARNING ENTRY !!!! [H.sapiens]	1.1
	336135	EOS36066	CH22_3525FG_704_3_LINK	DA59H18.GENSCAN.9-5 CH22_FGENES.704_3	1.1	
	318558	EOS18489	AW402677	Hs.90372	ESTs	1.1
45	328152	EOS28083	c_6_hs	gi 5868060 ref	gn 1 - 73981 74203 ex 1 8 CDSi 31.69 223 3411 CH.06_hs gi 5868060	1.1
	330211	EOS30142	c_5_p2	gi 6013592 gb A	gn 1 + 59158 59215 ex 2 4 CDSi 4.20 58 184 CH.05_p2 gi 6013592	1.1
50	339280	EOS39211	CH22_8234FG_LINK	BA354I12.GENSCAN.14-12 CH22_BA354I12.GENSCAN.14-12	1.1	
	332045	EOS31976	AA491253	Hs.155045	bromodomain adjacent to zinc finger domain; 2A	1.1
	313597	EOS13528	AW162263	Hs.249990	ESTs	1.1
	329503	EOS29434	c10_p2	gi 3983517 gb U	gn 2 - 1801 1937 ex 1 4 CDSi 4.33 137 101 CH.10_p2 gi 3983517	1.1
55	333488	EOS33419	CH22_740FG_167_3_LINK	EM:AC005500.GENSCAN.46-10 CH22_FGENES.167_3	1.1	
	311960	EOS11891	AW440133	Hs.189690	ESTs	1.1
	320590	EOS20521	U67058	Hs.168102	Human proteinase activated receptor-2 mRNA; 3'UTR	1.1
	334047	EOS33978	CH22_1325FG_326_5_LINK	EM:AC005500.GENSCAN.175-5 CH22_FGENES.326_5	1.1	
60	304782	EOS04713	AA582081		EST singleton (not in UniGene) with exon hit	1.1
	324231	EOS24162	W60827		EST cluster (not in UniGene)	1.1
	327212	EOS27143	c_1_hs	gi 5867463 ref	gn 1 - 42308 42424 ex 5 13 CDSi 6.58 117 325 CH.01_hs gi 5867463	1.1
65	335857	EOS35788	CH22_3232FG_629_1_LINK	EM:AC005500.GENSCAN.519-1 CH22_FGENES.629_1	1.1	
	317775	EOS17706	AA974603	Hs.181123	ESTs	1.1
	331053	EOS30984	N70242	Hs.183146	ESTs	1.1
	335940	EOS35871	CH22_3318FG_646_13_LINK	DJ246D7.GENSCAN.1-12 CH22_FGENES.646_13	1.1	
70	322568	EOS22499	W87342	Hs.209652	ESTs	1.1
	314091	EOS14022	A1253112	Hs.133540	ESTs	1.1
	313570	EOS13501	AA041455	Hs.209312	ESTs	1.1
	300967	EOS00898	AA565209	Hs.190216	ESTs	1.1
75	314544	EOS14475	AA399018	Hs.250835	ESTs	1.1
	328321	EOS28252	c_7_hs	gi 5868373 ref	gn 7 - 1029614 1029673 ex 1 3 CDSi -2.40 60 448 CH.07_hs gi 5868373	1.1
	310979	EOS10910	AW445166	Hs.170802	ESTs	1.1
	310730	EOS10661	AJ939421	Hs.160900	ESTs	1.1
80	318471	EOS18402	AW137725	Hs.146874	ESTs	1.1
	315533	EOS15464	AW206191	Hs.152774	ESTs	1.1
	325751	EOS25682	c14_hs	gi 6682474 ref	gn 4 + 130437 130520 ex 6 7 CDSi 0.22 84 1666 CH.14_hs gi 6682474	1.1
	318780	EOS18711	R90906	Hs.113307	ESTs	1.1
85	313271	EOS13202	AW444819	Hs.144851	ESTs; Weakly similar to C09F5.2 [C.elegans]	1.1
	304546	EOS04477	AA486074		EST singleton (not in UniGene) with exon hit	1.1
	330618	EOS30549	X55990	Hs.73839	ribonuclease; RNase A family; 3 (eosinophil cationic protein)	1.1

Table 2 provides the nucleic acid and protein sequence of the CBF9 gene as well as the Unigene and Exemplar accession numbers for CBF9.

TABLE 2 CBF9 DNA and Protein Sequences

CBF9 DNA sequence

Gene name: ESTs
 Unigene number: Hs.157601
 Probeset Accession #: W07459
 Nucleic Acid Accession #: AC005383
 Coding Sequence: 328-2751 (underlined sequences correspond to start and stop codons)

15	1	11	21	31	41	51	
	GACAGTGTTT	GCGGCTGCAC	CGCTCGGAGG	CTGGGTGACC	CGCGTAGAAG	TGAAGTACTT	60
	TTTATTTTGC	AGACCTGGGC	CGATGCCGCT	TTAAAAACG	CGAGGGGCTC	TATGCACCTC	120
	CCTGGCGGTA	GTTCCTCCGA	CCTCAGCCGG	GTCGGGTGCT	GCCGCCCTCT	CCCAGGAGAG	180
20	ACAAACAGGT	GTCCCACGTG	GCAGCCGCGC	CCCGGGCGCC	CCTCCTGTGA	TCCCGTAGCG	240
	CCCCCTGGCC	CGAGCCGCGC	CCGGGTCTGT	GAGTAGAGCC	GCCCCGGCAC	CGAGCGCTGG	300
	TCGCCGCTCT	CCTTCCGTTA	TATCAACATG	CCCCCTTTCC	TGTTGCTGGA	GGCCGTCTGT	360
	GTTTCTCTGT	TTTCCAGAGT	GCCCCCATCT	CTCCCTCTCC	AGGAAGTCCA	TGTAAGCAAA	420
	GAAACCATCG	GGAAGATTTT	AGCTGCCAGC	AAAATGATGT	GGTGCTCGGC	TGCAGTGGAC	480
25	ATCATGTTTC	TGTTAGATGG	GTCTAACAGC	GTCGGGAAAG	GGAGCTTTGA	AAGGTCCAAG	540
	CACTTTGCCA	TCACAGTCTG	TGACGGTCTG	GACATCAGCC	CCGAGAGGGT	CAGAGTGGGA	600
	GCATTCCAGT	TCAGTTCAC	TCCTCATCTG	GAATTCCCCT	TGGATTCAAT	TTCAACCCAA	660
	CAGGAAGTGA	AGGCAAGAAT	CAAGAGGATG	GTTTTCAAAG	GAGGGCGCAC	GGAGACGGAA	720
	CTTGCTCTGA	AATACCTTCT	GCACAGAGGG	TTGCCTGGAG	GCAGAAATGC	TTCTGTGCC	780
30	CAGATGTTTC	TGATCGTCAC	TGATGGGAAG	TCCCAGGGGG	ATGTGGCACT	GCCATCCAAG	840
	CAGCTGAAGG	AAAGGGGTGT	CACGTGTGTT	GCTGTGGGGG	TCAGGTTTCC	CAGGTGGGAG	900
	GAGCTGCATG	CACGTGCCAG	CGAGCCTAGA	GGGCAGCACG	TGCTGTTGGC	TGAGCAGGTG	960
	GAGGATGCCA	CCAACGGCCT	CTTCAGCACC	CTCAGCAGCT	CGGCCATCTG	CTCCAGCGCC	1020
	ACGCCAGACT	GCAGGGTCGA	GGCTCACCCC	TGTGAGCACA	GGACGCTGGA	GATGGTCCGG	1080
35	GAGTTCGCTG	GCAATGCCCC	ATGCTGAGAG	GGATCGCGGC	GGACCCCTTG	GGTGCTGGCT	1140
	GCACACTGTC	CCTTCTACAG	CTGGAAGAGA	GTGTTCCCTA	CCCACCCTGC	CACCTGCTAC	1200
	AGGACCACCT	GCCCAGGCC	CTGTGACTCG	CAGCCCTGCC	AGAATGGAGG	CACATGTGTT	1260
	CCAGAAGGAC	TGGACGGCTA	CCAGTGCCCT	TGCCCCGTGG	CCTTTGGAGG	GGAGGCTAAG	1320
	TGTGCCCTGA	AGCTGAGCCT	GGAATGCAGG	GTCGACCTCC	TCTTCTTGCT	GGACAGCTCT	1380
40	GCGGGCACCA	CTCTGACCG	CTTCTTCGGG	GCCAAAGTCT	TCGTGAAGCG	GTTTGTGCGG	1440
	GCCGTGCTGA	GCGAGGACTC	TCGGGCCCGA	GTGGGTGTGG	CCACATACAG	CAGGGAGCTG	1500
	CTGGTGGCGG	TGCCGTGTTG	GGAGTACCAG	GATGTGCCTG	ACCTGGTCTG	GAGCCTCGAT	1560
	GGCATTCCTT	TCCGTGGTGG	CCCCACCCTG	ACGGGCAGTG	CCTTGCGGCA	GGCGGCAGAG	1620
	CGTGGCTTCG	GGAGCGCCAC	CAGGACAGGC	CAGGACCGGC	CACGTAGAGT	GGTGGTTTTG	1680
45	CTCACTGAGT	CACACTCCGA	GGATGAGGTT	GCGGGCCAG	CGCGTCACGC	AAGGGCGCGA	1740
	GAGCTGCTCC	TGCTGGGTGT	AGGCAGTGAG	GCCGTGCGGG	CAGAGCTGGA	GGAGATCACA	1800
	GGCAGCCCAA	AGCATGTGAT	GGTCTACTCG	GATCCTCAGG	ATCTGTTCAA	CCAAATCCCT	1860
	GAGCTGCAGG	GGAAGCTGTG	CAGCCGGCAG	CGGCCAGGGT	GCCGGACACA	AGCCCTGGAG	1920
	CTCGTCTTCA	TGTTGGACAC	CTCTGCCTCA	GTAGGGCCCG	AGAATTTTGC	TCAGATGCAG	1980
50	AGCTTTGTGA	GAAGCTGTGC	CCTCCAGTTT	GAGGTGAACC	CTGACGTGAC	ACAGGTCCGC	2040
	CTGGTGGTGT	ATGGCAGCCA	GGTGCAGACT	GCCTTCGGGC	TGGACACCAA	ACCCACCCGG	2100
	GCTGCGATGC	TGCGGGCCAT	TAGCCAGGCC	CCCTACCTAG	GTGGGGTGGG	CTCAGCCGGC	2160
	ACCGCCCTGC	TGCACATCTA	TGACAAAGTG	ATGACCGTCC	AGAGGGGTGC	CCGGCCTGGT	2220
	GTCCCAAGAG	CTGTGGTGGT	GCTCACAGGC	GGGAGAGGCG	CAGAGGATGC	AGCCGTTCCCT	2280
55	GCCAGAGAAG	TGAGGAACAA	TGGCATCTCT	GCTTTGGTCG	TGGGCGTGGG	GCCTGCTCTA	2340
	AGTGAGGGTC	TGCGGAGGCT	TGCAGGTCCC	CGGGATTCCC	TGATCCACGT	GGCAGCTTAC	2400
	GCCGACCTGC	GGTACCACCA	GGACGTGCTC	ATTGAGTGCC	TGTGTGGAGA	AGCCAAGCAG	2460
	CCAGTCAACC	TCTGCAAACC	CAGCCCGTGC	ATGAATGAGG	GCAGCTGCGT	CCTGCAGAAAT	2520
	GGGAGCTACC	GCTGCAAGTG	TGCGGATGGC	TGGGAGGGCC	CCCCTGCGA	GAACCGTGAG	2580
60	TGGAGCTCTT	GCTCTGTATG	TGTGAGCCAG	GGATGGATTG	TTGAGACGCC	CCTGAGGCAC	2640

ATGGCTCCCG TGCAGGAGGG CAGCAGCCGT ACCCCTCCCA GCAACTACAG AGAAGGCCTG 2700
 GGCACTGAAA TGGTGCCTAC CTTCTGGAAT GTCTGTGCCC CAGGTCCTTA GAATGTCTGC 2760
 TCCCCGCCGT GGCCAGGACC ACTATTCTCA CTGAGGGAGG AGGATGTCCC AACTGCAGCC 2820
 5 ATGCTGCTTA GAGACAAGAA AGCAGCTGAT GTCACCCACA AACGATGTTG TTGAAAAGTT 2880
 TTGATGTGTA AGTAAATACC CACTTTCGTG ACCTGCTGTG CCTTGTTGAG GCTATGTCAT 2940
 CTGCCACCTT TCCCTTGAGG ATAAACAAGG GGTCTGAAG ACTTAAATTT AGCGGCCTGA 3000
 CGTTCCTTTG CACACAATCA ATGCTCGCCA GAATGTTGTT GACACAGTAA TGCCAGCAG 3060
 AGGCCTTTAC TAGAGCATCC TTTGGACGGC GAAGGCCACG GCCTTTCAAG ATGGAAAGCA 3120
 10 GCAGCTTTTC CACTTCCCCA GAGACATTCT GGATGCATTT GCATTGAGTC TGAAAGGGGG 3180
 CTTGAGGGAC GTTGTGACT TCTTGGCGAC TGCCTTTTGT GTGTGGAAGA GACTTGGAAG 3240
 GGTCTCAGAC TGAATGTGAC CAATTAACCA GCTTGGTTGA TGATGGGGGA GGGGCTGAGT 3300
 TGTGCATGGG CCCAGGCTCTG GAGGGCCACG TAAATCGTT CTGAGTCGTG AGCAGTGTCC 3360
 ACCTTGAAGG TCTTC

CBF9 Protein sequence

Gene name: ESTs
 Unigene number: Hs.157601

Protein Accession #: none found

Signal sequence: 1-17
 20 Transmembrane domains: none found
 VGW domains: 49-223; 341-518; 529-706
 EGF domains: 298-333; 715-748
 Cellular Localization: plasma membrane

1 11 21 31 41 51
 | | | | | |
 MPPFLLLEAV CVFLFSRVPP SLPLQEVHVS KETIGKISAA SKMMWCSAAV DIMFLLDGSN 60
 SVGKGSFERS KHFAITVCDG LDISPERVRV GAFQFSSTPH LEFPLDSFST QQEVKARIKR 120
 30 MVFKGGRTET ELALKYLLHR GLPGGRNASV PQILIIIVTDG KSQGDVALPS KQLKERGVTV 180
 FAVGVRFPRW EELHALASEP RGQHVLAEQ VEDATNGLFS TLSSSAICSS ATPDCRVEAH 240
 PCEHRTLEMV REFAGNAPCW RGSRRTLAVL AAHCPFYSWK RVFLTHPATC YRTTCPGPCD 300
 SQPCQNGGTC VPEGLDGYQC LCPLAFGGEA NCALKLSLEC RVDLLFLLDS SAGTTLDGFL 360
 RAKVFVKRFV RAVLSEDSRA RVGVATYSRE LLVAVPVGEY QDVPDLVWSL DGIPFRGGPT 420
 35 LTGSALRQAA ERGFGSATRT GQDRPRRVVV LLTESHSEDE VAGPARHARA RELLLLGVGS 480
 EAVRAELEEI TGSPKHMVMY SDPQDLFNQI PELQKLCSS QRPQCRTQAL DLVFMLDTSA 540
 SVGPENFAQM QSFVRSCALQ FEVNPDTVQV GLVVYGSQVQ TAFGLDTKPT RAAMLRAISQ 600
 APYLGGVGSA GTALLHIYDK VMTVQRGARP GVPKAVVVL T GGRGAEDAAV PAQKLRRNGI 660
 SVLVVGVPV LSEGLRRLAG PRDSLIVHAA YADLRYHQDV LIEWLCGEAK QPVNLCKPSP 720
 40 CMNEGSCVLQ NGSYRCKCRD GWEGPHCENR EWSSCSVCVS QGWILETPLR HMAPVQEGSS 780
 RTPPSNYREG LGTEMVPTFW NVCAPGP